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Equine populations worldwide are exposed to a large variety of infectious diseases. While 
these are detrimental to horse health and welfare, and potentially cause significant economic 
shortfalls, one must bear in mind that each infectious agent also carries a risk of zoonotic 
potential (1). Several outbreaks of highly pathogenic zoonotic diseases affecting humans in 
recent years underlines the interconnectedness of humans, animal and environmental species 
(1). Hence, equine health concerns a broad audience beyond equine professionals and 
enthusiasts. The most prevalent infectious equine diseases and infections, as listed by OIE, 
include infection with equid herpesvirus-1 (EHV-1), equine influenza, equine 
encephalomyelitis (Western) or Venezuelan equine encephalomyelitis among many others (2). 
EHV-1 is of particular interest as it is does not only cause rhinopneumonitis, but also abortions 
and neonatal foal death as well as the severe neurological condition known as Equine 
Herpesvirus myeloencephalopathy (EHM). It is easily transmissible via nasal secretions and 
highly contagious (3-6). On top of that, EHV-1, like most Herpesviruses, establishes a life-long 
latency within the equine host by evading immune responses, rendering the host a silent shedder 
of the virus (7). In that manner, it has been greatly successful pursuing its epidemiological 
strategy to ensure its spread and survival within the host population (3, 6, 8, 9). At this point in 
time, at least 60 % of the worldwide horse population are considered latently infected with 
EHV-1 (10). Current therapeutic options are non-existent and the main focus is on costly 
preventative measures including biosecurity or vaccination regimens (10). However, 
vaccinations are limited in their application spectrum as they fail to alter viremia or prevent 
latent infections (10, 11). Anti-viral therapeutics proven successful in human medicine are 
currently under investigation for use in horses (4, 10, 12, 13). This lack of anti-viral 
therapeutics, along with the existence of hardy pathogens with pandemic potential and the ever 
increasing antibiotic resistance have (re-)-ignited the necessity for antibody treatments, 
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including monoclonal antibodies as well as recombinant antibodies (14). Moreover, antibody 
reagents would greatly add to the armoury of biological reagents elucidating antigenic 
properties (15). The general consensus among EHV-1 experts considers equine-specific, 
recombinant antibodies to be a viable option to initially provide reagents and consequently, 
protection against EHV-1 (4, 10). 
In human medicine, recombinant antibodies have been developed over the past 30 years, 
resulting in numerous antibody preparations approved for treatments including infectious 
diseases, cancer, and auto immune diseases (16). Veterinary medicine has caught up and 
recently, two veterinary recombinant antibody preparations have received approval to be 
utilized in the treatment of pain and autoimmune diseases in cats and dogs (17). A major 
advantage of recombinant antibody formulation is the species-specificity of the formulation 
since immunogenicity to foreign proteins is thereby avoided and supports the healing process 
(16-19). Since the beginning of recombinant antibody generation a clear trend towards highly 
species-specific antibodies is observable (18): in the 1990ies merely 11,5 % of antibody 
candidates were fully human; ten years later a markedly higher percentage of 45 % are fully 
human (18). The two veterinary preparations have also been adjusted to be better tolerated in 
the target species and formulation have therefore been caninized and felinized (20, 21). 
State-of-the-art of recombinant antibody generation is the in vitro construction of species-
specific antibody libraries containing the immunoglobulin repertoire of all available 
immunoglobulin data of the target species mimicking the naturally occurring antibody 
repertoire (19, 22-24). Libraries are usually generated within certain antibody formats whereby 
the naturally occurring antibody is fragmented into smaller, still functioning, antibody 
molecules that have proven to be advantageous in the diagnosis and treatment of certain 
conditions (16). The single-chain-Fragment-variable (scFv) format has achieved popularity due 
to a large range of advantages including outstanding tissue penetration characteristics, higher 
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sensitivities and a high customizability (15, 19, 23, 25, 26). Most of these aspects are ascribable 
to a scFv fragments smaller size since it only contains the antigen binding domains of an 
antibody linked to each other via a glycine-serine linker (15, 19, 23, 25, 26). 
Recombinant antibodies raised in antibody libraries, are selected on a particular antigen 
through a microbial display system, whereby microbes display the antibody sequence on their 
surface (27). Exposure to the antigen of interest during so-called biopanning rounds determines 
well-binding antibody sequences (23). The most robust and widely used display method is 
phage display technology which has been involved in drug discovery since the beginning of 
recombinant antibody generation in both, human and veterinary medicine and research (16). 
Many human and non-human primate phage display libraries as well as veterinary scFv phage 
display libraries (e.g. chicken, camel, cattle, and rabbit) exist (28-33), but no equine scFv phage 
display library to isolate scFv antibodies exists to date.  
The present dissertation aims to meet this lack by constructing an equine scFv phage 
display library to isolate scFv antibodies to provide prognostic, diagnostic and therapeutic 
alternatives to investigate and treat equine conditions. The first study establishes and validates 
a primer set designed to capture the vast repertoire of equine immunoglobulin genes based on 
published data and genomic organisation (34-45) for the construction of an equine recombinant 
antibody library in the recombinant scFv format. The second study, is a proof-of-principle 
study, in which the suitability of phage display technology is assessed as a method to screen the 
library for an equine scFv antibody against the highly infectious EHV-1 virus and will include 
characterisation of isolated scFv in terms of production and binding capacities (18). Results of 
this dissertation will contribute to discovery and development of novel, alternative equine and 
veterinary prognostic and therapeutic agents against a vast variety of equine pathogens. The 
newly established library represents a starting point for future research and development in 
equine and veterinary drug development improving animal health and welfare.  
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3 LITERATURE REVIEW 
3.1 Equine Herpesvirus 
3.1.1 Classification and Structure  
 Classification 
Equine herpesviruses (EHVs) have been classified under the order Herpesvirales and 
the family of Herpesviridae (1, 2). The family of Herpesviridae is further subdivided into three 
subfamilies: α-, β- and γ- subfamilies (2). Division occurred according to tissue tropism, 
pathogenicity and behaviour in cell culture (1-4). EHVs however only belong to two of three 
subfamilies - α and γ (1, 2). In total, nine EHVs exist, of which EHV-1, -3, -4, -8 and -9 belong 
to the α-subfamily and are allocated to the genus Varicelloviruses (1). EHV-2, -5 and -7 belong 
to the γ-subfamily and are assigned to the genus Percaviruses (1, 2). Out of nine EHVs only 
five (EHV-1, -2, -3, -4 and -5) can cause diseases in horses (1, 2). While EHV-3 causes coital 
exanthema and EHV-2 and -5 are not associated with specific diseases but with respiratory 
problems and general malaise (5), EHV-1 and -4 cause the most detrimental health issues 
resulting in substantial economic deficits (1, 2). Both viruses affect the respiratory tract, yet 
only EHV-1 can causes further disorders including abortion, neonatal foal death and 
neurological disorders (1, 2). Table 1 shows an overview of EHV classification and disorders 




Table 1: Equine herpesvirus classification and resulting disorder in host species upon infection. 
Adapted from Paillot et al. (2). 
Host species Name Subfamily Disorder 
Equus caballus EHV-1 α Respiratory, abortion, neurological 
EHV-2 γ Associated with: respiratory, general malaise, poor 
performance 
EHV-3 α Coital exanthema 
EHV-4 α Respiratory 
EHV-5 γ Associated with: respiratory, general malaise, poor 
performance 
Equus asinus EHV-6 α Coital exanthema 
EHV-7 γ Associated with: respiratory, general malaise, poor 
performance 
EHV-8 α Rhinitis 
Gazella thomsoni EHV-9 α Neurological 
 
Structure of EHV-1  
The EHV-1 virion has an icosahedral nucleocapsid, containing the viral DNA, 
embedded into globular tegument and is encased by a shapeless envelope, which is surrounded 
by 12 glycoproteins (Figure 1) (1, 2, 5). The diameter of the virion is reported to be 
approximately 150 nm (1, 5). Similar to most herpesviruses, the EHV-1 nucleocapsid is 
composed of six proteins (2). Its structure is made up of 162 capsomers and twelve portal 
proteins, which form a ring-like structure within the capsid; these portal proteins are utilized by 
viral genomic information (DNA) to penetrate the capsid (2). Viral DNA is made up of a single, 
linear, double-stranded DNA molecule with a size of 150,223 bp and a GC content of 57% (1, 
2, 5, 6). The genome incorporates a unique long (UL) region adhering to a unique short (US) 
region, bordered by internal (IRS) and terminal (TRS) sequences (1, 5). Whole genome 
sequencing of a purified EHV-1 strain Ab4 clone (7) revealed the genome to consist of 80 open 
reading frames (ORFs), which includes 76 unique genes (5). The nucleocapsid containing the 
EHV-1 genome, is embedded into the tegument, which contains 12 viral proteins and enzymes 
responsible for replication mechanisms (5). The shapeless envelope, surrounding the 
nucleocapsid and the tegument, presents 11 glycoproteins on its surface – gB, gC, gD, gE, gG, 
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gH, gI, gK, gL, gM, gN, gp2 (2). Glycoproteins play a vital role during the adsorption and 
penetration process during virus pathogenicity including cell-to-cell spread, cell penetration, 
virus attachment and egression (5).  
 
Figure 1: EHV-1 virion shown schematically. Modified according to Paillot et al. (2). dsDNA 
– double-stranded DNA. Created with biorender.com. 
 
3.1.2 Prevalence, Transmission & Epidemiology 
 Prevalence and Transmission 
EHV-1 affects the family Equidae including horses, mules, zebras and donkeys (8). 
Horses of all ages and sexes can be affected, however, young foals, older horses and immune-
compromised horses are at a higher risk of infection (9). The prevalence is influenced by 
geographic factors, management practices, testing technology as well as sampled tissue (9). 
Reports claim outbreaks mostly occur at equine enterprises such as race tracks, riding facilities 
and veterinary clinics where animals from different locations and management styles 
congregate and a high stocking density is inevitably created (9).  
Literature Review 
11 
EHV-1 is extraordinarily contagious and transmitted by a variety of routes (5): the direct 
and most critical transmission route is horse-to-horse contact (Figure 2; (1, 5)). Indirect 
transmission occurs through inanimate objects by coming in contact with virus-contaminated 
nasal secretions and aerosols, aborted foetuses or foetal fluids as well as latently infected 
equines (Figure 2; (1, 5)). The survivability of EHV-1 in the environment is reported to range 
from less than one week to up to one month (1). A recent study has found it to be durable and 
remain transmittable in water for weeks (Figure 2; (8, 10)).  
 
 
Figure 2: Modes of transmission of EHV-1. Adapted from Kapoor et al. (1). Created with 
biorender.com.  
Reproductive transmission plays a crucial role as well: while trans-placental 
transmission of EHV-1 is well documented according to Hebia et al. (11), the venereal 
transmission route was proposed possible by one study as well since they detected EHV-1 in 
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semen of naturally infected stallions for up to 20 days post infection (12). Additionally, equine 
embryo transfer poses a risk for EHV-1 transmission to recipient mares, since recommended 
washing steps prior to inoculation have not proven successful in removing virus from embryos 
(11). 
Latently infected horses have been identified as one of the principal reservoirs of EHV-
1 transmission (5). They harbour the virus in trigeminal ganglia or lymphoid tissue presenting 
as source of viral particles which could be reactivated under stress (13). Stressors include 
strenuous physical exercise, transportation, pre-existing disease and a suppressed immune 
system (5). Once the virus has been reactivated and extended into the respiratory epithelium, it 
can be shed once more through nasal secretions thereby creating a source of EHV-1 infection 
to susceptible horses (refer to Figure 3) (13).  
 
Figure 3: Transmission cycle of EHV-1 infection among horses. Adapted from Kapoor et al. 
(1). Created with biorender.com. 
While Herpesviruses are usually species-specific and equids still remain the natural and 
definite host of EHV viruses, there is a small number of reports and occurrences on inter-species 
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transmission (14): EHV-1 has been detected in other equids including Persian onagers, various 
zebra species and Thomson’s gazelles (15). Donkeys are a potential host for EHV-1 and serve 
as silent reservoirs as well (16). Highly unexpected transmission of EHV-1 has occurred to two 
polar bears in a German zoo with one case resulting in fatality (14). Another study found EHV-
1 to have jumped to a female pregnant Indian rhinoceros, which aborted mid-pregnancy and 
suffered from severe neurological symptoms; this course of infection also resulted in fatality 
(14). Viral DNA isolated from this rhinoceros demonstrated 99% similarity with zebra-borne 
EHV-1 (14). Transmission in this case is proposed to have occurred through contaminated 
fomites, clothing of staff, aerosol transmission, or rodent vectors as the rhinoceros and zebra 
enclosures where not located close to each other and contact among animals can be excluded 
(14). Other species reported to have been infected with EHV-1 include deer, alpaca, gazelle and 
antelope, lamas as well as cattle according to Lecollinet et al. (8) and are considered as potential 
reservoir of the virus.  
 Epidemiology 
EHV-1 infection occurs world-wide and can be considered to be one of the most 
successful pathogens of horse populations (8). While the majority of scientific examination of 
EHV-1 is focussed on the characterisation of the virus, epidemiological studies have been 
neglected (17). This is most likely due to regulations concerning reporting EHV-1 outbreaks. 
In Germany, EHV-1 infection is not mandatory to be reported to the authorities (18). In the 
USA however, outbreaks of the neurological disease are mandatory to report (19). 
Independently of these obligations, a number of studies are available that detected EHV-1 in 
individual countries or continents; a visual summary is given in the map below (Figure 4). The 
map indicates the distribution of EHV-1 outbreaks reported in the scientific literature, by the 
OIE WAHIS (World Animal Health Information System) and the Fédération Equestrian 




Figure 4: Distribution of EHV-1 outbreaks. EHV-1 outbreaks have been reported in countries 
marked in red according to scientific literature, the OIE WAHIS interface and the FEI from 
2000 to 2020 (8, 10, 16-18, 20-33). Created with biorender.com. 
Recently, in early 2019, the FEI (34) reported 70 new outbreaks in several European 
countries as well as Canada and the USA, which led them to adjust their veterinary regulations. 
Horses showing clinical signs or are known to have been in contact with diseased horses, are 
excluded from FEI events and may not be allowed to compete until FEI health requirements are 
fulfilled (18).  
Due to a high contagiousness, it is estimated that at least 60 % of the world-wide horse 
population is latently infected with EHV-1, leaving the equine industry confronted with large 
economic impacts (8, 9, 19, 35). Biosecurity measures and quarantine interrupt the efficient 
workflow on breeding enterprises, training and competition schedules of sport horses as well 
as sales and auction events (9). While the occurrence of rhinopneumonitis and abortion due to 
EHV-1 infection are decreasing, the incidence of EHM outbreaks has increased over the past 
20 years in most parts of the world (8, 21). EHM is now classified as an evolving disease of 
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horses (35). Once the disease has progressed to EHM or it being the sole symptom, the mortality 
rate is up to 50% (20, 21).  
But not only well-developed countries suffer losses from this infection, in developing 
countries EHV-1 in equids such as donkeys and mules are detrimental to human survival as 
these equids present means of transport for humans and agricultural goods (16). They are at a 
greater risk of contracting and succumbing to the infection as they are subjected to heavy 
workloads, long distance travelling, poor condition, heavy parasite burdens and seasonally 
dependent availability of pastures (16). 
 
3.1.3 Pathogenicity and clinical signs  
EHV-1 infection is spread throughout the host’s body by intercellular routes and 
involves many cell types (2). Cell infection and replication begins with EHV-1 utilizing 
glycoproteins to bind to glycosaminoglycans on the surface of permissive cells (2). Viral 
glycoprotein gD and gM are recruited for the entry into cells (2). Once the virus is attached, it 
penetrates the cell either by fusion of the virus envelope with cell membranes or by non-
classical endocytosis (2). This process causes a discharge of viral nucleopcapsid and tegument 
proteins into the cell (2). The viral nucleocapsid binds to the nucleopore-complex of the cell 
thereby translocating viral DNA into the cell’s nucleus, while the nucleocapsid remains in the 
cytoplasm (2). Immediate early (IE) genes are stimulated by tegument proteins and in turn 
activate transcription of early and late genes (2). Early genes stimulate virus replication, late 
genes translate viral structural proteins (2). Within the cell nucleus, the new EHV-1 
nucleocapsid is assembled around scaffolding proteins and new viral DNA becomes 
encapsidated (2). The new nucleocapsid, surrounded by tegument proteins, leaves the nucleus 
and becomes enveloped in the inner nuclear membrane, including glycoproteins (2). This 
envelop dissolves when the new viral nucleocapsid buds through the outer nuclear membrane 
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(2). It now becomes enveloped again in cytoplasmic membranes which contain all viral surface 
glycoproteins (2). The new mature viral particle migrates through the secretory pathway (Golgi 
apparatus) and is released either into extracellular space or infects other cells by virus induced 
cell fusion (2).  
First site of infection are nasal and nasopharyngeal epithelial cells in absence of mucosal 
antibodies (2). Epithelial cell necrosis and acute inflammatory responses lead to erosion within 
the first week after infection (2). The virus can now spread quickly and be shed to other horses 
(2). The next type of cells to be infected are leucocytes and endothelial cells of blood vessels 
and lymphatic vessels due to cell-to-cell spread from the respiratory epithelium (2). The 
endothelium of blood vessels becomes infected within two to four days post infection (2). 
Respiratory symptoms in young horses include fever, serous to mucopurulent nasal discharge, 
coughing and lymphadenopathy (2). In older horses respiratory symptoms are expressed mildly 
or subclinically (2). EHV-1 infection mostly affects the upper respiratory tract (URT) but 
disorders of the lower respiratory tract are possible e.g. bronchopneumonia (2). If 
submandibular, retropharyngeal and bronchial lymph node cells become infected (2, 5, 19), 
during the second stage of illness, cell-associated viremia is established and the virus can spread 
rapidly (2, 5). The infection is amplified by lymph node cells including different types of 
leucocytes (e.g. macrophages, endothelial cells), which will circulate throughout the blood and 
the lymphatic systems, thereby reaching distant locations for instance the uterus and central 
nervous system (CNS) via cell-associated viremia (2, 5, 19, 36, 37).  
In 1932 in Kentucky, EHV-1 was first reported to be the responsible agent for abortion 
as reported by Paillot et al. (2). EHV-1 is transported to endometrial endothelial cells inducing 
thrombosis and ischemia in microcotyledons of the placenta resulting in premature separation 
of the placenta from the endometrium followed by death of the foetus, late-gestation abort of a 
virus-negative foal, stillbirth or weak neonatal foals (36). In vitro studies have observed that 
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chorionic gonadotrophin (CG), a major hormone released during pregnancy, reactivates latent 
EHV-1 (2). The higher susceptibility of pregnant mares is therefore believed to be linked to CG 
expression by the endometrium (1, 36, 38). Interleukin-2 is also considered to have an effect on 
reactivation since both, interleukin-2 and CG have been found to initiate reactivation of the 
virus from venous lymphocytes in an indirect fashion by releasing mediators form adherent 
cells which reactivate EHV-1 from T-cells (38). The less severe vasculitis may allow focal 
transfer of virus across the utero-placental barrier, infecting the foetus and cause multi-organ 
failures and macroscopic and microscopic lesions leading to abortion as well (1, 2, 36). If 
affected foals are born, they usually succumb to respiratory failure (2).  
Cell-associated viremia can also transport EHV-1 to the vasculature of the CNS (2). 
Endothelial cells of the CNS become infected, small blood vessels in brain and spinal cord 
experience vasculitis and thrombosis (2). Clinical signs of involvement of the CNS range from 
mild hind limb ataxia to quadriplegia and usually occur one week after infection (2). 
The severity of neuropathogenicity and abortigenic potential is considered to be strain-
dependent (37, 39). A single nucleotide polymorphism (SNP) in the viral polymerase (Pol) gene 
within (ORF30) is contemplated the decisive indicator for the neuropathogenic aptitude of the 
strain (Figure 5) (16, 39, 40).  
 
Figure 5: Schematic overview of SNP in EHV-1 Pol gene within ORF30 and resulting viral 
strains. Created with biorender.com.  
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There is a difference between A2254/N752 and G2254/D752 Pol variants in regards to their 
capability to cause EHM disease outbreak (16, 39, 40). While G2254/D752 variant is mostly 
isolated from EHM cases, A2254/N752 is mainly isolated from abortion incidences rather than 
EHM incidences (39). Neuropathogenic EHV-1 strains reproduce faster and achieve 10-fold 
elevated levels of leucocyte-associated viremia as compared to non-neuropathic strains (16). 
Other factors that are affecting the risk of developing EHM are breed, sex, age or vaccination 
status (39). Most studies and reviews report EHM outbreaks in horses older than 2 years of age 
(39). The neuropathogenic variant G2254/D752 Pol has become more predominant in recent years 
according to Walter et al. (39). Furthermore, EHV-1 strains are classified into high virulence 
strain and low virulence strain depending on their effect on high levels of viremia and 
endotheliotropism (39). The high virulence strain Ab4 has been known to cause abortion and 
neurological disease on countless occasions (37). The low virulence strain V592 on the other 
hand, has reported to merely result in level viremia and restricted endotheliotropism (37). 
Nowadays genetically differing strains of EHV-1 are in circulation simultaneously (37).  
 
3.1.4 Latency & Immune evasion strategies 
 Latency 
The ability to establish life-long latency in their respective host is one of the trademark 
properties of herpesviruses (41). Alphaherpesviruses utilize long-term latency as an 
epidemiological strategy avoiding an active host immune system to ensure their spread and 
survival within the host population (35, 36, 42, 43). During latency, the virus is expressed at a 
low, nearly undetectable rate, yet is able to re-infect the host and in turn be spread to other 
horses while the host is not eliciting symptoms, obvious virus shedding or cell-associated 
viremia (2, 35, 42). Latently infected horses are termed silent shedders and pose a threat to 
susceptible horses by transmitting the virus through nasal secretions or aborted foetuses (2, 35, 
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36, 42). EHV-1 infection can periodically be re-activated from the latent state either 
spontaneously or after induction by external stimuli e.g. relocation and transport, training and 
competitions, illnesses, operations and treatment (2, 35, 36, 41, 44, 45). In particular, treatment 
with corticosteroids has shown to re-activate latent virus (2, 35, 36, 41, 44, 45). 
Generally, a productive EHV-1 infection activates viral gene expression (35). During 
latency viral gene expression is restricted and synthesis of viral factors is not possible, hence 
infectious viral particles are absent (35). The primary site harbouring circulating latent EHV-1 
are considered to be lymphocytes as established in numerous studies (35, 46, 47). Eighty 
percent of CD5+/CD8+ have been verified to enable latency; CD8-/CD4- have also been found 
to enable establishment of latency (35, 38). Other studies have proven latent EHV-1 to be 
harboured within the sensory nerve cell bodies in the trigeminal ganglia (35, 45, 48, 49). During 
latency, the viral genome is concealed while latency-associated transcripts, antisense to IE viral 
genes or regulatory early viral genes are detectable (2, 35, 38, 41, 49). The exact molecular and 
physiological mechanisms are still poorly understood and transformation to a latent stage is 
considered a deliberate biological behaviour (35). Suggestion however include, that 
lymphocytes advance toward active transcription resulting in DNA restoration and active virus 
replication (45) or IE gene promoter being trans-activated in presence of another equine 
Herpesvirus (38). Understanding molecular and physiological factors reactivating the virus are 
vital to comprehend, not only to grasp reactivation and reproduction thereafter, but also for 
epidemiological reasons (43).  
 Immune evasion strategies 
The conventional immune response to epithelial cells becoming infected by a respiratory 
virus begins with the induction of synthesis of interferon (IFN) and interleukin-6 (2). These 
induce the up-regulation of major histocompatibility complex (MHC) class 1 molecules, which 
will bind viral peptides and present them on a virus-infected cell’s surface for recognition by 
Literature Review 
20 
lymphocytes (2). Meanwhile, antiviral resistance in uninfected cells is stimulated by IFN and 
interleukin-6 (2). Pro-inflammatory cytokines are released by macrophages and neutrophils, 
thereby restraining infection, elevating body temperature and recruiting phagocytic and natural 
killer (NK) cells (2). Macrophages will also synthesise IFNα and interleukin-12, which recruit 
further NK cells, which will exert their cytotoxic activity on infected cells (12). NK cells 
synthesise IFNγ, thereby urging the development of the adaptive immune system elicited in 
nasal associate lymphoid tissue and mucosal associated lymphoid tissue (2). The synthesis of 
serum or mucosal antibodies, is induced by viral antigen in lymphoid tissue and are exerting 
their neutralising activity and enhance humoral antibody dependent cell cytotoxicity (ADCC) 
(2). Virus-specific cytotoxic T- Lymphocytes (CTL) are stimulated as well and lyse virus-
infected cells (2). All of these immune effector mechanisms are orchestrated by chemical 
messengers termed cytokines (50, 51).  
Throughout evolution, herpesviruses, including EHV-1, co-evolved with their host and 
developed immune evasion strategies to circumvent each of the effector mechanisms as well as 
the cytokine orchestration (2, 50): during the early phase of infection, customarily, immediate 
protection is provided by the innate immune response. EHV-1 developed strategies to avoid 
this innate or non-specific immune response by tempering with its recognition mechanisms: 
glycoprotein C of EHV-1 binds to a protein within the immune system which usually activates 
the complement pathway and would, under normal circumstances, generate a membrane-attack-
complex. By binding to this protein, this mechanism is blocked.  
EHV-1 circumvents the specific immune response by avoiding the virus neutralizing 
antibodies by becoming intracellular and undetectable rapidly within a few hours after infection 
(43, 50). Moreover, EHV-1 glycoproteins form a complex mimicking an antibody and thereby 
blocking antibody–mediated functions such as complement activation or ADCC (43, 50). EHV-
1 infected peripheral blood mononuclear cells (PBMCs) cannot express the virus on their 
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surface, also leaving these cells undetectable to the immune system and insensitive to ADCC 
and CTL (50). A further evasion strategy of EHV-1 is the interference with NK cell-mediated 
lysis (50): if cells do not present viral proteins or MHC-1 post infection and are rendered 
insensitive to ADCC and CTL recognition and destruction, they may remain vulnerable to lysis 
by NK cells (50). Yet, herpesviruses have developed evasion strategies to avoid detection and 
activation by NK cells as well (50): EHV-1 is able to lower the concentration of MHC-1 
presented on the cell surface, thereby avoiding recognition by NK cells (43, 50, 51). 
Downregulation of MHC-1 has been found to be strain dependent (43): while EHV-1 viral Ab4 
induced significant downregulation, viral strain RacL11 only led to mild downregulation (43). 
Additionally, it is not only virus strain dependent but also locus or allele dependent (43).  
EHV-1 also evades or interferes with the cytokine network by either mimicking 
cytokines or blocking their activity: usually, cytokines act as chemical messengers between 
cells during an innate or adaptive immune answer (43, 50). Upon secretion, they bind to 
cytokine receptors immune cells and induce their functions (43, 50). Viruses might mimic these 
cytokines’ activities by emitting cytokine binding proteins themselves or introducing cytokines 
with inhibitory action on immune cells (50). EHV-1 employed an immune suppressive activity 
in ponies which was believed to be connected with a circulating cytokine, transforming growth 
factor (TGF), exerting multiple inhibitory effects on immune cells (50). Once again, it is the 
viral surface proteins interfering with cytokine mediated immune response (50). Viral surface 
protein gB has the ability to bind to certain chemokines and thereby obstructs interaction with 
receptors, proper signal transduction and migration (43, 50). Ultimately, it will inhibit 





The most widely used and preferred method to confirm EHV-1 infection is polymerase 
chain reaction (PCR) as it has proven to be a reliable, rapid and sensitive method, which does 
not depend on the infectivity of the virus (8, 52, 53). Templates are easily obtained by aseptical 
collection of nasal or nasopharyngeal swabs during viral replication in the nasal mucosa or 
whole blood (EDTA) samples (8, 52, 53). It is recommended to obtain swabs during the acute, 
febrile phase of the disease via the nares (53). Extraction of DNA can be carried out using 
commercially available kits (8, 52, 53).  
Since the nineties researchers have developed a number of PCR protocols: Borchers and 
Slater (54) developed a nested PCR that enabled detection as well as differentiation between 
EHV-1 and EHV-4. Since nested PCR is prone to cross-contamination, the sensitive rapid one-
step protocol developed by Lawrence et al (55) was preferred for differentiation (53). Varrasso 
et al (56) developed a semi-nested multiplex PCR for the distinction of EHV-1 and EHV-4 
before Diallo et al. (57) developed a real-time PCR that could detect EHV-1 without further 
need for restriction enzyme analysis (REA) and was less prone to cross-contamination (57). 
Diallo et al. (58) also developed a multiplex PCR that would differentiate EHV-1 and -4 in a 
single reaction (58), which is the most widely used protocol to date and the current standard 
method at the World Organisation for Animal Health (OIE) reference laboratory (20, 53).  
The next step in PCR diagnosis was the development of strain typing methods to 
differentiate between EHV-1 strains carrying the ORF30 neuropathogenic marker SNP (A2254 
to G2254) to become aware of the risk of neurological complications in outbreak situations (53). 
For this purpose, Allen et al (59) developed a single-step quantitative RT-PCR, that could 
differentiate neuropathogenic from non-neuropathogenic EHV-1 strain (59). Fritsche and 
Borchers (60) also developed a conventional PCR with adjacent REA enabling strain-typing 
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(60). Samples most useful for strain-typing are obtained from aborted foetuses, adult horses’ 
cerebrospinal fluids, placenta, lung and liver, EDTA blood and nasal swabs (61). 
PCR results should be complemented with laboratory isolation of the viral agent in cell 
culture, as PCR may not be sufficient and should be interpreted in correlation to virus isolation 
results (8, 53, 56). For virus isolation techniques, viral material is best obtained from nasal or 
nasopharyngeal swabs obtained during the febrile phase of URT infection, but also from 
placenta, liver, lungs, spleen or thymus of aborted foetuses or corpses, or from the leukocyte 
fraction of acutely infected horses (53). EHV-1 is easily propagated in equine as well as non-
equine cells (53); this ability, viral propagation in non-equine cells, is a convenient method to 
distinguish EHV-1 from EHV-4, since EHV-4 can only be isolated from equine cells (53).  
Other methods aiding EHV-1 detection and diagnosis include direct 
immunofluorescence in cryostat sections of placental and foetal tissue for rapid, yet 
presumptive diagnosis (53). It is not a type-specific method and must be combined with PCR 
or virus isolation (53). Placental and foetal tissue are also useful in post-mortem examination 
when histopathological lesions are observable (53). Histopathological examination can detect 
intra-nuclear inclusion bodies, characteristic for herpesvirus infection as well as miscroscopic 
lesions (53). Serology is another detection method for EHV-1 infection, however, results are to 
be interpreted with care, since most horses are either acutely or latently infected, most horses 
will demonstrate a positive antibody titre (52). Further considerations include vaccination 
history and possible cross-reactivity with EHV-4 (52). A type-specific ELISA has been 
developed but is not available for commercial use yet (62). Other laboratory methods that have 
been used in recent studies include ORF30 sequencing as well as Multi Locus Sequence Typing 
to determine and emphasize diversity of EHV-1 strains encountered (10). 
Some challenges present themselves when diagnosing EHV-1 infection: latently 
infected animals are not shedding infectious virus during the latent stage and the titre may be 
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below detection limits (52). Latent infection cannot be excluded from a seronegative horse (52). 
Moreover, latently infected cells are difficult to obtain since they are harboured in the trigeminal 
ganglion (52). Neurological disease detection is challenging, since there is no one specific 
method to diagnose it (52). However, sampling cerebrospinal fluid of febrile horses and testing 
it for EHV-1 infection would meet this gap of EHM diagnosis in the alive horse, but are 
challenging to obtain (52). Diagnosis of EHM before death is presumptive and must take 
clinical, epidemiological and laboratory results into consideration including the exclusion of 
additional possible origins of neurological disease (52). Similarly to diagnosing respiratory 
disease caused by EHV-1, it must be kept in mind, that several pathogens can cause URT 
disease and the possibilities of detecting subclinical EHV-1 is likely, when in fact another 
pathogen is aetiologically involved in the development of respiratory disease (52). Diagnosis 
of all three main diseases (respiratory, abortion, EHM) should be a combination of clinical 
history, appearance and laboratory results in nasal swabs, blood, and foetal tissue by the 
abovementioned laboratory techniques (52). 
 
3.1.6 Prevention & Treatment 
Biosecurity 
Prevention and control measures can be divided into several sections: biosecurity 
through managerial strategies and vaccination. The goals of managerial control measures are 
either prevention or reduction of the likelihood of outbreaks or limiting transmission of disease 
once outbreak occurs (9). Actions to attain biosecurity goals include isolation of new or 
returning horses arriving at the enterprise before introducing them to resident horses (9, 52). 
Additionally, dividing herds into smaller herds according to age and risk of disease 
development e.g. high shedders such as foals and weanlings, could be advantageous (9, 52). In 
case of an outbreak, strict biosecurity measures have to be put into place as soon as possible to 
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stop virus spreading (8): isolation and quarantine of horses exhibiting clinical symptoms or 
respiratory disease is mandatory to screen and separate potential spreaders or virus shedders 
from unaffected horses (8, 52); enlistment of specific care takers for affected horses and 
provision of staff with distinct supplies such as gloves, boots, coats and provision of a footbath 
at entrance and exit ways (8). If it is not possible to enlist specific care takers, healthy horses 
should be handled before isolated horses, ideally with separate or disinfected equipment (52). 
Disinfection of all tools and buildings should occur on a regular basis (52). Three weeks of 
quarantine is advised once the last reported case is declared free of symptoms (8). Preventing 
recrudesce, minimization of stressors such as transport, incompetent handling, competition for 
food and shelter or insufficient pasture quality must be afforded (9, 52). Additionally, 
development and adherence to a vaccination schedule is strongly advised (9, 52) 
Vaccines 
EHV-1 vaccines were first introduced in the 1960ies (1, 2). Vaccines offer a high degree 
of safety since they stimulate an immune responses that limit virus replication, infection and 
development of disease as well as cell-associated viremia and re-activation of latent virus (1, 2, 
9). Currently licensed vaccines against EHV-1 (see Table 2) have proven to decrease clinical 
symptoms of rhinopneumonitis, viral load in nasal mucus, reduce transmission and aid in the 
prevention of abortions (1, 2, 8, 53). These vaccines are either inactivated vaccines or live 
attenuated vaccines and contain different permutations of EHV-1 targeting envelope 
glycoproteins of the virus (1, 2, 8, 53). Different vaccines have different aims: while one vaccine 
aims to prevent EHV-1 related rhinopneumonitis, another vaccine aims to prevent abortion; a 
few vaccines claim to aid protection against both (2, 53). All currently available vaccines do 
not provide protection against EHM but enable decreased viral load and transmission in a 
vaccinated population, when a schedule of two primers at a one month interval (3 to 4 months 
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concerning the live attenuated vaccines) and half-yearly to yearly booster vaccination is adhered 
to (8, 9, 53). Vaccination schedules can however vary with vaccine (53). 
Table 2: Vaccines licensed for use in Germany by Paul-Ehrlich-Institute (accessed 
30.08.2020). 
Vaccine type Vaccine Marketing authorization holder 
Inactivated BIOEQUIN H® BIOVETA a.s. Czech Republic  
Vetcool B.V. Netherlands 
EquiShield EHV Dechra Regulatory B.V: Netherlands 
EQUIP EHV1,4® Zoetis Deutschland GmbH 
Live 
attenuated 
PREVACCINOL® (only licensed in Germany) MSD Animal Health 
Intervet Deutschland GmbH 
 
Nowadays, inactivated vaccines are widely used and have been reported to elicit a strong 
humoral response by eliciting complement fixation and virus neutralising (VN) antibody 
production (1, 2). Additional advantages of inactivated vaccines are absence of pathogenicity, 
virus replication and subsequent spreading (2). Disadvantageous outcomes of vaccination with 
inactivated vaccines might be local intolerance, fever and the risk remaining of incomplete 
inactivation and subsequent possible infection (2). Despite its wide spread use, inactivated 
vaccines remain problematic since numerous studies have generated controversial results: while 
some report success in reducing clinical symptoms and transmission (63), others report no 
response to vaccination in vaccinated mares and vaccinated foals (64). Moreover, abortion 
storms still occur despite vaccination (65). 
Live attenuated vaccines consist of live microorganisms or genetically modified 
organisms used as vector for the pathogen’s antigen and elicit an immune response similar to 
natural infection (1). They are often administered intra-nasally, to induce a local immune 
response at the primary site of infection (1, 9). Live attenuated vaccines do not establish 
virulence or latency, yet remain immunogenicity and stability; however the risk of reversion to 
virulence is apparent and remains a problem (1).  
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Since currently available vaccines have generated controversial results, they are slowly 
but surely being replaced by other vaccine compositions. Complex-based subunit or split 
vaccines against EHV-1, containing fragments of a pathogen, have been trialled in vitro in 
rodents and produced induction of a humoral response (66). Further vaccine compositions 
currently under investigation include, DNA vaccines (67), non-infectious EHV L particles (68) 
as well as poxvirus-based vector vaccines (69); these are either being trialled or improved, as 
they proofed immune-stimulation.  
Inducing protective immunity against EHV-1 remains a substantial challenge and a 
general conclusion is that protection against EHV-1 will require neutralizing antibodies as well 
as CTL response (9).  
Treatment options 
Despite vaccination schedules, outbreaks might still occur as they cannot completely 
eliminate viral shedding, prevent viremia or the outbreak of EHM (70). On top of that, treatment 
options and their efficacy are currently only of theoretic value. The only currently 
recommended treatment options consist of anti-inflammatory agents as well as antiviral agents. 
Anti-inflammatory medication includes dexamethasone and prednisolone as well as free-radical 
scavengers (52). Aspirin in combination with Vitamin E supplementation has also been 
suggested to be efficacious (52, 71). Other supportive treatments such as antimicrobials can 
also be implemented depending on the individual horse’s condition (52). Antimicrobials have 
been reported to reduce viral loads after infection with Epstein Barr virus, a human Herpesvirus 
(72). 
Antiviral medication in connection with EHV-1 has been proposed to reduce viral 
shedding and found to improve the clinical outcome of EHM (52, 70). Currently available 
antiviral medication for the treatment of Alphaherpesvirinae infection in humans and equines 
are nucleoside analogues (70). These have been found to reduce the convalescent period as well 
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as rate of transmission by decreasing the amount of infectious viral particles (70). The key 
feature of nucleoside analogues is the interaction with the DNA polymerase of the virus, which 
under normal circumstances would be heavily involved in virus replication (70). The nucleoside 
analogues thereby interfere with the replication process by either competing with the natural 
deoxyribose nucleoside triphosphate (dNTP) substrate or being incorporated as alternative 
substrate, both essential mechanisms for antiviral activity (70). Antiviral agents Acyclovir and 
Ganciclovir have been developed in the late 1970s and were highly specific towards herpes 
simplex virus and Varicello Zoster virus (70, 72). Since Acyclovir proved highly efficacious in 
humans, it has been trialled against EHV-1 infection on numerous occasions and also been 
found effective in in vitro studies and proposed to potentially decrease severity of EHM thereby 
increasing survival rates (52, 70, 72). Acyclovir was also successful in reducing the number of 
viral genome copies (72). The next generation, prodrug, of Acyclovir, Valacyclovir has been 
proposed as an alternative nucleoside analogue, with improved bioavailability over acyclovir, 
and may provide an option for treatment of EHM-diseased animals and is currently 
recommended for treatment in the case of an outbreak (52, 70).  
Other antiviral medications have also achieved promising results in in vitro studies: 
Ganciclovir has proven to be efficacious against three differing strains of EHV-1 in vitro and 
presented more effective than Acyclovir overall (70, 72). A further antiviral agent trialled 
against EHV-1, Penciclovir, has limited virus replication in respiratory tissues and reduced 
viremia in murine models in in vitro studies (73). Cidofovir, has shown promising results 
against equid herpesviruses but only in vitro so far (70). Many more compounds are being 
trialled in the antiviral sector such as Foscarnet or Guanosine analogues A-5021, deemed to be 
more potent than Acyclovir (70). Other compounds targeting other replication mechanisms 
such as helicase primase are also under development (70). A recent study also detected 
Spironolactone, a mineralocorticoid and antagonist, to be a potential new inhibitor of EHV-1 
(72). However, no antiviral therapeutic agent has had an effect in horses in vivo yet (70, 72). 
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Results in regards to EHV-1 remain controversial and further support that research and 
protection against EHV-1 will require equine-specific antibodies to elucidate viral mechanisms 
(9).  
 
3.2 Recombinant Antibodies  
3.2.1 Antibody structure and function 
Antibodies are soluble immunoglobulins (Igs) found in blood of all vertebrates. Most 
vertebrates , including the horse, have five main classes of Igs: IgG, IgA, IgM, IgD and IgE 
(74). This classification is based upon differences in structure and function, which is depicted 
in Figure 5 and summarised in Table 3 (74).  
 
 





Table 3: Overview of all five equine immunoglobulin isotypes, including their structure and 
function. 
Immunoglobulin Structure Function 
IgM Monomer, 
Pentamer 
Primary Immune response; agglutinates invading pathogens, 
promotes lysis and phagocytosis  
IgD Monomer B-cell receptor and B-cell eliminator 
IgG Monomer Enhances phagocytosis, neutralizes toxins, inactivates virus, 
kills bacteria, initiates ADCC  
IgA Monomer, 
Dimer  
”Gate-keeper”; prevents further dissemination of pathogen  
IgE Monomer Mediator of allergic reactions, lysis and degradation of 
protozoa, helminths and arthropods; initiates inflammation 
 
These main classes are further divided into subclasses which are differentiated 
according to the number of disulphide bonds connecting antibody structures (74). Each Ig class 
has a certain amount of subclasses, which varies in between species. Horses are outstanding in 
this context since they possess seven subclasses of IgG (75-77). IgG is by far the most versatile 
of all isotypes and can offer all antibody functions such as antigen binding, complement fixation 
and binding to various cells and contributes 75% of all antibodies (77). This versatility is further 
enhanced by the large amount of subclasses, IgG1 to IgG7, which are classified according to 
differences within their genetic composition (75-77). Each subclass retains differing antigenic 
defence properties and thereby takes specific roles in protective immunity (77). For instance, 
IgG1, IgG4 and IgG7 play a key role in limiting the spread and severity of EHV-1 (77).  
 
Figure 7: Map of the equine IGHC region depicting all immunoglobulin isotypes; in particular 
seven subclasses of IgG. Boxes indicate IGHC genes. Map is adapted from Wagner et al. (75) 
and Sun et al. (76). Created with biorender.com. 
The antibody structure is best explained based on the most abundant IgG molecules 
(74): there are four subunits to its Y-shape structure composed of two identical heavy chains 
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and two identical light chains (refer to Figure 7) (74). Light chains either belong to the κ-or λ-
type (74). Constant regions of the heavy chains belong either to α, γ, μ, δ or ε types (74). All 
subunits connected by covalent disulphide bridges in between cysteine remnants and participate 
in building the antibody molecule (74). Some domains of the subunits remain constant, while 
others domains differ from molecule to molecule (74). Hence one refers to the constant region 
and the variable regions of an antibody (refer to Figure 7) (74). The constant region is mainly 
responsible for effector functions such as complement activation, while the variable regions 
(Fv) is mainly responsible for specific antigen binding (74). Forces driving this binding 
procedure are either electrostatic, van-der-Walls forces or hydrogen bonds and are expressed as 
the affinity between antibody and antigen (74). The higher the affinity of an antibody, the less 
the necessary concentration to reach equilibrium, meaning saturation of all antigens by 
antibodies (74).  
 




3.2.2 Antibody development and diversification 
The constant region as well as the variable region of each chain are encrypted by 
individual gene segments (78): variable (V) gene segments, diversity (D) gene segments and 
joining (J) gene segments and constant gene segments ( C ) (78). The heavy chain is usually 
arranged into a VDJC pattern and the light chain into VJC. (76). The variable region is further 
divided into three hypervariable regions, the complementarity determining regions (CDRs) 
embedded in between four stable framework (FRs) regions (78). CDRs are epitope-specific 
paratopes of an antigen, which enclose the epitope of the antigen, similarly to a key-lock-
principal (74).  
The number of gene segments is species-specific and horses stand out among mammals since 
they possess 50 immunoglobulin heavy chain V genes (IGHV) of which 12 are functional 
genes, 33 are pseudogenes and five are ORF, 40 immunoglobulin heavy chain D genes (IGHD) 
genes, 11 immunoglobulin heavy chain C genes (IGHC) genes and eight immunoglobulin 
heavy chain J genes (IGHJ) genes on heavy chain gene loci, contig Un0011, along with two 
further functional IGHV genes, one ORF and one pseudogene on contig Un0038 (75-77). 
Further IGHC are available on chromosome 24 comprising 11 genes (75-77).  
Horses express two different types of light chains, kappa (κ) and lambda (λ); their 
differences lie within their amino acid residue motifs, antigenic properties and chemical 
structure (77). Equine λ light chain genes are located on Equus caballus (ECA) chromosome 8 
and contain 144 IGLV genes, seven IGLJ genes and seven IGLC genes (75-77). Equine IGLV 
genes are divided into two clusters according to their transcriptional orientation, both containing 
functional and pseudogenes. Presenting two clusters is an exclusive feature only occurring in 
equines (75-77). Equine κ light chain genes are located in one cluster on ECA15, containing 60 
IGKV genes, five IGKJ genes and one IGKC gene. Ninety-five percent of equine serum 
antibodies combine λ light chains with heavy chains (77). 
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Due to these large numbers of available V gene segments, horses have enhanced 
combinatorial possibilities: the diversity of antibodies is usually generated by V(D)J 
recombination, during B cell development. Gene segments are surrounded by recombination 
signal sequences (RSSs), which are paired at the beginning of recombination by RAG1 and 
RAG2 proteins, which will induce breaks between RSSs and coding segments. The non-
homologous end joining pathway initiates joining of the ends of different genes segments and 
the RSSs to form coding and signal joints (76). Differing combinations of V, (D) and J segments 
combined with junctional diversity produced during imprecise processing, result in an immense 
repertoire of primary B cell receptors. Additionally, binding affinity of antibodies to antigen is 
improved when B cells undergo somatic hyper mutations (SHM) in form of nucleotide 
substitutions, insertions and deletions; CDRs are considered most prone to SHM (76). Horses 
are hypothesized to develop the majority of antibody diversity through SHM (75). 
 
Figure 9: Germline configuration of equine immunoglobulin heavy and light chain loci, 
including number of gene segments available to horses. IG – immunoglobulin; H - heavy chain, 






3.2.3 Recombinant antibodies and antibody libraries 
Recombinant antibodies 
Ever since Behring and Kitasato (79) discovered that specific binding molecules can be 
extracted from blood (80), antibodies became popular tools in research and diagnostics, due to 
highly specific binding affinities and great stability. Emil von Behring is since considered the 
founder of antibody and antitoxic serum discovery (79). Him and his colleagues immunized 
rats and rabbits in a laboratory setting, extracted serum and tested it in children, suffering from 
diphtheria with favourable results and called it antitoxic serum from thereinafter (81). 
Following this result, the firm Hoechst began to immunize rodents in a factory setting in 1892 
and began production of the antitoxic serum for commercial use (81). Emile Roux and Louis 
Martin were the first to immunize horses and thus enable production of antitoxic serum on a 
large scale (81). In 1901 ,both Behring and Roux (Figure 10) received the Nobel Prize for their 
discoveries (81).  
 
Figure 10: On the left, Emil von Behring. On the right, Pierre Emile Roux producing antitoxic 
sera from horses to treat diphtheria. 
The classical pathway for the generation of antibodies used to begin by immunizing 
laboratory animals with the antigen of interest (80). Within the following weeks, desired 
antibodies were detected in the blood serum of these animals, so called antiserum, was extracted 
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(80). Antisera contain a mixture of different antibody proteins of different binding affinities 
including antibodies present prior to immunisation (80). The mixture consists of polyclonal 
antibodies, which are secreted by several B cells and react against the specific antigen, yet each 
identifying a different epitope of the antibody. 
In the 1970ies Köhler und Milstein (82) developed a new technology to produce 
antibodies: hybridoma technology (80). This technology also relies on immunisation, but 
antibodies are not extracted from blood sera (80). Instead, B lymphocytes are isolated from 
spleens (80). Each B lymphocyte produces only one unique antibody, due to its unique genetic 
arrangement with one single binding affinity (80). Clones of this B lymphocyte will produce 
specific antibodies of a single specificity (80). To initiate this process, B lymphocytes are 
propagated in cell culture in in vitro production, fused with plasma cells and thereby generating 
hybridoma cells (80). Hybridoma cells contain properties of both, the B lymphocyte as well the 
plasma cell (80). They possess the immortality of the plasma cell, and produce specific 
antibodies similar to the B cell (80). Since these antibodies are only specific to one epitope, 
they are called monoclonal antibodies (mAbs) (80). MAbs have been favoured from this point 
on as they can be produced in unlimited amounts, easily standardized and bind to any antigen 
(83). Moreover, hybridoma technology results in immortal cells that can be produced and 
harvested repeatedly (80). However, the fusion of cell types also risks contamination with B 
lymphocytes producing irrelevant antibodies (80). Hence thousands of screening and selection 
procedures are required to test B cell clones for their specificity (80, 83). Additional difficulties 
arise when these mAbs are administered to treat human conditions, as they are exclusively 
murine in origin and could therefore induce a human anti-mouse antibody, also known as 
HAMA reaction, which limits the clinical application, if the antibody therapeutic is not species-
specific (83). Moreover it does not produce high-affinity binders (83).  
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The most recent development of antibody production relies on genetic engineering by 
producing recombinant antibodies (80). Immunisation of laboratory animals is no longer 
necessary, instead antibody fragments are produced in vitro in bacteria or cell culture (80). Once 
antibody fragments are cloned into bacterial systems it is possible to select high-affinity and 
highly specific binders by simulating SHM during an immune response (83). This technology 
is advancing to replace animal immunization or hybridism technology (83). The main focus 
when generating recombinant antibodies is on the antigen binding regions of an antibody (80). 
For higher yield of antibodies, it is preferred to emit the remaining parts of the antibody and to 
retain the intact antigen binding sites while reducing the size of the antibody (83). Newly 
created recombinant antibodies no longer have the natural abilities of an antibody, yet are easily 
fused to other antibodies or enzymes and thereby gain new properties (80).  
Popular recombinant antibody formats include single domain antibodies (sdAb), 
fragment variable (Fv) antibodies, fragment antibodies (Fab), and single-chain-Fragment-
variable (scFv) antibodies. The smallest possible molecule are Fv antibodies. sdAb and Fvs 
consist solely of one variable region, either light or heavy chain (see Figure 10) yet retain 
antigen binding properties (80). Fvs lack covalent binding of both chains, therefore require 
stabilisation (80). Fab antibodies are larger molecules than Fv since they consist of variable 
regions of both chains, connected by respective constant regions (Figure 10) (80). scFv are 
generated when connecting variable regions of both chains by a peptide linker to a single protein 
strand, which retains antigen binding properties of both chains, yet is smaller in size than a Fab 
(Figure 10) (80). ScFv can be expressed in functional form in E. coli cells and be manipulated 
within this system to select high-affinity and highly specific binders (80, 83).  
Smaller molecules such as the scFv antibody fragment, penetrate tumours more easily 
and spend less retention time in kidneys (80). Both properties are desirable when diagnosing 
tumours through immune scintigraphy (80). More advantages of smaller antibody molecules 
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include more rapid blood clearance, lower retention times in non-target tissue and lessened 
immunogenicity (83). The fusion of heavy and light chain genes into one gene, enables a 
straightforward transfection of a functioning antibody fragment into cells and the risk of 
integrating heavy and light chain at separate location within the genome is deleted (83). The 
additional risk of producing differing amounts of protein is thereby eliminated and expression 
of equal amounts in E. coli cells of both chains guaranteed (80). The winning combination of 
small antibody molecules produced in microbial systems enables the production of homogenous 
protein in amounts sufficient for diagnostic and therapeutic purposes (83).  
 
Figure 11: Illustration of recombinant antibody formats compared to a full-size IgG antibody. 





Since the early Nineties, hundreds of antibody libraries have been constructed. This was 
enabled by the advances of sequence data of immunoglobulin genes and the onset of PCR 
technology enabling amplification of antibody repertoires (85). Four different types of libraries 
can be generated: immune, naïve, semi-synthetic and synthetic libraries (86). Each type of 
library is meant to present a vast variety of antibodies against any antigen resembling a natural 
immunoglobulin reservoir (86). Library quality can be assessed by estimating the size, referring 
to the number of individual clones, the diversity among clones, biophysical properties and 
production characteristic (87). 
Immune libraries are usually generated by extracting immunoglobulin genes from 
lymphocytes of already either synthetically or naturally immunized donors (86). The likelihood 
to extract antigen-specific antibody genes and affinity matured clones from immune libraries is 
more likely due to previous exposure to the antigen of interest (86). The first immunised library 
consisted of the immunoglobulin repertoire of mice and was generated by PCR from immunised 
animals (88). Other examples of immunized libraries include a human scFv library (89), a non-
human library derived from macaques, both in the scFv format (90), bovine scFv library (91), 
a rabbit immune library (92), a camel immune library (93) or chicken immune library in the 
scFv format (94). The immunization procedure prior to library generation conveys the 
disadvantages of being time consuming, and bears the risk of lack of efficacy of the vaccine or 
immune response and its unpredictability (86).  
The construction of an immunized library begins with the generation of scFv fragments: 
this entails blood and lymphocyte collection after completed immunization procedures. 
Immunoglobulin genes are extracted from lymphocytes and variable regions are amplified 
using species-specific PCR primers (83). The variable regions of both chains are connected into 
scFv fragments which from thereon contain a linker in between chains (83). Newly generated 
Literature Review 
39 
scFv fragments are ligated into plasmid vectors (80). This step should create a sheer variety of 
differing antibody genes, similar to random combinatorial processes within the natural host 
(80). Plasmid-DNA, now including the scFv fragment, is transformed into a microbial host 
thereby producing antibody libraries of more than 107 individual clones (80).  
Naïve, synthetic and semi-synthetic libraries can be generated independently of 
exposure to antigen (86). Naïve libraries are derived by amplifying naturally occurring 
immunoglobulin genes (86). The amplified heavy and light chain genes are randomly 
recombined to create a recombinatorial scFv library (86). Contrary to scFv of an immune 
library, these scFv have not been exposed to antigen therefore may show lower affinities to the 
antigen (86). Naïve human libraries exist as well in the scFv (89) and the Fab format (95). scFv 
have also been selected from murine naïve libraries (96), camelids such as llama (97) and alpaca 
libraries (98) and production animals such as naïve chicken libraries (99). 
Synthetic and semi-synthetic libraries generate immunoglobulin diversity differently to 
the recombinatorial immune and naïve libraries (85): semi-synthetic libraries contain scFv 
fragments which are created from naturally occurring diversity and artificially inserted diversity 
by inserting oligonucleotides (86). Since the source of antibody genes has not been exposed to 
antigen and parts of the antibody domain are assembled from synthetic oligonucleotides, 
complete or partial sequence degeneracy are introduced into the CDR loops (85). This allows a 
synthetic diversity that is independent of natural biases and redundancies and thereby creating 
a larger amount of antibodies against any desired antigen (85, 86). A well-known example of a 
human synthetic library is Tomlinson I (100). The first human semi-synthetic library was 
constructed in 1992 by Hoogenboom et al (101) and contains a scFv repertoire constructed from 
germline immunoglobulin gene segments rearranged in vitro with synthetic CDR residues (85). 
Since then, efforts have been made to further enhance its diversity by insertion of synthetic 
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oligonucleotides into CDR regions (85). Before diversity was reduced to make up for a lack of 
robustness of antibody fragments (85).  
 
3.2.4 Phage Display 
The isolation of antibody fragments from abovementioned antibody libraries requires in 
vitro antibody selection methods (87). These selection methods have been developed over the 
past decades and include phage display technology, ribosomal display and bacterial, yeast or 
mammalian cell surface display serving as selection methods for antibody-antigen interaction 
(87). Most of these selection methods can be applied to a vast array of antigens and the selection 
conditions can be tailored to the requirements (87). For instance, ribosome display, developed 
by Hanes and Plueckthun (102) serves as a selection method for scFv fragments, but presents 
to be technically challenging and is limited to the scFv format only (87). Yeast display of scFv 
antibodies was developed by Boder and Wittrup (103) in the late Nineties and was proven 
effective by Feldhaus et al. (104), who isolated human scFv from a naïve library. Yeast display 
allows selection of therapeutic format full-size IgG molecules rather than recombinant 
fragments (103, 104). Moreover, it prevents impaired affinities due to antibody format changes 
and is compatible with fluorescence-activated cell sorting (FACS) sorting techniques, which 
allows further selection and parallel assessment of antibody characteristics (87, 103, 104). 
However, a key disadvantage of yeast display are a limited transformation efficiency, thereby 
significantly reducing library size (87).  
Phage display technology promised to overcome these obstacles and has since become 
a commonly used technology to screen antibody libraries (105). The crucial element of phage 
display technology is a linkage between the genotype and the phenotype of a phage, where 
filamentous phages express a foreign protein in their genotype and their phenotype by 
displaying the foreign protein as a phage surface protein (105).  
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Crucial to phage display technology are the characteristics of the bacteriophage itself 
(106). Several bacteriophages are available for phage display technology including the T4 
phage, lambda phage or the filamentous M13 bacteriophage of which the latter has been utilized 
the most (106). M13 phages belong to the group of Ff phages, the only phages that infect E. 
coli cell strains that express an F pilus on which absorption of the phage to the bacterium 
depends on (106). M13 phages are neither temperate nor lytic, but establish a chronic infection 
and repeatedly release new phages (106). The phage itself contains a genome of single-stranded 
DNA consisting of nine genes encoding 11 proteins (106). Five of these proteins are surface 
proteins, six are involved in replication and assembly of the phage (106). Of these five surface 
proteins, it is G3P that is mainly responsible for adsorption purposes during infection (106). 
Infection continues by the N2 domain of the G3P protein of the phage binding to the tip of the 
E.coli F pilus (see Figure 11) (106). Upon binding, the phage is brought closer to the surface of 
the bacterium (see Figure 11) and initiates the G3P-N1 domain to bind to TolA (see Figure 11), 
which functions as an additional receptor on the bacterium’s surface (see Figure 11) (106). 
Three Tol proteins are present within an E.coli cell and all facilitate infection by depolarization 
of the phage coat and translocation of the phage’s ssDNA into the bacterium (106). The phage’s 
ssDNA is then synthesised into a supercoiled dsDNA phage chromosome within the E.coli cell, 




Figure 12: Infection of E. coli cell by M13 bacteriophage. Phage surface protein G3P binds to 
F pilus on E.coli cell. F pilus disassembles and transports phage closer to bacterial surface. 
Phage interacts with TolA receptor and induces uptake of phage genome (106). Created with 
biorender.com. 
Smith was the first to successfully fuse foreign DNA into the M13 bacteriophage (106, 
107). McCafferty et al were the first to fuse scFv fragments to G3P (106, 108). Since then, a 
large variety of differing antibody formats have been employed in the construction of antibody 
displaying phage libraries: human (109), camelid (93) or shark variable regions (110), bovine 
scFv (91), diabodies (111), Fab (95, 111, 112) just to name a few. All were fused to the G3P 
surface protein of M13 (106).   
The actual selection of antibody fragments through phage display technology occurs by 
binding of phages to the desired antigen in a process called biopanning (105, 106). Biopanning 
rounds consist of five main events (105, 106): incubating the phage library on the immobilized 
antigen on a surface (refer to Figure 12) (105, 106). Immobilization of the antigen can be 
achieved by direct coating thus absorption or a capture system e.g. streptavidin-biotin (105, 
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106). The second step consist of phages displaying scFv fragments with affinities binding to 
the antigen, followed by several washing steps to remove low-affinity binders (refer to Figure 
12) (105, 106). Following washing procedures, high-affinity binders are eluted by either pH 
shift or enzymatic treatment (refer to Figure 12) (105, 106). Following elution, helper phages 
are added to aid amplification of eluted infective phages in E. coli cells for a consecutive round 
of biopanning (105, 106). This procedure is usually repeated one to five times to enrich 
specifically binding phage particles and accumulate phages displaying high-affinity binders 
(105, 106). Each round, selection conditions become more stringent by e.g. increasing the 
number of washing steps, decreasing antigen coating concentrations and thereby selecting for 
high-affinity binders (105). Titration of phage output numbers should be monitored to observe 
enchrichment progress and phage ELISA to confirm affinity is increasing (106). 
 
Figure 13: Scheme of scFv phage display selection and screening adapted from Russo et al 
(113). Created with biorender.com. 
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Prior to utilizing phage display technology, antibody or scFv antibody fragments have 
to be ligated into phage compatible phage or phagemid vectors. Since antibody fragments 
displayed on phage vectors are limited by their capacity to be expressed efficiently by E.coli 
cells, a second type of phage vector systems have been developed, the phagemid vector system 
(87). The main difference between phage and phagemid vectors lies in the display of antibodies 
on phage surface: in the phage vector system, each phage carries three to five copies on its 
surface (multivalent display) (87). In the phagemid vector system, each phage carries solely 
one copy on its surface (monovalent) and only less than ten percent of all phages carry an 
antibody fragment on their surface (87). Phagemid vectors are smaller in size and easier to 
clone, resulting in larger library sizes (87). Commonly both systems are used subsequently, 
using the avidity effect on a multivalent display to their advantage in the first biopanning round, 
and increasing the stringency by using a monovalent display in following rounds (87).  
If the antibody library contains fragments within a phagemid system, antibody display 
levels can be increased by applying hyper phages instead of helper phages (87). A helper phage 
carries all genetic information, required for infection, including the surface protein G3P (87). 
A phagemid vector also contains G3P (87). In case of infecting a phagemid library with a helper 
phage, the majority of resulting phages will carry phagemid DNA and incorporate G3P from 
both the helper phage as well as the phagemid (106). This would result in a competition, and 
the wild-type G3P from the helper phage is preferred, yielding bald phages not displaying 
antibody fragments (106). The hyper phage carries a G3P deletion thus preventing a 




3.2.5 Clinical Relevance 
Human medicine 
Recent antibody engineering combined with microbial expression systems provide a 
powerful source of tailor-made antibody therapeutics (83, 114). An important advantage of 
recombinant antibody therapeutics over conventional medication is the agent’s specificity, 
which facilitates precise action, as well as long half-lives, which allow less frequent dosing 
(114). Their species-specificity prevents any adverse reactions to animal constituents within the 
therapeutic agent (115). More than 500 recombinant antibodies are currently being under 
development for several arms of the industry such as biotechnology, immunology, and human 
medicine, for a number of purposes such as immunotoxins, therapeutic gene delivery or 
anticancer intrabodies (see Table 4) (83, 114, 116). The first monoclonal antibody therapeutic 
was Orthoclone OKT3, approved by the Food and Drug Administration (FDA) in 1986 and 
used to treat the rejection of acute transplant rejection (115). Since then many more antibody 
therapeutics have been developed for treatment of human conditions such as cancer, 
autoimmune and inflammatory diseases (115). In the industry of human antibody therapeutics, 
one speaks of the big five, that have had a major influence (115): infliximab (Remicade; 
Centocor, Merck), a tumour necrosis factor specific antibody, adalimumab (Humira, Trudexa, 
Abbott), to treat rheumatoid arthritis, Crohn’s disease and psoriasis, trastuzumab (Herceptin; 
Genentech, Roche), a human epidermal growth factor receptor specific antibody, and 
bevacizumab (Avastin, Genentech) a vascular endothelial cell specific antibody (115). 
Trastuzumab and Bevacizumab are used for the treatment of numerous types of cancer (115). 
The fifth, rituximab (Rituxan/Mabhera; Genentech, Roche, Bioen Idec) is used to treat 
rheumatoid arthritis as well and non-Hodgkin’s lymphoma (83, 115).  
Therapeutic recombinant antibodies exert their effects in either one of three 
mechanisms: the first mechanisms consists of binding or incorporating soluble target particles 
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(e.g. cytokines) before these can reach their target tissue (117). The second mechanism is an 
antagonistic one where the therapeutic agent binds to target receptor cells thereby blocking 
antigen reception and signal transduction (117). Most of human recombinant antibodies 
therapeutics act through this mechanisms (117). The third mechanism consists of binding of the 
therapeutic agent to the infectious agent or cancerous cell and induce cell lysis or clearance by 
ADCC (117). Many recombinant antibody therapeutics are administered by injection to prevent 
enzymatic breakdown and denaturation by stomach environment when administered orally 
(117). Once injected, their half-lives are approximately 20 days, similar to naturally occurring 
antibodies (117).  
The market for monoclonal antibodies has grown exponentially over the past 20 years 
(115) and especially the scFv fragment has been of particular interest, since it retains the 
complete antigen-binding capacity of an antibody and provides a unique molecule particularly 
interesting for cancer treatment due to its reduced size (83). The small molecule, can penetrate 
tumours more easily and more rapidly than full Ab (83). Alternatively, scFv are considered to 
be able to play a role in gene therapy of cancerous patients since they can be delivered to target 
tissue and release their anti-cancerous genes into the affected cell, by infecting it and 





Table 4: Overview of all scFv generated by phage display approved in the EU and USA and 
their applications in human medicine according to www.antibodysociety.org (accessed 
23.10.2020). INN - International non- proprietary name. 
INN  Brand 
name  






Adalimumab  Humira  Humanized 
scFv  
Rheumatoid arthritis  2003 2002 
Belimumab  Benlysta  scFv  Systemic lupus 
erythematosus  
2011 2011 
Blinatumomab   Blincyto Murine 
bispecific 
tandem scFv  














Bladder cancer  NA  In 
review  
Raxibacumab  (Pending) scFv Anthrax infection  NA  2012 
 
Another promising use of recombinant antibodies produced through phage display 
technique is cell classification and characterisation using a technique referred to as phage-
antibody next generation sequencing (PhaNGS) (116). It will allow assessment of surface 
protein changes in diseased cells and identification of new biomarkers and drug targets (116). 
Moreover, structural studies like to employ antibodies to aid in imaging procedures such as 
electron microscopy, cryo-electron microscopy and X-ray crystallography (116).  
 Veterinary medicine 
The majority of recombinant antibodies have been designed for human use, yet advances 
in recombinant antibody design have also been made in veterinary medicine as diagnostic, 
prophylactic or therapeutic drugs to treat or prevent autoimmune diseases or cancerous diseases 
(84). The trend goes towards production animals such as pigs, cows and poultry, but also 
towards companion animals such as dogs and cats.  
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Porcine recombinant antibodies are under development for diagnostic and therapeutic 
purposes. For instance, recombinant antibodies are designed to diagnose porcine circovirus type 
II (PCV II) infection, classic swine fever virus (CSF) infection and bacterial infections (84, 
118). A sdAb was developed to detect PCV 1 and yielded promising results, as no cross-
reactivity was noticed (119). Further porcine recombinant antibodies have been developed for 
the diagnosis of classical swine fever virus and showed promising results in vivo in regards to 
neutralization of the antigen (119). Several porcine recombinant antibodies are being 
investigated for treatment purposes of numerous porcine infections with the majority of efforts 
directed toward porcine reproductive and respiratory syndrome (PRRSV), nowadays known as 
Betaarterivirus 1 (120-122). One particular scFv-Fc fragment was designed to fuse with PRRSV 
structural proteins and improved humoral and cellular response, but not fully induce protective 
immunity (122). Additional porcine recombinant antibodies are researched for their effect on 
infections with foot and mouth disease virus (FMDV), African swine fever virus (ASFV) and 
bacterial infections of which one sdAb proved successful in introducing a reduction of clinical 
symptoms and transmission (123).  
Bovine recombinant antibodies have been developed for diagnostic purposes of FMDV, 
Mycobacterium bovis (M. bovis), bovine spongiform encephalopathy (BSE) and bovine 
immunodeficiency virus (BIV) (84, 124). A scFv fragment designed for detection of FMDV 
has proven successful in the differentiation of vaccinated and infected animals with FMDV 
(125). However, this particular scFv was not derived from bovine immunoglobulin genes, rather 
chicken and Tobacco plants genes serving as detectors of the 3ABC gene of FMDV (125). A 
further scFv developed meant to improve diagnosis of M. bovis was also not entirely of bovine 
origin, since it had been fused with a heavy chain derived from chickens to improve its stability 
while retaining functionality (84). A further chicken scFv was developed to diagnose BSE and 
other prion infections (126). However, a scFv produced to diagnose BIV was generated entirely 
from bovine Ig genes and provided more sensitive results than the gold standard mAb (127). 
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Bovine recombinant antibodies for treatment purposes were designed for bacterial infections, 
enterotoxigenic E. coli (ETEC), bovine mastitis and S. aureus infections. One of these bovine 
recombinant antibodies, a scFv, was evaluated in vivo and resulted in reduced fluid 
accumulation, which would otherwise be indicative of an ETEC infection (84).  
scFv fragments have been developed for poultry species to diagnose and treat diseases 
like avian influenza virus (AIV) (128), Newcastle disease virus (NDV), infectious bursal 
disease virus (IBDV) and avian coccidiosis (129). Throughout, scFv antibodies showed higher 
sensitivities and potential as detection tool in ELISA and WB (84). Further avian recombinant 
antibodies for immune-prophylaxis showed reduced viral titres not only in vivo but also in ovo 
(130). Another avian recombinant antibodies showed neutralizing effects against NDV (131).  
Concerning companion animals, a number of canine recombinant antibodies are 
currently under investigation to treat tumour patients, inflammatory diseases or dermatitis (84). 
In terms of tumour treatment, advantage was taken of high similarity between human epidermal 
growth factor receptor and its canine homologue and two recombinant antibodies with cross-
reactivity generated; both seemed suitable for detection of malignant cells when tested to detect 
breast cancer cells (132).  
There is one fully licensed and commercially available canine recombinant antibody 
product, Lokivetmab (Cytopoint™) produced by Zoetis for the treatment of canine allergic 
dermatitis (117). Lokivetmab exerts its action by binding to soluble antigenic targets thereby 
preventing it from reaching their target cell receptors and tissues (117). It is a caninized anti-
interleukin-31 (IL-31) mAb which neutralizes soluble IL-31 which has shown to be involved 
in the development of atopic dermatitis (117). Its efficacy and safety was demonstrated in 
clinical studies, who reported no hypersensitivities and only mild discomfort upon the 
application of Lokivetmab (133). Next to this, a further therapeutic recombinant antibody for 
dogs has been developed to alleviate osteoarthirits-related pain, the mAb Renevetmab targeting 
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nerve growth factor (NGF). Its efficacy and safety have been assessed and deemed sufficient 
(134). A feline counterpart also relieving the animal of osteoarthirits-related pain has been 
developed and assessed, Frunevetmab (135). Both recombinant antibody therapeutics promise 
a great advance in pain-relieve therapy for dogs and cats but are not available for use yet.  
In the equine sector only limited efforts have been made to identify equine recombinant 
antibodies as diagnostic or therapeutic agents. 20 years ago one study utilized phage display 
technology to identify an equine full-size IgG molecule against EHV-1 for diagnostic purposes 
(136). Other than that merely human-like or for human purposes designed recombinant 
antibodies have been investigated against equine viruses that also affects humans such as 
Western Equine Encephalitis Virus (137) or for non-human primates suffering from 
Venezuelan Equine Encephalitis Virus infection (138). In future, the use of recombinant 
antibodies to control or treat human as well as animal diseases will be a reality and become a 
part of the pharmaceutical economy. Currently investigated recombinant antibodies for 
veterinary purposes are summarised in Table 5.  
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 Table 5: Summary of recombinant antibodies under imvestigation for potetntial use in 
veterinary medicine. Adapted from Bustamante-Córdova et al. (84).  
Application Ab format Target Species Indication 
Diagnosis scFv Pig B .hyodysenteriae  
 scFv Cow FMDV 
 scFv Cow FMDV 
 scFv Cow BIV 
 scFv Cow M. tuberculosis  
 scFv Chicken AIV 
 scFv Birds NDV 
 scFv Chicken IBDV 
 scFv Chicken E. tenella, avian coccidiosis 
Prophylaxis scFv-Fc Pig PEDV, PRRSV 
 scFv-Fc Pig PEDV 
 scFv-Fc Pig PEDV 
 scFv Pig PEDV 
 scFv Pig pAPN 
 scFv Pig ASFV 
 scFv Cow ETEC 
 scFv Cow ETEC 
 scFv Cow ETEC 
 scFv Chicken IBV 
 scFv Chicken IBDV 
 scFv Chicken IBDV 
 scFv Chicken NDV 
 scFv Chicken E. tenella 
 scFv Chicken E. tenella 
 scFv Sheep Rift Vally Fever virus 
Therapeutics scFv Cow S. aureus, Bovine mastitis 
 scFv Chicken Avian Influenza virus 




3.3  Aim of the thesis 
The aim of the thesis is to generate an equine-specific antibody library to meet the lack 
thereof within veterinary medicine and research. The first aim was to construct scFv fragments 
based on Ig genes of an immunized donor and utilizing a species-specific PCR primer set. 
Equine scFv fragments were then ligated into a phagemid vector and the library assembled 
using phage-competent E.coli cells. This would lay the groundworks for phage display 
screening procedures against any desired equine pathogen. We chose to screen against EHV-1 
due to its high infectivity, ubiquitous occurrence and detrimental effects on equine health and 
equine-related economies. The isolated anti-EHV-1 scFv fragment was propagated and its 
properties further characterised in terms of affinity to EHV-1.  
The thesis will contribute to the development of novel, therapeutic recombinant antibody 
solutions for horses and presents a starting point for further developments in the search for 
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4.1.1 Abstract  
Species-specific recombinant antibodies including single chain fragment variable (scFv) 
immunoglobulins are an increasingly popular tool to prevent or treat veterinary conditions. The 
ability to assemble them to match any given epitope makes them particularly versatile. 
Moreover, recombinant antibodies can be produced fast, inexpensively and they can be stored 
up to several years under cooled or frozen conditions. In this study, we design recombinant 
equine antibodies in the scFv format and construct a scFv immunoglobulin library, generated 
from a donor previously immunized against EHV-1 (strain live-attenuated RAC-H and 
inactivated strain 438/77). We started with a detailed analysis of the equine immunoglobulin 
sequence data available in the NCBI GenBank using BLAST analysis. Subsequently, universal 
primer sets for the construction of an equine scFv were designed to amplify variable antibody 
domains of an immunized Hanoverian warmblood gelding. Variable domains were fused by 
splicing-by-overlap-extension PCR (SOE PCR) using primer sets containing a glycine-serine 
linker sequence as overlap sequence. Fused variable domains were ligated into a phagemid 
vector and transformed into phage display compatible E. coli cells with a transformation 
efficiency of 4.8x108 cfu/µg. Subsequent sequence analysis revealed g3 signal sequence, equine 
variable region of the heavy chain, the linker to the light chain variable region, and ligation into 
phagemid vector pCANTAB 5E in one reading frame. Presence of conserved key amino acid 
residues Cys, Trp and Leu was confirmed. A 3D model of an exemplary protein structures was 
calculated and revealed compact molecule showing crucial antigen binding structures. These 
products provide the basis for the isolation of high-affinity, neutralizing scFv molecules by 
phage display against any desired antigenic site e.g. EHV-1. 






Since the 19th century, equine antibodies have played a key role in human and 
veterinary immunology. Equine antisera have aided the therapy of numerous human diseases 
such as tuberculosis and pneumonia (1-6), organ transplants, autoimmune diseases (7, 8), or 
poisoning (9). Moreover, hyper-immune equine sera have been used to treat and prevent equine 
diseases such as neonatal foal septicaemia (10). Similar to humans, horses also express all five 
immunoglobulin isotypes and are heterotetrameric in structure consisting of two identical heavy 
chains and two light chains (11). Equine immunoglobulin heavy and light chains are 
functionally and genetically divided into variable and constant domains; the constant domain 
of the heavy chain retains effector functions (11). The variable domains of either chain are 
created in the natural host by random fusion of variable (V), diversity (D), and joining (J) gene 
segments; the variable domain of the heavy chain is subsequently combined with a constant 
region gene (C) (11). The variable domains of heavy and light chain contain complementary 
determining regions (CDR) which serve as perfect counterparts to various antigen epitope 
regions, as these are highly diverse. Immunoglobulin diversity within a species and an 
individual is generated by combinatorial and junctional processes such as imprecise joining of 
gene segments, non-templated (N) or palindromic (P) nucleotide insertions or somatic hyper-
mutations and is further enhanced by gene conversions and isotype switches (11). Horses in 
particular have enhanced combinatorial possibilities as they feature large numbers of available 
V gene segments: with 50 immunoglobulin heavy chain V genes (IGHV; 12 functional genes, 
33 pseudogenes, and 5 open reading frames (ORF)), 40 IGHD genes, eight IGHJ and 11 IGHC 
genes on heavy chain gene loci contig Un0011 along with two additional functional IGHV 
genes, one ORF and one pseudogene on contig Un0038 (12). Only the African elephant 
featuring 41 IGHD genes and the guinea pig with 87 IGHD genes are comparable (11). Equine 
IGHC genes are available on chromosome 24 comprising 11 genes, which is only comparable 
to pigs, who are featuring the same number of IGHC genes (11). Yet another unique property 
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of horses are the characteristics of equine immunoglobulin IgG. IgG is by far the most versatile 
of all isotypes and can offer all antibody functions such as antigen binding, complement 
fixation, and binding to various cells and contributes 75% of all antibodies (11). Horses possess 
7 subclasses, IgG1 to IgG7 which are classified according to differences within the C domain 
genes (11, 12). Each subgroup retains differing antigenic defence properties and thereby takes 
specific roles in protective immunity (11). IgG1, IgG4, and IgG7 play a key role in limiting the 
spread and severity of EHV-1 (11). The genetic variation in C genes are best explained by 
multiple duplications, gene conversions or cross overs, which is yet another exclusive 
phenomenon in horses (11).  
Not only heavy chains contribute to immunoglobulin diversity, but also light chains 
increase and contribute to it (11). Equines express two different types of light chains, kappa (κ) 
and lambda (λ); their differences lie within their amino acid residue motifs, antigenic properties 
and chemical structure (11). Equine λ light chain genes are located on Equus caballus (ECA) 
chromosome 8 and contain 144 IGLV genes, seven IGLJ genes, and seven IGLC genes (11). 
Equine IGLV genes are divided into two clusters according to their transcriptional orientation, 
both containing functional and pseudogenes; presenting two clusters is yet another unique trait 
only occurring in horses (11). Equine κ light chain genes are located on ECA15, containing 60 
IGKV genes, organized into one cluster, five IGKJ genes and one IGKC gene. Even though 
both types are present, 95 % of equine serum antibodies combine λ light chains with heavy 
chains (11).  
Even though the use of equine sera to treat human conditions has been successful and 
would appear to offer a great variety of possibilities to treat veterinary as well as human 
conditions alike, a major disadvantage in species other than horses remains that foreign proteins 
are immunogenic and can result in the formation of anti-species antibodies. Equine sera do, 
therefore, not provide a feasible option where repeated immunoglobulin therapy is indicated 
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(13, 14). To circumvent this problem, designing species-specific recombinant antibodies has 
become a reliable method of generating more compatible antibody therapeutics (15). Species-
specific antibody libraries contain the immunoglobulin repertoire of all available 
immunoglobulin data of one species. Recombinant antibody formats considered favourable for 
this purpose have been trialled on numerous occasions such as Fab, dAb and Diabody (16), yet, 
the single-chain-Fragment-variable antibody (scFv) format has proven to show outstanding 
tissue penetration characteristics owing to its smaller size in comparison to other antibody 
formats and reduced immunogenicity in vivo compared to non-species-specific antibodies (17-
19). The scFv antibody consists of the variable domains of an antibody heavy chain (VH) and 
light chains (Vλ and Vκ). Both domains are generated by PCR utilizing comprehensive primer 
sets, designed taking all available immunoglobulin data into consideration. Once domains are 
amplified they are connected by a peptide linker in a splicing-by-overlap extension PCR (SOE-
PCR).  
In humans, recombinant scFv have already been established and used for therapeutic 
intervention (20). Several studies constructed recombinant antibodies from animal species such 
as cattle (21), chicken (22), mice (23), rabbit (24), macaques (25), sharks (26), and camels (27), 
partly for human medicinal use or veterinary use. Currently, two veterinary therapeutic antibody 
agents for the treatment of autoimmune diseases and osteoarthritis-related pain for dogs and 
cats are available (28). In addition, despite the vast availability of equine immunoglobulin gene 
data and genomic organisation, (11, 29-40), a primer set comprising the equine immunoglobulin 
repertoire for the construction of recombinant equine scFvs is still not available. In this study, 
we aimed to establish and validate a primer set for the construction of an equine 




4.1.3 Material and Methods 
Animal immunization 
An 18-year old Hanoverian gelding received three intra muscular EHV vaccinations: 
live-attenuated Prevaccinol® (EHV-1, Strain RAC-H; Intervet Deutschland GmbH, 
Unterschleißheim, Germany), and inactivated Equip EHV1,4 (EHV-1, Strain 438/77; EHV-4 
Strain 405/76; Pfizer, Berlin, Germany) prior to the study as part of a standard immunization 




Figure 1: Schematic overview of all processes involved in constructing the equine 
immunoglobulin library. V – variable gene segment, D - diversity gene segment, J – joining 
gene segment, C – constant gene segment. VH – variable domain of heavy chain. Vλ - variable 





Ethics, blood collection and lymphocyte isolation 
An EDTA-blood sample was collected during routine titre determination under 
consideration of the German codex “Good Veterinary Practice” (Bundesverband 
Praktizierender Tierärzte, Frankfurt am Main, Germany). The study has been approved by the 
Animal Welfare and Ethics Committee of the Georg-August University of Goettingen (Ref E3-
20). 
Density gradient centrifugation using Ficoll Paque Plus (GE Healthcare, Chalfont St. 
Giles, UK) was used to isolate peripheral blood mononuclear cells (PBMCs; see Figure 1) from 
EDTA-blood according to manufacturer’s protocol. Cells were washed with PBS (12 mM 
Phosphate, 137 mM NaCl, 2.7 mM KCl, pH 7.4; Carl Roth GmbH&Co.KG, Karlsruhe, 
Germany) and erythrocytes were removed during incubation in red blood cell lysis buffer (12 
mM NaHCO3, 155 mM NH4Cl, 0.1 mM EDTA; Carl Roth GmbH&Co.KG, Karlsruhe, 
Germany) for 5 min on ice. Isolated PBMCs were kept in liquid nitrogen until further use. 
Total RNA isolation and cDNA synthesis 
Total RNA was obtained from PBMCs (see Figure 1) using the RNeasy Mini Kit as 
described by the manufacturer (Qiagen, Hilden, Germany). Quantity and purity were verified 
by UV absorbance at 260 and 280 nm in a NanoDrop 1000 spectrophotometer (peQLab 
Biotechnology GmbH, Erlangen, Germany). Reverse transcription (see Figure 1) was achieved 
using the SuperScript III first-strand Synthesis Supermix (Invitrogen, Carlsbad, USA). Master 
mix 1 for the reverse transcription reaction contained 1 µl Annealing Buffer, 1 µl of random 
hexamers (50 ng/µl) and 6 µl total RNA. Master mix 1 was denatured at 65°C for 5 min 
followed by the addition of 10 µl of 2X First-Strand Reaction Mix and 2µl SuperScript® 
III/RNaseOUT™ Enzyme Mix. RNA was transcribed at 25°C for 10 min, incubated at 55°C 





Primer design was established according to published equine immunoglobulin isotype 
IgG, subtypes IgG1-7, sequences and database entries. Using BLAST software (41), the 
database was screened for variable, joining, and first constant immunoglobulin gene segments 
of equine heavy and light chain sequences. Homologue sequences were aligned and analysed 
for similarity; duplicates were eliminated. Primers were designed using the resulting sequence 
alignment. Wobble bases were used in case of single nucleotide polymorphisms. Forward 
primer sets for PCR 1 were designed to bind to the 5´ end variable gene segments of the 
respective chains (sense). Reverse primer sets of the heavy chain binds to the 3´end of the first 
constant gene segments of IgG heavy chain isotypes (antisense). Reverse primers of both light 
chains bind to the 3´end of the respective constant regions. Generated VH fragments were 
expected to be 650 - 700 bp in length, while Vλ light chain fragments were expected to be 
approximately 600 bp in length and Vκ light chain fragments to range between 350 and 400 bp. 
Forward primer sets for PCR 2 of the heavy chain remained the same as for PCR 1. The reverse 
primer set were designed to bind to the joining region of VH and contain an overhang of 30 
nucleotides coding partially for the N-terminal part of the (Gly4Ser)3 linker sequence. Forward 
primer sets for PCR 2 of the light chains were designed to anneal at the 5`end of variable 
domains and contain an overhang of 36 nucleotides coding for the C-terminal part of the 
(Gly4Ser)3 linker sequence. Reverse primers of the light chains were generated to bind to the 
3`end of light chain joining regions. All generated fragments of all chains after PCR 2 were 
expected to be approximately 400 bp long. The (Gly4Ser)3 linker sequence is 45-nucleotide 
sequence (CAG GTG GAG GCG GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG 
GAT) and connects VH with the Vλ or Vκ during SOE-PCR. Primers for the re-amplification 
of the SOE-PCR fusion product were designed to contain overhangs coding for restriction 
enzyme sites SfiI (GCG GCC CAG C) and NotI (GCG GCC GC) for ligation purposes. Figure 
1 shows a schematic overview of all gene segments amplified during all PCRs. Primers were 
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synthesized by Eurofins (Ebersberg, Germany). All sequences that were used for the primer 
design, are available in the Table S1.  
Amplification of the equine heavy and light chain variable domains 
Prior to this study our research group confirmed that all designed primers yield 
amplification products when combined individually. Out of 13 primers designed to bind to VH, 
only one forward primer, EqVH12_BACK, failed to amplify VH fragments when combined 
with reverse primer GSP2. Ten primers were designed to bind to the Vλ. EqVL9_BACK and 
EqVL10_BACK failed to produce amplification products when combined with IGLC1-7_FOR. 
EqVK6_BACK; EqVK8_BACK and EqVK12_BACK failed to amplify Vκ in combination 
with JK1-5_FOR. Primers that failed to amplify variable domains were excluded from this 
study. Primers that successfully amplified variable domains were pooled and PCR conditions 
optimised to determine suitable conditions for primer sets used for library construction. 
Each pooled forward primer set (e.g. PCR1Hpool_FOR, PCR1Kpool_FOR) was 
combined with the respective reverse primer set and reactions were run in a 12-temperature-
step (50°C - 70°C) gradient PCR cycler (Tprofessional, Biometra, Goettingen, Germany) to 
ascertain the most suitable annealing temperatures. Moreover, master mixes were prepared with 
differing concentrations of dimethyl sulfoxide (DMSO; Carl Roth GmbH&Co.KG, Karlsruhe, 
Germany), 0 %, 2.5 %, 5 %, and 7.5 % to determine optimal binding conditions for the primer 
pools. As a positive control for effective RNA isolation and reverse transcription into cDNA, 
the housekeeping gene equine glycerine-3-phosphate-dehydrogenase-housekeeping gene 
(eGAPDH; eGAPDH_for: 5’- TTG GCC GTA TTG GGC GCC CTG -3’; eGAPDH_rev: 3’- 
GGC AGG TCA GAT CCA CG -5’) - was amplified and generated a fragment of 675 bp in 
length as well as a negative control (HPLC water; Carl Roth GmbH&Co.KG, Karlsruhe, 
Germany) to ascertain pureness of components. All amplifications were processed in a T3000 
cycler (Biometra, Goettingen, Germany). Amplification was evaluated by agarose gel 
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electrophoresis on a 1% gel and DNA sequencing at a commercial sequencing facility (SeqLab, 
Goettingen, Germany). 
cDNA encoding the V, D, J, and C gene segments of VH as well as the V, J, and C genes 
of Vλ and Vκ were amplified using the primers designed for PCR 1 and are summarised in 
Table 2. The master mixes for VH/Vλ/Vκ contained 5 µl 10x Standard Reaction Buffer with 
MgCl2 (Biotools B&M Labs S.A., Madrid, Spain), 10 µM forward primer pool, 10 µM reverse 
primer pool , 2,5 % DMSO (Carl Roth GmbH&Co.KG, Karlsruhe, Germany), 10 mM dNTPs 
(Carl Roth GmbH&Co.KG, Karlsruhe, Germany), 1 U/µl DNA Polymerase (Biotools B&M 
Labs S.A., Madrid, Spain) and 2 µl cDNA. The overall reaction volume was adjusted to 50 µl 
with HPLC water (Carl Roth GmbH&Co.KG, Karlsruhe, Germany). The PCR was processed 
in a T3000 cycler (Biometra, Goettingen, Germany) and the cycling conditions for PCR 1 were 
as follows: 10 min at 95°C, followed by 35 cycles of 95°C for 1 min, 56°C for 1 min and 72°C 
for 2 min. The reaction was finalized with an elongation step at 72°C for 10 min. PCR products 
were purified using Min Elute Gel Extraction Kit (Qiagen, Hilden, Germany) according to 
manufacturer’s instructions to avoid contamination from side products during further use. The 
quantity and purity of the extracted DNA fragments were measured in a NanoDrop 1000 
Spectrophotometer at UV absorbance of 260 and 280 nm. 
Amplification of equine VH, Vλ and Vκ with linker overhang 
As previously described, PCR 2 amplified the V, D, and J gene segments of VH as well 
as the V and J gene segments of Vλ and Vκ. Primers comprise an overlapping 45 nucleotide 
sequence translating a (Gly4Ser)3 linker to facilitate the joining of the variable regions in a 
subsequent PCR step and are summarised in Table 3. The master mix for PCR 2 is constituted 
of 10 µl 5x GC Reaction Buffer with MgCl2 (Peqlab, Erlangen, Germany), 10 µM forward 
primer pool, 10 µM reverse primer pool, 10 mM dNTPs ,1 U/µl KAPA Hifi Polymerase 
(PeqLab, Erlangen, Germany) and 25 ng purified DNA of PCR 1. The reaction volume was 
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adjusted to 50 µl with HPLC water. PCR 2 reaction began with 5 min at 95°C, followed by 30 
cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 45 sec. Final elongation was appointed 
at 72°C for 10 min. PCR 2 was also run in a T3000 cycler (Biometra, Goettingen, Germany). 
PCR products of correct size were extracted and purified using the Min Elute Gel Extraction 
Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. The quantity and 
purity of the extracted DNA fragments were measured at UV absorbance of 260 and 280 nm in 
the NanoDrop 1000 Spectrophotometer. 
Generation of single chain antibody fragments VH - Vκ and VH - Vλ  
The scFv fragments VH - Vκ and VH - Vλ were generated by SOE PCR. The linker 
overhang introduced in PCR 2 served as overlapping complementary sequence and recombines 
the VH with Vκ and VH with Vλ, respectively, during an initial recombination step of the SOE 
PCR. The fused product was re-amplified using primer sets that contained restriction enzyme 
sites for SfiI and NotI (Table 4). These restriction enzyme sites are compatible with restriction 
enzymes sites of the phagemid vector pCANTAB 5E, which was used to construct the equine 
scFv immunoglobulin library. 
For the first recombination step, 300 ng of gel-purified VH PCR 2 product was 
combined with either 300 ng of Vλ PCR 2 product for VH – Vλ recombination or 300 ng of Vκ 
PCR 2 product for VH – Vκ recombination. The reaction mix was constituted of 5 µl 10x 
Standard Reaction Buffer (Biotools B&M Labs S.A., Madrid, Spain) with MgCl2, 2.5% DMSO, 
10 mM dNTPs, 1 U/µl DNA polymerase (Biotools B&M Labs S.A., Madrid, Spain) and 
reaction volume was adjusted with HPLC water to 50 µl. The recombination was initiated at 
95°C for 10 min, 15 cycles of 95°C for 1 min, 60°C for 1 min, 72°C for 2 min and a final 
elongation step at 72°C for 10 min. SOE-PCR was run in a T3000 cycler (Biometra, Goettingen, 
Germany). The recombination product was analysed by gel electrophoresis on a 1 % agarose 
gel and had an expected size of approximately 800 bp and was purified using QIAquick PCR 
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Purification Kit according to the manufacturer and re-amplified with primer pools containing 
the restriction cleavage sites for SfiI and NotI (Table 4). The reaction mix contained 5 µl 10x 
Standard Reaction Buffer with MgCl2 (Biotools B&M Labs S.A., Madrid, Spain), 10 µM 
forward primer pool, 10 µM reverse primer pool, 2.5 % DMSO, 10 mM dNTPs, 1 U/µl DNA 
polymerase and 25 ng of recombination product for VH - Vλ scFv fragments and 50 ng for VH-
Vκ scFv fragments. The final reaction volume was adjusted to 50 µl with HPLC water. Re-
amplification SOE PCR was initialized at 95°C for 10 min, followed by 30 cycles of 95°C for 
1 min, 67°C for 1 min, 72°C for 2 min and a final elongation step at 72°C for 10 min. 
Construction of scFv library in pCANTAB 5E 
The phagemid vector pCANTAB 5E (GE Healthcare, Chalfont St. Giles, UK) was 
utilized to construct the immunized equine scFv library. This vector contains insertion sites 
flanked by the restriction enzyme cleavage sites for SfiI and NotI and followed by an E-Tag 
sequence and an amber stop codon. The stop codon separates the E-Tag sequence from the fd-
phage-gene 3, which codes for the minor coat protein III of the phage M13. The phagemid 
vector was extracted from dam-/dcm- E. coli cells (New England Biolabs GmbH, Frankfurt, 
Germany) using the Qiagen Spin Miniprep Kit (Qiagen, Hilden, Germany). scFv-insert DNA 
and vector DNA were cleaved with SfiI (New England Biolabs GmbH, Frankfurt, Germany) 
and NotI (New England Biolabs GmbH, Frankfurt, Germany) prior to ligation according to the 
manufacturer’s guidelines with some minor modification as described in Protocol S1. Digested 
scFv-insert DNA and dephosphorylated vector DNA were purified using the Monarch® PCR & 
DNA Cleanup Kit (New England Biolabs GmbH, Frankfurt, Germany) and ligated into a 
circular plasmid at a molar ratio of 1:5 (vector : insert). The ligation reaction mix contained 1 
µl T4 Ligase (New England Biolabs GmbH, Frankfurt, Germany), 2 µl T4 Ligation Buffer 
(New England Biolabs GmbH, Frankfurt, Germany), 100 ng of vector DNA and the appropriate 
concentration of insert DNA. The reaction was incubated overnight at 16°C and heat inactivated 
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at 65°C for 90 Minutes. Monarch® PCR & DNA Cleanup Kit (New England Biolabs GmbH, 
Frankfurt, Germany) was used to purify and concentrate ligated DNA by removing salts and 
enzyme residues prior to electroporation. Purified, ligated DNA (100 ng) was transformed into 
Phage Display Electrocompetent TG1 cells (Lucigen Corporation, Middleton, USA). 
Electroporation was conducted using the BIO-RAD Gene Pulser® (Bio-Rad Laboratories 
GmbH, Munich, Germany) in a 1 mm electroporation cuvette (Bio-Rad Laboratories GmbH, 
Munich, Germany). Transformation was achieved using an electro pulse of 1,800 Volt, 100 
Ohm, a capacitance of 50 µF and a TC of 5.0 ms. Subsequently, the transformed bacterial cells 
were grown in a 15 ml culture tube for 1 hour at 37°C in Recovery Medium (Lucigen 
Corporation, Middleton, USA). Transformation reactions were titrated in log10 steps until 10
-6, 
adding 100 µl into 900 µl 2x TYGA medium (16 g tryptone, 10 g yeast extract, 20 g glucose, 5 
g NaCl, 100 µg/ml ampicillin, ad 1 L sterile water; all from Carl Roth GmbH & Co.KG, 
Karlsruhe, Germany), plated onto 2xTYGA agar plates (16 g tryptone, 10 g yeast extract, 20 g 
glucose, 5 g NaCl, 100 µg/ml ampicillin, 15 g agar-agar, 100 µg/ml ampicillin, ad 1 L sterile 
water; all from Carl Roth GmbH & Co.KG, Karlsruhe, Germany) and propagated overnight at 
37°C. The dilution series of transformed bacteria on 2xTYGA agar plates was utilized to 
calculate the transformation efficiency (TE). Only successfully transformed bacteria 
propagated on these plates, since these bacteria are resistant to ampicillin. Bacteria were scraped 
from the plates using a Drigalski spatula with 6 ml 2xTYGA medium including 15% glycerol 
(Carl Roth GmbH&Co.KG, Karlsruhe, Germany). The bacterial glycerol stock was aliquoted 
to 1 ml and kept at -80°C. Ten clones of each sublibrary were analysed to encompass full-length 
inserts by colony PCR and Sanger sequencing of PCR products. Single colonies were picked 
for the colony PCR, and immersed into a 20 µl master mix made up of 2 µl 10x Standard 
Reaction Buffer with MgCl2 (Biotools B&M Labs S.A., Madrid, Spain), 10 µM primer R1 (5’-
CCA TGA TTA CGC CAA GCT TTG GAG CC-3’) and primer 10 µM R2 ( 3’-CCT TTC TGC 
TGT TTT GAA ATC TAG C-5’; both synthesised at Eurofins Genomics Germany GmbH, 
Studies performed 
79 
Ebersberg, Germany), 10 mM dNTPs (Carl Roth GmbH&Co.KG, Karlsruhe, Germany), 1 U/µl 
DNA polymerase (Biotools B&M Labs S.A., Madrid, Spain); the final volume was adjusted 
with HPLC water (Carl Roth GmbH&Co.KG, Karlsruhe, Germany). PCR ran in a T3000 cycler 
(Biometra, Goettingen, Germany) under the following settings: 94°C for 10 min, 30 cycles at 
94°C for 1 min, 55°C for 1 min and 72°C for 2 min, followed by 72°C for 15 min. Individual 
clones that showed bands of expected size were proven to contain an ORF encoding full-size 
scFv fragments by sequencing utilizing primers R1 and R2, after plasmid DNA extraction. 
Plasmid DNA was extracted using the QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) 
according to manufacturer’s instructions. Ligations and transformations were repeated until a 
TE of 4.8x108 individual clones was achieved. 
Sequence Data Analysis 
Software used to import, analyse and align sequences included Lasergene EditSeq, and 
MegAlign (DNAStar, 12.3.1.4 Madison, USA). For primer design, homologue sequences were 
aligned using Lasergene MegAlign software (DNAStar, 12.3.1.4 Madison, USA) employing 
the ClustalW algorithm and analysed for similarity; duplicates were eliminated. Sequences 
from clones were also aligned using the ClustalW algorithm in MegAlign. SeqBuilder software 
(DNAStar, 12.3.1.4 Madison, USA) was used to translate nucleotide sequences into amino acid 
sequences and obtain ORF. The IMGT database (41) was used to determine CDR frameworks. 
A 3D model was calculated of the protein structure of a scFv antibody based on protein 
similarity found by the Phyre2 server (42) and annotated using Protean 3D (DNAStar, 12.3.1.4 
Madison, USA). ProABC-2 was utilized to obtain probabilities of CDRs likely to interact with 





Fingerprint analysis assessed library diversity using the enzyme BstNI (New England 
Biolabs GmbH, Frankfurt, Germany). The fingerprint analysis master mix contained 5 µl 10x 
NEBuffer 3.1 (New England Biolabs GmbH, Frankfurt, Germany), 0.5 µl BstNI (New England 
Biolabs GmbH, Frankfurt, Germany), and 10 µl of colony PCR product; fifty µl HPLC water 
was used to adjust to the final volume. Cleaved colony PCR products were analysed by gel 




A detailed analysis of equine immunoglobulin genetics was conducted for the assembly 
of the equine scFv antibody library. Primer design was based on the up-to-date description of 
necessary gene loci by Sun et al (2010) and aligned with additional sequences available in the 
NCBI database to cover all possible genes. The analysis included database entries by Schrenzel 
et al. (1997), Tallmadge et al. (2003), Almagro et al. (2006), Home et al. (1992), Ford et al. 
(1994), and Wade et al. (2009) (12, 39, 40, 45-48). Table 1 provides an overview of the number 
of sequences analysed per gene segment and the number of primers designed to cover several 
genes per segment simultaneously. For this purpose, primers were designed to include wobble 
bases and primer pools were used for gene amplification, which was possible after prior 
confirmation of amplification success of individual primer pairings and amplification 
optimisation experiments for primer pools. 
One IGKC gene is published and validated by our BLAST analysis, therefore only one primer 
was designed to cover the kappa constant gene. Furthermore, IGLC genes differed markedly, 
which resulted in almost an equal number of primers to the amount of genes; we designed five 
primers to amplify seven genes. Primers for PCR 2 were designed to contain the (Gly4Ser)3 
peptide linker sequence to connect variable domains during SOE-PCR. SOE-PCR primers were 
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elongated with restriction enzyme cleavage sites for SfiI and NotI. All primer pools are listed in 
Table 2, 3, and 4, including individual primer sequences, length, as well as accession number 
and binding positions of exemplary reference sequences.  
Table 1: Number of equine variable gene segments per chain, including number of sequences 
used for analysis retrieved from NCBI data bank and the locations of these genes on the Equine 
Genome (EquCab 3.0) and the number of primers designed to cover all corresponding genes.  
Immunoglobulin 
chain 




Locations Number of 
primers 











IGHJ 8 73 6 
IGHC 11 1 Chromosome 24 
(NC_009167.3) 
1 





IGLJ 7 204 7 
IGLC 7 20 Chromosome 8 
(NC_009151.3) 
5 





IGKJ 5 97 5 







Table 2: Primer sets for PCR 1: primer set (forward and reverse) for amplification of the V, D, J and C gene segments of VH. Primer sets (forward 
and reverse) for V, J and C genes of the Vλ and Vκ. Primer names, sequence, length, accession number, and binding positions of exemplary reference 
sequences. Wobble bases are shown in bold and defined according to the IUPAC code.  
Primer Name  Sequence (5‘- 3‘) Length (bp) Accession Number  Position 
PCR 1 - Forward primer set for the amplification of equine VH (PCR1Hpool_FOR)  
EqVH1_BACK CAG RTR CAA STG AAG GAG TCA GG 23 HM176092 58 - 80 
EqVH2_BACK CAG GTW CAA STG AAG GAG TCR GG 23 HM175938 58 - 80 
EqVH3_BACK CAG GTG CAA STG MAG GAS TCR GG 23 HM175992 58 - 80 
EqVH4_BACK CAG GTG SAR CTG ARG GAR TCR GG 23 HM175979 58 - 80 
EqVH5_BACK CAG GTG CAA MTG AAG GAG YYG GG 23 HM175919 58 - 80 
EqVH6_BACK CAG GTG MMA CTG AAG GAG KCY GG 23 HM176027 58 - 80 
EqVH7_BACK CAG RTS AGS CTG CAG GAG TCW GS 23 NW_001876796 141209 - 141509 
EqVH8_BACK CAG GTG MAG YTG MAG GAG TCR GG 23 HM175915 58 - 80 
EqVH9_BACK CAG GTR CAG CTG CAG RAG KTG RG 23 NW_001876796 232063 - 232361 
EqVH10_BACK SAG GTR CAG CTS RTG RAG YCY GG 23 NW_001876796 283617 - 283909 
EqVH11_BACK RAG TSC AKC TGG TGS AGT CTG R 23 NW_001876796 211197 - 211492 
EqVH13_BACK GAG GGT CAG CTG GAA CAG TCG GG 23 NW_001876796 175891 - 176186 
  
PCR 1 - Reverse primer set for the amplification of equine VH (PCR1Hpool_REV) 
GSP2 CTA CGY TGC AGA TGT AGG TCT 21 NW_001876796 730907 - 730887 
  
PCR 1 - Forward primer set for the amplification of equine Vκ (PCR1Kpool_FOR) 
EqVK1_BACK GRS RTC GTG ATG AYY CAG WYT CC 23 NW_001867379.1 16739610 - 16739895  
EqVK2_BACK GAC ATC GKG TTG AYC CAG TYT CC 23 X75612.1 67 - 89 
EqVK3_BACK GAC MTC GTG ATG ACG CAG TCT CC 23 NW_001867379.1 17057542 - 17057828  
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EqVK4_BACK GAT RTT GTG WTG ACC CAG ACT CC 23 NW_001867379.1 16599670 - 16599971  
EqVK5_BACK GAS AYT GTG HTG ACS CAG TYT CC 23 NW_001867379.1 16560248 - 16560552  
EqVK6_BACK GAA ATA ACA GTC ACA CAG TCT CC 23 NW_001867379.1 16431518 - 16431804  
EqVK7_BACK GAC GTC RTD WTG ACC CAG TCT CC 23 NW_001867379.1 16431518 - 16431804  
EqVK8_BACK GAG WYT GTG CTG ACT CAG TCT CC 23 NW_001867379.1 17071497 - 17071783 
EqVK9_BACK GAC ATC RTG WTG ACC CAG TCT CC 23 NW_001867379.1 16313053 - 16313339  
EqVK10_BACK GAC ATC GTG TTG ACC CAG TCT CC 23 NW_001867379.1 17010212 - 17010498 
EqVK11_BACK GAC ATC GTC WTG ACC CAG TCT CC 23 NW_001867379.1 16941855 - 16942141  
EqVK12_BACK GAC AKY GTA CTC ACC CAG TCT CC 23 NW_001867379.1 16855771 - 16856057  
EqVK13_BACK GAC ACA GTK TTG ACC CAG WCY CC 23 NW_001867379.1 16360142 - 16360443  
EqVK14_BACK GAC ATT ATD CTG ACC CAG TCT CC 23 NW_001867379.1 16933657 - 16933943  
EqVK15_BACK RAG ATC VTG WTG ACC CAG TCT CC 23 NW_001867379.1 16502696 - 16502982  
  
PCR 1 - Reverse primer set for the amplification of equine Vκ  (PCR1Kpool_REV) 
EqKC1_FOR GGA AGA TGA AGG CAG ATG GCT TAG C 23 NW_001867379.1 13731499 - 13731821 
  
PCR 1 - Forward primer set for the amplification of equine Vλ (PCR1Lpool_FOR) 
EqVL1_BACK CAG YCT CTG ACT CAR CCC GC 20 HM176432 58 - 77 
EqVL2_BACK CAG TCT STG ACS CAG CCC GC 20 HM176296 58 - 77 
EqVL3_BACK CAG TCT GCC CTG ACT CAG CCT GC 23 NW_001867428.1 4590316 - 4590612  
EqVL4_BACK TCC TYG GAG CTG AMT CAG CCA SC 23 HM176470 58 - 80 
EqVL5_BACK TCT TCT GAG STG ACT CAG CCA MC 23 HM176469 58 - 80 
EqVL6_BACK TCT TCT AAG CTG ACT CAG CCA TC 23 HM176468 58 - 80 
EqVL7_BACK TCT TCT GCA STG ACT CAG CCR TC 23 HM176467 58 - 80 
EqVL8_BACK CAG WCT STG RCT CAG CCY GC 20 HM176394 58 - 77 
EqVL9_BACK  CAG GMT GTG GTG ATY CAG GAM YC 23 NW_001867428.1  4763155 - 4763451  




PCR 1 - Reverse primer set for the amplification of equine Vλ (PCR1Lpool_REV) 
IGLC1_FOR CTG CTG GAC GAT TTC CAC TG 20 JN228102 232 - 251 
IGLC2_FOR CTG CTG TAA GAT TTC CAC TG 20 NW_001867428 4139041 - 4139460 
IGLC3_FOR CTG CTG TAT GAT TTC CAC TG 20 NW_001867428 4134043  -4134062 
IGLC4/6/7_FOR CTG CTG TAC GAT TTC CAC TG 20 JN228115 232 - 251 
IGLC5_FOR CTG CTG TAC GAT TTC CAC TC 20 JN228115 232 - 251 
 
Table 3: Primer sets for PCR 2: primer set (forward and reverse) for amplification of the V, D, and J gene segments of VH. Primer sets (forward and 
reverse) for V and J genes of Vλ and Vκ. Primers PCR2Hpool_REV, PCR2Kpool_FOR and PCR2Lpool_FOR include an overlapping 45-nucleotide 
sequence translating a (Gly4Ser)3 linker. Primer names, sequence, length, accession number and binding positions of exemplary reference sequences. 
Wobble bases are shown in bold and defined according to the IUPAC code. Letters in italic indicate the nucleotide sequence of the peptide linker. 
Primer Name  Sequence (5‘- 3‘) Length (bp) Accession Number Position 
PCR 2 – Reverse primer set for the amplification of equine VH and glycine-serine linker adhesion (PCR2Hpool_REV) 
EqJH1_FOR AGA ACC ACC TCC GCC TGA ACC GCC TCC ACC TGA GGA 
GAC GGT GAC CAG GRT GC 
23 HM175973 392 - 414 
EqJH2_FOR AGA ACC ACC TCC GCC TGA ACC GCC TCC ACC TGA GGA 
GAC GAA GAC CAG GAT GC 
23 HM176051 401 - 423 
EqJH3_FOR AGA ACC ACC TCC GCC TGA ACC GCC TCC ACC TGA GGA 
SAC GGT GAY CAG GGY GC 
23 HM175991 398 - 420 
EqJH4_FOR AGA ACC ACC TCC GCC TGA ACC GCC TCC ACC TGA GGA 
GAC RGT GAC CAG AGT GC 
23 HM175957 413 - 435 
EqJH5_FOR AGA ACC ACC TCC GCC TGA ACC GCC TCC ACC TRA SGA 
GAC RGT GAC CAG GAT RC 
23 HM176028 401 - 423 
EqJH6_FOR AGA ACC ACC TCC GCC TGA ACC GCC TCC ACC TGA GGA 
GAC GGT GAC CAG WAT GC 




PCR 2 – Forward primer set for the amplification of equine Vκ and glycine-serine linker adhesion (PCR2Kpool_FOR) 
EqVK1_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGG RSR TCG TGA TGA YYC AGW YTC C 
58 NW_001867379.1 16739610 - 16739895  
EqVK2_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGG ACA TCG KGT TGA YCC AGT YTC C 
58 X75612.1 67 - 89 
EqVK3_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGG ACM TCG TGA TGA CGC AGT CTC C 
58 NW_001867379.1 17057542 - 17057828  
EqVK4_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGG ATR TTG TGW TGA CCC AGA CTC C 
58 NW_001867379.1 16599670 - 16599971 
EqVK5_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGG ASA YTG TGH TGA CSC AGT YTC C 
58 NW_001867379.1 16560248 - 16560552  
EqVK7_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGG ACG TCR TDW TGA CCC AGT CTC C 
58 NW_001867379.1 16431518 - 16431804 
EqVK9_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGG ACA TCR TGW TGA CCC AGT CTC C 
58 NW_001867379.1 16313053 - 16313339  
EqVK10_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGG ACA TCG TGT TGA CCC AGT CTC C 
58 NW_001867379.1 17010212 - 17010498  
EqVK11_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGG ACA TCG TCW TGA CCC AGT CTC C 
58 NW_001867379.1 16941855 - 16942141  
EqVK13_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGG ACA CAG TKT TGA CCC AGW CYC C 
58 NW_001867379.1 16360142 - 16360443  
EqVK14_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGG ACA TTA TDC TGA CCC AGT CTC C 
58 NW_001867379.1 16933657 - 16933943  
EqVK15_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGR AGA TCV TGW TGA CCC AGT CTC C 
58 NW_001867379.1 16502696 - 16502982  
 
PCR 2 – Reverse primer set for the amplification of equine Vκ and glycine-serine linker adhesion (PCR2Kpool_REV) 
EqJK1_FOR GTB YGA KCT CCA GCT TGG TCC CCT 24 NW_001867379.1 13728269 - 13728232 
EqJK2_FOR KYT TGA TYT CCA GYT TKG TCC CYT 24 NW_001867379.1 13727624 - 13727586 
EqJK3_FOR KTT TGA TCT CCA MYT TGG TCC CYT 24 NW_001867379.1 13727931 - 13727894 
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EqJK4_FOR GYT TGA TTT CCA RCT TGG TCC CGG 24 NW_001867379.1 13727254 - 13727217  
EqJK5_FOR TTT TAA TGT CCA GAC GCG TCC CTT 24 NW_001867379.1 13728570 - 13728534  
 
PCR 2 – Forward primer set for the amplification of equine Vλ and glycine-serine linker adhesion (PCR2Lpool_FOR) 
EqVL1_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGC AGY CTC TGA CTC ARC CCG C 
55 HM176432 58 - 77 
EqVL2_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGC AGT CTS TGA CSC AGC CCG C 
55 HM176296 58 - 77 
EqVL3_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGC AGT CTG CCC TGA CTC AGC CTG C 
58 NW_001867428.1 4590316 - 4590612  
EqVL4_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGT CCT YGG AGC TGA MTC AGC CAS C 
58 HM176470 58 - 80 
EqVL5_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGT CTT CTG AGS TGA CTC AGC CAM C 
58 HM176469 58 - 80 
EqVL6_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGT CTT CTA AGC TGA CTC AGC CAT C 
58 HM176468 58  -80 
EqVL7_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGT CTT CTG CAS TGA CTC AGC CRT C 
58 HM176467 58 - 80 
EqVL8_Linker_BACK GTT CAG GCG GAG GTG GTT CTG GCG GTG GCG GAT 
CGC AGW CTS TGR CTC AGC CYG C 
58 HM176394 58 - 77 
 
PCR 2 – Reverse primer set for the amplification of equine Vλ and glycine-serine linker adhesion (PCR2Lpool_REV) 
EqJL1_FOR CAG GAC GMT GAG GTG GGT CCC GCY 24 NW_001867428.1 4146337 - 4146302 
EqJL2_FOR TRR GAY GGT CAG RTG GGT RCC TCY 24 NW_001867428.1 4141033 - 4140996  
EqJL3_FOR TAG GAC TAT CAG CTG GGT CCC TCA 24 NW_001867428.1 4135576 - 4135541 
EqJL4_FOR TGY GAG GGT CAG GTG GGT GCC TCC 24 NW_001867428.1 4132448 - 4132410 
EqJL5_FOR TGY GAY GGT CAG GTG GGT GCC TCC 24 NW_001867428.1 4129086 - 4129050  
EqJL6_FOR TRC RAT GGT CAG GTG GGT GCC TCC 24 NW_001867428.1 4125743 - 4125707  




Table 4: Primer sets for splicing-by-overlap-extension (SOE) PCR: primer sets (forward and reverse) for re-amplification of recombined VH - Vκ 
and VH – Vλ products and extension of restriction enzyme sites SfiI and NotI for ligation. Table shows primer names, sequence, size, accession 
number, and binding positions. Wobble bases are shown in bold and defined according to the IUPAC code. Underlined nucleotides signify restriction 
enzyme recognition sites for SfiI and NotI.  
Primer Name  Sequence (5‘- 3‘) Length (bp) 
SOE – PCR Forward primer set for the amplification of the recombined product (VH +Vλ and VH + Vκ) including enzyme restriction site SfiI (SOE_H_pool) 
EqVH1BACKSfiI GTC CTC GCA ACT GCG GCC CAG CCG GCC CAG RTR CAA STG AAG GAG TCA GG 50 
EqVH2BACKSfil GTC CTC GCA ACT GCG GCC CAG CCG GCC CAG GTW CAA STG AAG GAG TCR GG 50 
EqVH3BACKSfil GTC CTC GCA ACT GCG GCC CAG CCG GCC CAG GTG CAA STG MAG GAS TCR GG 50 
EqVH4BACKSfil GTC CTC GCA ACT GCG GCC CAG CCG GCC CAG GTG SAR CTG ATG GAT TCR GG 50 
EqVH5BACKSfil GTC CTC GCA ACT GCG GCC CAG CCG GCC CAG GTG CAA MTG AAG GAG YYG GG 50 
EqVH6BACKSfil GTC CTC GCA ACT GCG GCC CAG CCG GCC CAG GTG MMA CTG AAG GAG KCY GG 50 
EqVH7BACKSfil GTC CTC GCA ACT GCG GCC CAG CCG GCC CAG RTS AGS CTG CAG GAG TCW GS 50 
EqVH8BACKSfil GTC CTC GCA ACT GCG GCC CAG CCG GCC CAG GTG MAG YTG MAG GAG TCR GG 50 
EqVH9BACKSfil GTC CTC GCA ACT GCG GCC CAG CCG GCC CAG GTR CAG CTG CAG RAG KTG RG 50 
EqVH10BACKSfil GTC CTG CAA CTG CGG CCC AGC CGG CCR AGG TSC AKC TGG TGS AGT CTG R 50 
EqVH11BACKSfil GTC CTC GCA ACT GCG GCC CAG CCG GCC RAG GTS CAK CTG GTG SAG TCT GR 50 
EqVH13BACKSfil GTC CTC GCA ACT GCG GCC CAG CCG GCC GAG GGT CAG CTG GAA CAG TCG GG 50 
 
SOE – PCR Reverse primer set for the amplification of the recombined product (VH + Vκ) including enzyme restriction site NotI (SOE_K_pool) 
EqJK1FORNotl GAG TCA TTC TCG ACT TGC GGC CGC GTB YGA KCT CCA GCT TGG TCC CCT 48 
EqJK2FORNotl GAG TCA TTC TCG ACT TGC GGC CGC KYT TGA TYT CCA GYT TKG TCC CYT 48 
EqJK3FORNotl GAG TCA TTC TCG ACT TGC GGC CGC KTT TGA TCT CCA MYT TGG TCC CYT 48 
EqJK4FORNotl GAG TCA TTC TCG ACT TGC GGC CGC GYT TGC TTT CCA RCT TGG TCC CGG 48 
EqJK5FORNotl GAG TCA TTC TCG ACT TGC GGC CGC TTT TAA TGT CCA GAC GCG TCC CTT 48 
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SOE – PCR Reverse primer set for the amplification of the recombined product (VH + Vλ) including enzyme restriction site NotI (SOE_L_pool) 
EqJL1FORNotl GAG TCA TTC TCG ACT TGC GGC CGC CAG GAC GMT GAG GTG GGT CCC GCY 48 
EqJL2FORNotl GAG TCA TTC TCG ACT TGC GGC CGC TRR GAY GGT CAG RTG GGT RCC TCY 48 
EqJL3FORNotl GAG TCA TTC TCG ACT TGC GGC CGC TAG GAC TAT CAG CTG GGT CCC TCA 48 
EqJL4FORNotl GAG TCA TTC TCG ACT TGC GGC CGC TGY GAG GGT CAG GTG GGT GCC TCC 48 
EqJL5FORNotl GAG TCA TTC TCG ACT TGC GGC CGC TGY GAY GGT CAG GTG GGT GCC TCC 48 
EqJL6FORNotl GAG TCA TTC TCG ACT TGC GGC CGC TRC RAT GGT CAG GTG GGT GCC TCC 48 
EqJL7FORNotl GAG TCA TTC TCG ACT TGC GGC CGC TGC RAC GGT CAG GTG GGT GCC TCC 48 
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Amplification of cDNA encoding equine immunoglobulin chains 
The V, D, J, and C gene segments of VH as well as the V, J, and C genes of Vλ and Vκ 
were successfully amplified during PCR 1. Following initial confirmation that all primer 
combinations individually result in amplification products and excluding primer pairings that 
failed to amplify, primers were pooled and PCR optimisation experiments for PCR 1 primer 
pools have shown that distinguishable products are detectable in gel electrophoresis when 2.5 
% DMSO are included in the master mix and annealing is set to 56°C. Primer pools for PCR 1 
resulted in differing numbers of bands and band intensity. PCR 1 for Vκ amplified a fragment 
of approximately 350 - 400 bp as appeared on a 1% agarose gel. Cloning and sequencing (n=3) 
proved that PCR 1 Vκ products of 355 - 379 bp contained an ORF (Figure S1). PCR 1 of Vλ 
amplified products of approximately 600 bp. Cloning and sequencing (n=3) proved that PCR 1 
Vλ fragments of 571 - 596 bp represent functional antibody sequences (Figure S1). PCR 1 of 
VH amplified products of approximately 650 - 700 bp. Cloning and sequencing (n=3) proved 
that PCR 1 VH fragments of 650 bp to contain ORFs (Figure S3). All PCR 1 products are shown 




Figure 2: Amplification of equine cDNA by PCR 1 using pooled primer sets 
(PCR1_pool_FOR/PCR1_pool_REV of respective chain). Lane 1 and 9: 1 kb+ Ladder 
(Invitrogen, Carlsbad, USA). Lanes 2 and 8: 100 bp Ladder (Invitrogen, Carlsbad, USA). Lane 
3: equine heavy chain (VH). Lane 4: equine lambda light chain (Vλ). Lane 5: equine kappa 
light chain (Vκ). Lane 6: positive control (PC; equine GAPDH). Lane 7: negative control (NC; 
HPCL). 
Amplification of equine VH, Vλ and Vκ, linker adhesion 
V, D, and J gene segments of VH as well as the V and J gene segments of Vλ or Vκ 
were amplified during PCR 2 and extended by (Gly4Ser)3 linker sequences on the 5’ and 3’ 
ends, respectively. PCR optimisation experiments for PCR 2 primer pools have shown that 
distinguishable products are detectable in gel electrophoresis when no DMSO was added to the 
master mix and annealing temperature was set to 60°C. PCR 2 of the VH region amplified 
products detectable in gel electrophoresis of approximately 400 - 500 bp as depicted in Figure 
3. Cloning and sequencing (n=3) proved that PCR 2 VH fragments of 400 bp represent putative 
functional antibody sequences including the (Gly4Ser)3 linker sequence (Figure S1). PCR 2 for 
the Vλ amplified products of approximately 400 bp (Figure 3). Cloning and sequencing (n=3) 
proved that PCR 2 Vλ fragments of 375-395 bp represent functional antibody sequences and 
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include the (Gly4Ser)3 linker sequence (Figure S1). PCR 2 for the Vκ regions amplified products 
of approximately 400 bp (Figure 3). Cloning and sequencing (n=3) revealed that fragments of 
361 - 381 bp to represent putative functional antibody sequences and to include the (Gly4Ser)3 
linker sequence (Figure S1). 
 
Figure 3: Amplification of equine cDNA by PCR 2 utilizing pooled primer sets 
(PCR2_pool_FOR/PCR2_pool_REV of respective chain). Lane 1 and 8: 1 kb+ Ladder. Lanes 
2 and 7: 100 bp Ladder. Lane 3: equine heavy chain (VH). Lane 4: equine lambda light chain 
(Vλ). Lane 5: equine kappa light chain (Vκ). Lane 6: negative control (NC; HPLC). 
 
Generation of scFv sequences 
For the generation of scFv encoding DNA sequences, the PCR 2 products encoding VH 
were either recombined with Vλ or Vκ through the overlapping (Gly4Ser)3 linker sequence 
during SOE-PCR. Successful recombination was determined by 1 % agarose gel 
electrophoresis which revealed a band of 800 bp for the successfully recombined fragments 
(Figure 4). Sanger sequencing confirmed the products of 800 bp to represent complete scFv 
sequences. BLAST analysis revealed that VH and Vλ/Vκ were recombined into a single ORF, 
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containing the restriction enzyme cleavage sites as well as the E-tag sequence and Amber Stop 
codon of the phagemid vector pCANTAB 5E.  
 
Figure 4: Recombination products of VH - Vλ and VH - Vκ. Lane 1 and 19: 1 kb+ ladder. 
Lanes 2, 10 and 18: 100 bp Ladder. Lane 3 to 9: VH - Vλ Splicing-by-overlap-extension (SOE) 
PCR recombination products. Lane 11 to 17: VH - Vκ SOE-PCR recombination products. 
 
Construction of scFv library in pCANTAB 5E 
The two sublibraries contained scFv sequences comprising recombination products of 
VH - Vλ and VH - Vκ, respectively. Three λ transformations with an average TE of 4.5x108 
cfu/µg were combined with three κ transformations with an average TE of 7.8x108 cfu/µg. 
Sublibraries were considered for further use when at least 80% of selected clones revealed full-
size scFv fragments as compared to empty vectors within a colony PCR. Fingerprint analysis 
using BstNI was used to evaluate clones from each sublibrary. Both sublibraries contain clones 
with differing restriction patterns and no duplications of one pattern (Figure 5). Therefore 




Figure 5: Colony PCR products after fingerprint analysis (BstNI) of 10 bacterial clones of the 
λ sublibrary. Lane 1 & 14: 1kb ladder. Lane 2 & 13: 100 bp ladder. Lane 3 - 12: products of the 
BstNI digest of 10 independent clones. 
Prior to further downstream applications, vector-insert constructs were confirmed to 
contain an ORF, including g3 signal sequence, equine variable region of the heavy chain, the 
linker to the light chain variable region, and the E-Tag sequence and amber stop codon, further 
confirming ligation into phagemid vector pCANTAB 5E. Therefore, 3 clones per sublibrary 
were picked, cultivated overnight, plasmid DNA extracted and Sanger sequenced. An 
exemplary sequence (MW082605) is shown in Figure 6 and a 3D model is shown in Figure 7. 
The sequence of the exemplary scFv in Figure 6 shows the functionality of this clone as a 
complete scFv sequence was given since the ORF, contained all relevant sequences mentioned 
above. Sequence analysis of the CDRs shows both, hydrophobic as well as hydrophilic amino 
acid residues, yet hydrophilic residues predominate. Serine is the dominating amino acid, 
closely followed by an abundant amount of Glycine and Tyrosine. Analysis of amino acid 
residues within the ORF included Cys23 and alterations of conserved amino acid residues 
Trp41, Leu89, Cys104. These were substituted by Alanine, Valine, Threonine and Glycine. The 
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3D prediction in Figure 7 shows a molecule with the structures crucial for solvent exposed 
antigen binding regions (CDRs). As expected, CDR-H3 is lying at the center of the molecule 
and remaining CDRs are lying on the surface, close to each other, enabling antigen binding 
according to the key-lock model. Highest probability to interact with the antigen was obtained 





Figure 6: Nucleotide sequence of scFv clone HL1. Highlighted are CDRs (light blue) of heavy chain and λ light chain as well as the linker sequence 





Figure 7: 3D model of exemplary scFv clone HL1. Marked are the linker and CDR regions of 
heavy chain and λ light chain. The heavy chain (VH) is marked in dark blue on the left side, the 
λ light chain (Vλ) is marked in purple on the right side. All CDRs are highlighted in light blue. 
The (Gly4Ser)3 linker is marked in yellow. 
 
4.1.5 Discussion 
The primer sets designed in this study to construct recombinant equine antibodies 
successfully amplified equine variable domains and connected them to scFv antibody 
fragments. Fragments were successfully cloned into phage competent E. coli cells and an equine 
scFv library was assembled providing a basis for antibody isolation by phage display 
technology in future studies. Phage display technology requires a high-quality antibody gene 
library, which is given if it contains a large gene collection, representing a vast diversity of 
antibodies, numerically speaking when it contains more than one million individual antibody 
sequences (44). While we were able to generate an equine library of that size, containing 
4.8x108 antibody sequences, each presumed to be unique according to fingerprint analysis 
results (see Figure 5), it could be argued that diversity could be increased even further. In this 
study, antibody encoding genes were obtained from B cells of a single warmblood gelding. 
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However, a large number of donors from various breeds, equine enterprises or parts of the 
world, would ensure a broader coverage of the species’ allelic diversity (44). Human antibody 
library HAL4/7/8 was constructed from 44 donors, yielding five billion independent clones 
within their library (45). The next generation of human library of this particular group was 
constructed from as many as 98 donors, yielding 10 billion independent clones (46). 
Individual pairings of forward and reverse primers resulted in amplification products for 
most combinations that were confirmed by sequencing to be equine variable segments. 
Unsuccessful amplification of individual primer pairings could be due to the formation of 
primer dimers or secondary structures consequently inhibiting amplification of target DNA 
sequences. Unproductive primer pairings were excluded from the primer sets for library 
construction. 
The primer sets used in this study consist of a total of 115 primers with primer sets 
containing between five and 13 primers. This is comparable to the construction of human scFv 
antibodies to the extent that their number of primers per set also ranged between 4 and 7 (47). 
It is however not comparable to the total amount of primers used as it only takes a total of 33 
primers to construct human scFv antibodies (47). It takes a total of 19 primers to construct rabbit 
scFv antibodies (48) and a total of 13 primers to construct an immunized mouse antibody library 
(49). A study assembling a bovine scFv library used 46 primers (50). The noticeable differences 
between horses and other species lies within the amount of immunoglobulin gene segments of 
each species. Horses have a markedly higher number of variable gene segments having 52 
IGHV genes, 60 IGKV genes and 144 IGLV genes, which is contributing to the 
immunoglobulin diversity and the ability to respond to numerous antigens (11). In contrast, 
humans for example only have 38-46 IGHV genes, 34-38 IGKV genes and 29-33 IGLV genes 
(11). Furthermore, it is described that immunoglobulin gene usage and expression changes with 
age (11, 51) and among breeds as observed between Rhenish German warmblood and 
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Hanoverian warmblood (52). Since an intra-breed variability as well as an age variability in 
regards to gene expression cannot be excluded, it was important to include all equine 
immunoglobulin sequences that were available on the NCBI data base (53). Next to warmblood 
breeds, thoroughbred, Arabs, the Mongolian breed Ajinai, of different ages were available. All 
this information must be considered when establishing an equine IgG primer set intended for 
all breeds of all ages. 
Primer sets generated multiple products during PCR 1 in particular during amplification 
of VH and Vλ. Multiple products were also observable during SOE-PCR, particularly while 
recombining VH with Vκ. The formation of multiple products could be due to differences in 
length of individual variable domain gene segments. Generally, immunoglobulin diversity of 
the heavy chain is characterized by the rearrangement of individual V, D, J gene segments. It 
has however been observed that in equines a D-D fusion recombination takes place, rendering 
the order to V-D-D-J, thereby elongating the fragment substantially (12). While common equine 
recombination products are on average 30.5 bp, D-D fusion rearrangements range from 32 to 
58 bp (12). Additional findings contributing to size differences of amplification products, are 
N- and P- nucleotide insertions further enhancing diversity (12). On top of that, D gene 
segments vary in their individual sizes and can be found in three possible reading frames (RF) 
on each side, each RF varying in size as well; D genes of the equine heavy chain range from 18 
to 48 bp (12) posing a substantial difference in size that should not to be overlooked (11). 
Further consideration in regards to the formation of multiple bands should be taken in 
regards to wobble bases, or the GC content of a primer as they might render primers prone to 
the formation of secondary structures which result in either no yield at all or have adverse 
effects on annealing temperature and amplification. In this study, special consideration was 
taken to thoroughly optimising PCR conditions (54). Gel excision, cloning and sequencing of 
each band revealed only products of expected sizes to contain functional sequences, while other 
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products did not contain complete equine variable domains and were deemed unconstructive 
for library construction since they revealed premature stop codons within the sequence.  
Successfully amplified functional variable domains were recombined to scFv antibody 
fragments of approximately 800 bp by SOE-PCR. This is in accordance with other studies 
where human and murine scFv antibody sizes are approximately 750 - 800 bp (49, 55); bovine 
scFv antibodies were as long as approximately 800 bp due to their extra-long CDR 3 regions 
(50). It is not possible to compare species-specific equine scFv antibodies constructed in this 
study to other studies constructing recombinant equine antibodies since to this date none have 
been developed. There are simply murine or human scFv that have been produced against 
Venezuelan Equine Encephalitis Virus (56, 57) and Western Equine Encephalitis Virus (58) 
however in the context of treating human conditions. In veterinary medicine, most advances in 
recombinant antibody production, have been made in the field of production animals such as 
swine, cattle, and poultry as well as companion animals (59, 60). The scFv antibody format has 
proven to be the most popular format (61) and has been developed to, e.g. diagnose swine 
dysentery or Avian Influenza; therapeutic and prophylactic agents in the scFv format have also 
been developed for swine, cattle, and poultry (59). 
ScFv antibodies have shown to represent a suitable and commonly used recombinant 
format for antibody isolation by phage display along with naïve, Fab antibody fragments, and 
can easily be re-formatted to full sized antibodies or Fabs if necessary (44). They are producible 
at low cost, while exhibiting better specificity and solubility, reduced immunogenicity as well 
as neutralisation ability (61, 62). A scFv antibody trialled against peptides playing a role in 
Alzheimer’s disease has proven to retain specificity and protective properties of the parental 
antibody, while a full-length immunoglobulin in the same trial led to adverse effects (62). ScFv 
antibodies are also a popular tool in the development of biorecognition elements due to their 
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versatility, customizability and their immobilization properties on surfaces where whole 
antibodies would be difficult to immobilize (63). 
When constructing scFv antibodies it is important to use the peptide linker (Gly4Ser)3; 
Fragment variable (Fv) antibodies are unstable due to the differences of CDR 3 length (63). The 
glycine-serine linker provides the stability for the variable antibody fragments. Its widespread 
use in the construction of scFv molecules (64, 65) is due to its reliability in terms of not only 
stability but also flexibility. This is essential for the correct orientation of variable heavy chain 
and variable light chain domains in the scFv molecule (66). A study by van Rosmalen et al. 
(2017) has shown, that any linker longer than (Gly4Ser)3 or with a lower glycine content will 
result in lower efficiency and increased stiffness, preventing proper protein folding.  
Another important consideration during scFv construction is the purification of 
amplification products. This study has shown that templates used for the recombination reaction 
best be gel-purified as other methods result in products that still contain amplification by-
products; these could possibly inhibit proper recombination reactions.  
The genetic code of a complete, recombinant, functional equine scFv fusion protein was 
ligated into the phagemid vector pCANTAB 5E. This phage-competent vector has been and is 
still used widely across human (67) and veterinary scFv production (50, 68). Moreover, 
phagemid vectors promise higher TE than phage vectors, resulting in larger antibody libraries 
exhibiting a greater diversity (69). The restriction enzyme cleavage sites in this vector ensure 
direct cloning of the scFv sequences. The E-Tag sequence allows for an effortless purification 
and detection of soluble scFv antibodies. An alternative method to ligating the full scFv 
construct into the vector in between the cleavage sites is using a vector that already contains 
the linker sequence such as pHAL14 or its modified version pHAL30 (70). Firstly, the light 
chain will be ligated into the vector, before the heavy chain is ligated into the construct (70). 
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Ligated plasmids were transformed into electro-competent TG1 E. coli cells through 
electroporation. These cells contain an F-pilus which is necessary for infection by M13 phages 
when constructing a phage display library later on. Multiple transformation reactions were 
carried out which is in accordance with recent publications and protocols that suggested 
performing up to 100 ligations for large libraries (70). Transformation outputs are subject to 
purity of DNA in relation to electro-competent transformation parameters and should be 
adjusted accordingly. 
The overall TE of 4.8x108 cfu/µg was deemed satisfactory, as it is widely known that 
immunised antibody libraries yield a lower number of antibodies than non-immunised libraries, 
as the immune system of the B-lymphocyte donor has already undergone affinity maturation 
(71). Nian et al. (2016) constructed a human scFv library from a donor which was immunized 
against Staphylococcus aureus reaching a TE of 1.7 x 107 cfu/µg, while Li et al. (2000) reached 
a TE of 8.7 x 108 cfu/µg constructing an immunized scFv rabbit library. 
Fingerprint analysis of the sublibraries revealed highly diverse sublibraries as clones 
exhibited unique restriction patterns. The sequencing result of the exemplary λ clone among 
others proofed that the libraries contain functional scFv clones, containing ORFs, consisting of 
equine variable regions and successful ligation into phagemid vector pCANTAB 5E. Sequence 
analysis revealed hydrophilic and hydrophobic amino acid residues, but predominantly 
hydrophilic residues. Hydrophilicity is advantageous as it enhances flexibility (72). Antibody 
sequences should contain an abundant amount of Serine, Glycine and Tyrosine and the key 
amino acid residues Cys23, Trp41, Leu89 and Cys104. This was the case for the sequence on 
hand, however Trp41, Leu89 and Cys104 were substituted by Alanine, Valine, Threonine and 
Glycine, which bear similar biochemical characteristics. CDR regions were confirmed to lie in 
their expected positions, with the CDR-H3 lying at the center of the molecule and remaining 
CDR-regions are lying on the surface. Highest probability to interact with the antigen was 
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obtained for CDR-H2 (Pt 0,49) and CDR-L1 (Pt 0.5) (43) confirming successful construction 
of antigen binding scFv antibodies. Yet, the exemplary scFv sequence lacks Cysteine residues 
within CDRs which would enhance its stability. 
 
4.1.6 Conclusion 
New PCR primers were developed to amplify variable domains of equine IgG1-7 
antibody genes. The primers enable the construction of equine scFv antibodies and the 
construction of an immunized equine scFv antibody library in bacterial systems with a diversity 
of 4.8x108 cfu/µg. The equine antibody library provides the basis for the isolation of 
neutralizing scFv fragments by phage display technology. Isolates will have affinities towards 
EHV-1 and -4 as well as other pathogenic agents the donor had been immunized with as part 
of a standard immunization regimen (Influenza and Tetanus). Primers for this purpose did not 
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4.2.1 Abstract  
Equine herpesvirus type 1 (EHV-1) is one of the most prevalent viral pathogens 
infecting horses worldwide causing respiratory diseases, abortion or severe neurological 
disorders. Not only is it a highly contagious virus but the most critical form of transmission are 
the silent shedders once the virus has undergone latency. No current prevention or treatment 
methods have proven ground breaking in altering duration of viremia or protecting against 
latent infection. Hence, it has been suggested that recombinant antibodies may contribute to 
protection and treatment of EHV-1. This study aimed to select a recombinant equine anti-EHV-
1 antibody in the single-chain-Fragment-variable format (scFv) from a newly generated equine, 
immunised scFv antibody library by phage display technology and examine the scFv antibody’s 
characteristics. The antibody library, with a diversity of 4.8 x 108 individual clones, was 
packaged into M13KO7 bacteriophages. This newly created equine phage display library was 
exposed to EHV-1 during three rounds of biopanning. One anti-EHV-1 scFv antibody was 
isolated from the library as it showed enhanced binding capacities as determined by ELISA. Its 
antibody capacities were confirmed by the presence of key conserved amino acid residues 
Cysteine, Tryptophan and Leucine. One amino acid substitution in the linker sequence was 
observable but the 3D-model of scFv-3H2 revealed no effects on protein folding due to the 
substitution. Affinity and concentration were low after purification as determined by ELISA, 
SDS-PAGE and western blot analysis. This study proved efficient selection of an equine scFv 
candidate, yet methods require optimisation. The results contribute to the broader establishment 








Equine herpesvirus Type 1 (EHV-1) is one of the most prevalent viral pathogens 
infecting horses worldwide. It infects via the nasal passage eliciting symptoms ranging from 
mild signs of respiratory disease to potentially fatal neonatal pneumonia, abortion during late 
gestation or equine myeloencephalopathy (EHM) (1-3). EHV-1 virus is highly contagious and 
spreads easily among horses mainly through nasal secretions, fomites and aerosols (4). Yet the 
most critical form of transmission are the silent shedders once the virus has undergone latency 
(1). During latency, the virus is expressed at a low rate in seemingly healthy horses, yet can be 
re-activated during stressful periods, re-infecting the host and be shed via nasal secretions (1, 
4). More than 60% of the worldwide horse population is considered to be latently infected with 
EHV-1 (5). Current prevention methods consist of vaccination programs that aim to reduce 
transmission and prevent subsequent diseases (5). Four vaccines are currently licensed by Paul-
Ehrlich Institute (http:\\www.pei.de) for use in Germany. Vaccination however, does not alter 
duration of viremia (5) nor does it protect against latent infection (1). Therapeutic agents are 
being trialled against EHV-1 infection, but their efficacy remains of theoretic value at this point. 
Antiviral therapeutics acyclovir, valacyclovir or histones have demonstrated in vitro efficacy 
by inhibiting viral replication, however, neither drug inhibited viremia and in vivo studies are 
yet to be performed and prove effective (2, 5-7). A general consensus points toward 
development of equine-specific reagents e.g. monoclonal antibodies to study and subsequently 
prevent cellular adhesion of viral antigens, which are currently missing (2).  
Species-specific, neutralizing antibodies are produced by recombining antibody 
fragments into new recombinant antibody formats (8). Popular recombinant formats are single-
domain antibodies (sdAb), monoclonal antibodies (mAb), fragment antibodies (Fab) or single-
chain-Fragment-variable (scFv) antibodies (9). The latter consist of the variable domains of the 
light and heavy chains, connected by a flexible glycine-serine linker (10). scFv antibodies are 
much smaller than mAbs or Fabs, resulting in higher sensitivities (10, 11). On top of that, they 
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are highly customizable and can undergo affinity maturation (10). Development of scFv 
antibodies begins with PCR-isolation and connection of antibody fragments and their assembly 
into antibody libraries containing up to 10 billion different clones (8, 10, 11). Antigen-specific 
scFv antibodies can be isolated from a library through selection on a particular antigen (11). 
This selection may occur through a number of microbial display systems e.g. ribosomal display, 
yeast display or phage display systems, of which the latter is the most utilized due to its 
robustness and versatility (10). Phage display utilizes bacteriophages for infection of a library 
taking advantage of phages’ ability to display the gene encoding the scFv in their genome as 
well as on their phage coat proteins (8-10). Thereby, each phage is encoding and presenting a 
different antibody, thus creating an antibody phage library, allowing the simulation of an 
antibody repertoire similar to the natural immune system (8). This phage library is exposed to 
an immobilized antigen of interest whereby phages encoding high affinity scFv antibodies will 
bind to the antigen and weak binding phages are eliminated during a procedure termed 
biopanning (8, 9). High affinity scFv antibodies are either eluted for further characterisation or 
used for reinfection of the phage library for re-amplification and selection of binders with higher 
affinities under more stringent conditions (9). Typically three to five rounds of biopanning are 
necessary to select specifically binding phage particles (9).  
Next to phage display many different selection methods have been trialled over the 
years: prokaryotic or mammalian cells to display antibodies, enrichment on tissue or 
biotinylated antigen, ribosome display, yeast display or using cell sorting procedures such as 
fluorescent-activated-cell-sorting (FACS) and magnetic-activated-cell-sorting (MACS) (11). 
Comparing these methods to phage display, phage display technique offers several advantages: 
it allows automation of antibody production and manipulation of biopanning conditions to 
enhance stringency, which can strongly influence the nature of the antibodies selected from a 
library (11). Furthermore, phage display technique has successfully been used for drug 
discovery since the nineties and by 2017, six human antibodies discovered by phage display 
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had been approved for use and more were in clinical trials (8). Phage display is a well-
established and reliable source for the generation of therapeutic antibodies, both human and 
veterinary (8).  
In this study, we screen an immunized, equine antibody library in the scFv format using 
phage display technique to isolate an anti-EHV-1 scFv antibody and compare it to an equine 
mAb in regards to expression and binding capacity. 
 
4.2.3 Material and Methods 
Virus production and purification  
EHV–1 was obtained by infecting rabbit kidney cells (RK-13, Friedrich Loeffler 
Institut, Riems, Germany) with 5 ml live-attenuated Prevaccinol® (EHV-1, Strain RAC-H; 
Intervet Deutschland GmbH, Unterschleißheim, Germany). Infected cell culture was incubated 
in Minimum Essential Medium (MEM; Anprotec, Bruckberg, Germany) containing 2 % fetal 
calf serum (FCS; Anprotec, Bruckberg, Germany) at 37°C. After 72 hours and appearance of 
lytic cytopathogenic effect (CPE), virus-infected cell culture was frozen at -80°C, thawed at 
room temperature (RT) and centrifuged at 12500 g (Sorvall® RC-5B, Rotor GSA, Du Pont 
Instruments, Midland, USA) at 4°C for 30 minutes to eliminate cell debris. The supernatant was 
centrifuged in a SW 28-rotor at 112000 g (Combi Plus, Rotor AH-629, Du Pont Instruments, 
Midland, USA) for one hour. Virus pellets were re-suspended in phosphate buffered saline 
(PBS) buffer (8000 mg NaCl,  200 mg KCl, 120  mg KH2PO4, 910 mg Na2HPO4, ad 1 L 
distilled water; every constituent from Carl Roth GmbH + Co. KG, Karlsruhe, Germany) and 
layered on a step-wise sucrose gradient (20%, 40% and 60%, w/w in 
tris(hydroxymethyl)aminomethane (TRIS) - HCl buffer pH 9.0 (1mM)). Centrifugation was 
carried out in a SW 40-rotor (L-60 ultracentrifuge, rotor SW 40 Ti, Beckman Coulter GmbH, 
Krefeld, Germany) at 4°C for 90 minutes (40000 g). Lateral puncture facilitated collection of 
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the virus, which was pelleted in the SW 28-rotor for one hour (112000 g) and re-suspended in 
TRIS buffer. Virus concentration was determined by Lowry protein assay and the optical 
density (OD) was measured with the Sunrise microplate reader (Tecan, Maennedorf, 
Switzerland) at 450 nm. The purified virus was kept at -80°C. Binding between EHV-1-specific 
equine monoclonal antibody mAb 6B11 (12) conjugated with α-mouse horse radish peroxidase 
(HRP; Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) was confirmed in an ELISA 
(Protocol S1 and results in Figure S1 and Figure S2). The virus propagation and purification 




The equine immunized scFv library contains a library diversity of 4.8x108 individual 
clones and the percentage of clones containing inserts relative to the empty phagemid vector is 
80 %. Inserts are made up of equine variable gene regions of IgG heavy and light chains (λ and 
κ) connected to each other by a Glycine-Serine linker (Gly4Ser)3. ScFv fragments are displayed 
on the minor coat protein pIII in phagemid vector pCANTAB 5E (GE Healthcare, Chalfont St. 
Giles, UK, 25), which contains an E tag sequence and an Amber Stop Codon. The library was 
assembled into phage-competent TG1 E. coli cells (Lucigen Corporation, Middelton, USA). 
The library was constructed from a warmblood gelding that had been immunised with live-
attenuated Prevaccinol® (EHV-1, Strain RAC-H; Intervet Deutschland GmbH, 
Unterschleißheim, Germany), and inactivated Equip EHV1,4 (EHV-1, Strain 438/77; EHV-4 
Strain 405/76; Pfizer, Berlin, Germany) prior to library construction. In advance of antibody 
selection, presence of antibodies specifically against EHV-1 was detected in an ELISA assay 
using EHV-1-specific equine monoclonal antibody mAb 6B11 (12); negative control (NC) 
consisted of a monoclonal antibody (mAb 5B4/2F2 (13)) against bovine enteric coronavirus, 
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conjugated with the detection antibodies α-mouse horse radish peroxidase (HRP; Sigma-
Aldrich, Merck KGaA, Darmstadt, Germany) (Protocol S2, results in Figure S3).  
Infection with hyper- and helperphages 
A 500 µl aliquot of the library was thawed on ice and grown in 1 L 2xTY+2 % G+A 
medium (16 g tryptone, 10 g yeast extract, 20 g glucose, 5 g NaCl, 1 ml ampicillin (100 µg/ml), 
final volume was adjusted to 1 L with sterile water; all from Carl Roth GmbH & Co.KG, 
Karlsruhe, Germany) at 30°C with 250 revolutions per minute (rpm; Sartorius, Certomat-BS1, 
Göttingen, Germany) to achieve log phase (OD 0.4 – 0.6) and thereby amplify the library (as 
depicted in Figure 1 as Step 1). A 100 ml aliquot of the amplified library was infected with 
M13KO7ΔpIII hyperphages (Progen, Heidelberg, Germany) (Step 2 in Figure 1), for 
oligovalent display at a multiplicity of infection (MOI) of 30 and incubated stationary at 37°C 
for 30 minutes, followed by gentle shaking (Titramax 1000, Heidolph Instruments GmbH und 
Co.KG, Schwabach, Germany) at 37°C for a further 30 minutes. Throughout the following 
phage display rounds, libraries were re-infected with helperphages M13K07 (1x1011 pfu/ml; 
New England Biolabs GmbH Frankfurt am Main, Germany) to produce a monovalent display 




Figure 1: Schematic overview of antibody selection, purification and characterisation 
processes. Created with biorender.com. 
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The phage-infected culture was centrifuged at 4°C for 15 minutes at 3220 g 
(HERAEUSTM MultifugeTM 3 S-R, Rotor 7500 6445; Thermo Fisher Scientific Inc., Waltham, 
USA). Supernatant was discarded and the phage-infected cell pellet was re-suspended in 1 L 
2xTY medium (16 g tryptone, 10 g yeast extract, 5 g NaCl, ad 1 L sterile water; every 
constituent from Carl Roth GmbH & Co.KG, Karlsruhe, Germany), supplemented with 
ampicillin and kanamycin (100 µg/ml and 50 µg/ml respectively; both from Carl Roth GmbH 
& Co.KG, Karlsruhe, Germany). The re-suspended pellet was aliquoted into two 1 L 
Erlenmeyer Flasks (Corning® Incorporated Life Science, Oneonta, USA) and propagated at 
30°C and 200 rpm over night (Titramax 1000, Heidolph Instruments GmbH und Co.KG, 
Schwabach, Germany). Bacteria were pelleted once again at 4°C for 10 minutes at 3220 g 
(HERAEUSTM MultifugeTM 3 S-R, Rotor 7500 6445; Thermo Fisher Scientific Inc., Waltham, 
USA) to separate supernatant, now containing phages, and cell pellet, prior to phage 
precipitation.  
Phage precipitation 
The bacterial pellet was discarded and phages within the supernatant precipitated. 
Precipitation was initiated by addition of 8 ml of 20 % PEG (200 g of 20 % PEG8000, 146.1 g 
2.5 M NaCl, ad one L distilled water; both from Carl Roth GmbH & Co.KG, Karlsruhe, 
Germany) at a ratio of 1:5 and gentle shaking of the solution on ice for 45 minutes, followed 
by static incubation on ice for 45 minutes. Precipitates were centrifuged to obtain pellets at 4°C 
for 1 h at 4500 g (HERAEUSTM MultifugeTM 3 S-R, Rotor 7500 6445; Thermo Fisher Scientific 
Inc., Waltham, USA). Subsequently, pellets were re-suspended in PBS without Ca2+ and Mg2+ 
(8,000 mg NaCl, 200 mg KCl, 2,890 mg Na2HPO4, 200 mg KH2PO4, 1 mg glucose, ad 1 L 
distilled water; all from Carl Roth GmbH + Co. KG, Karlsruhe, Germany) and precipitation 
was repeated. After the second precipitation, the pellet was re-suspended in 1 ml PBS+15% 
glycerol and centrifuged anew at 4°C for 10 minutes at 9500 g (Biofuge Pico, Heraeus, Hanau, 
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Germany). The resulting supernatant, containing the phage library, was either kept short-term 
at 4°C or at -80°C for long-term storage.  
The concentration of phages within the supernatant was determined by diluting a 10 µl 
aliquot in 990 µl 2xTY+2% G and preparing a dilution series (log 100). 100 µl of each dilution 
were added to 900 µl TG1 E. coli cells and incubated at 37°C for 30 minutes without shaking 
followed by an incubation at 37°C for 30 minutes with shaking (250 rpm; Certomat BS-1, 
Sartorius, Göttingen, Germany). The dilution series was plated onto 2xTY+2 % G+A agar 
plates and incubated at 30°C over night. A positive control was incubated alongside consisting 
of TG1 E. coli cells spread onto a 2xTY+2 % G agar plate without ampicillin. A negative control 
consisted of TG1 E. coli cells spread onto a 2xTY+2 % G agar plate including ampicillin. All 
plates were prepared in duplicates. The phage titre was determined the following day by 
counting bacterial colonies on the plates.  
Biopanning 
For the first panning round a 96-well NUNC MaxiSorb plate (NUNCTM, Langenselbold, 
Germany), was coated with 5 µg/ml EHV-1 and incubated at 37°C for 4 hours (Step 4 in Figure 
1). Virus coating concentration decreased during the following panning rounds (1st round: 5 
µg/ml; 2nd round: 2 µg/ml; 3rd round: 1 µg/ml) to enhance selection stringency. After incubation, 
the plate was washed three times with PBS+0,1 % Tween (T; 8 g NaCl, 0.2 g KCl, 0.12 g 
KH2PO4, 0.91 g Na2HPO4, 1 ml Tween-20, ad 1 L sterile water; all constituents from Carl Roth 
GmbH & Co.KG, Karlsruhe, Germany) and blocked with 300 ml blocking solution (2 % 
skimmed milk powder (SMP; Carl Roth GmbH & Co.KG, Karlsruhe, Germany), 10 % FCS, 
PBS) at 37°C for 2 hours. Following incubation, washing the plate occurred three times with 
PBS+0,1 % T. Supernatant, containing the phage library, pre-incubated in blocking solution for 
1 hour at RT, was added to the plate at an input concentration of 1x1011 cfu/ml (2nd round: 
1x1013 cfu/ml; 3rd round: 1x1013 cfu/ml) and incubated at RT for 2 hours. The pre-incubation 
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step was omitted in all following panning rounds. After incubation, wells were washed 10 times 
(2nd round: 20 times; 3rd round: 30 times) with PBS+0,1 % T to remove unbound phages. Bound 
phages were eluted (Step 5 in Figure 1) enzymatically with 200 µl Trypsin (10 µg/ml; Carl Roth 
GmbH & Co. KG, Karlsruhe, Germany) and gentle shaking at 37°C for 30 minutes.  
Phage titration 
Eluted phage suspension was titrated in TG1 E. coli cells to determine the concentration 
of eluted phages after each panning round and serve as selected scFv phage library for following 
phage display rounds (Step 6 in Figure 1). Simultaneously, scFv genes, displayed by the eluted 
phages, were cloned into a non-suppressor E. coli strain HB2151 (Amersham Biosciences Inc., 
Buckinghamshire, United Kingdom) to produce soluble scFv (Step 6 in Figure 1). Both strains 
of E. coli cells were cultured in 2xTY+2 % G medium. After E. coli cells reached log phase 
(OD 0.4-0.6), 10 µl of eluted phages were added to 1 ml of HB2151 E. coli cells and 190 µl of 
eluted phages were added to 10 ml of TG1 E. coli cells and incubated at 37°C for 30 minutes 
stationary, followed by incubation at 37°C for 30 minutes and 250 rpm. After incubation, 10 µl 
of both infected E. coli cell strains were diluted in 990 µl 2xTY+2 % G medium and diluted 
serially (log100). The dilution series were plated onto 2xTY+2 % G+A agar plates (16 g 
tryptone, 10 g yeast extract, 20 g glucose, 5 g NaCl, 15 g agar-agar, 100 µg/ml ampicillin, ad 1 
L sterile water; all constituents from Carl Roth GmbH & Co.KG, Karlsruhe, Germany). 
Remaining TG1 E. coli cells were pelleted at 4°C for 10 minutes and 3000 g, re-suspended in 
2xTY+2 % G medium and plated onto 24 cm x 24 cm 2xTY+2 % G+A agar plates (NUNCTM, 
Langenselbold, Germany). Remaining HB2151 cells were transferred onto two 15 cm 2xTY+2 
% G+A agar plates. Uninfected cells from both strains were plated onto 2xTY+2 % G+A agar 
plates serving as negative control and onto 2xTY+2 % G agar plates to serve as positive control. 
All plates were incubated at 30°C over night. Following incubation, colonies were counted and 
cfu/ml determined. TG1 cells were scraped from the plate with 2xTY+2 % G+A medium 
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containing 15% glycerol and stored at -80°C to serve as selected scFv phage library for 
following phage display rounds (Step 6 in Figure 1). 
Production of scFv and ELISA 
Infected HB2151 E. coli colonies were picked randomly (384 – 480 colonies per 
panning round) and over-night cultures were prepared: individual colonies were submerged in 
2xTY+2 % G+A medium on a 96-well microtiter plate (one clone per well) and incubated at 
37° over night and constant shaking at 450 rpm (Titramax 1000, Heidolph Instruments GmbH 
und Co.KG, Schwabach, Germany) in order to produce scFv preparations, unlinked to phages. 
On the following day, 0.5 µl of over-night cultures were grown in 100 µl 2xTY+0.1 % G+A 
medium at 30°C and 300 rpm for 4 hours (Titramax 1000, Heidolph Instruments GmbH und 
Co.KG, Schwabach, Germany). After 4 hours of incubation, scFv expression by the prokaryotic 
lacZ promotor in E. coli was induced by adding 50 µl of 2xTY+A+1M isopropyl-beta-D-
thiogalacto-pyranoside (IPTG) per well (Carl Roth GmbH & Co. KG, Karlsruhe, Germany) and 
incubation at 30°C over night and 300 rpm (Titramax 1000, Heidolph Instruments GmbH und 
Co.KG, Schwabach, Germany). Induced HB2151 cells were centrifuged at 3000 g, for 10 
minutes at 4°C. Supernatants were used in ELISA to assess OD of EHV-1-binding scFvs after 
every panning round alongside a positive control consisting of an EHV-1 specific equine 
monoclonal antibody (Mab 6B11; (12)), conjugated with α-mouse horse radish peroxidase 
(HRP 1:2000 in 2% SMP in PBS+0.1 % T; Sigma-Aldrich, Merck KGaA, Darmstadt, 
Germany) for the positive control and α-E-Tag HRP (1:2000 in 2% SMP in PBS+ 0.1 % T, 
abcam, Cambridge, UK) for scFvs (detailed ELISA protocol S3 and exemplary result in Figure 
S4).  
Colony PCR and Sequencing  
Clones exhibiting OD measurements above 0.25 were analysed by colony PCR to 
contain full-length inserts using 10 µM of primer R1 (5´-CCA TGA TTA CGC CAA GCT TTG 
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GAG CC-3´), 10 µM of primer R2 (3´-CCT TTC TGC TGT TT GAA ATC TAG C-5`). For a 
detailed protocol and result refer to Protocol S4 and Figure S5. 
The software used to import, analyse and align sequences included Lasergene EditSeq, 
SeqBuilder, Protean 3D and MegAlign (DNAStar, 12.3.1.4 Madison, USA). Sequences from 
clones as well as generated primer sets were aligned using the Clustal W algorithm. The IMGT 
database was used to determine CDR frameworks. A 3D model was calculated of protein 
structures of a scFv antibody established according to protein homology using the Phyre2 
server. ProABC-2 was used to determine probabilities of CDR regions likely to interact with 
antigen (14). Calculations and graphs were generated using GraphPad Prism 8.0.0 (San Diego, 
California USA).  
 
Antibody purification 
Propagation and induction  
A 10 µl aliquot of the candidate scFv supernatant was propagated in 2xTY+2 % G+A 
medium at 37°C and 200 rpm over night (Titramax 1000, Heidolph Instruments GmbH und 
Co.KG, Schwabach, Germany). The following day, the suspension was added to 750 ml 
2xTY+0.1 % G+A and incubated at 37°C and 170 rpm until it reached log phase (OD 0.4 – 
0.5). Once log phase was reached, a 1 ml aliquot was removed and stored to serve as control of 
the suspension prior to induction (from now on referred to as “pre-induction”). Once log phase 
was reached 250 ml of 2xTY+A+ 2mM IPTG were added and the culture was incubated at 
30°C for 23 hours and 170 rpm. After 23 hours a 1 ml aliquot was removed and stored to serve 
as control of the suspension after induction (from now on referred to as “post-induction”). The 
remaining suspension was centrifuged to separate supernatant and peri-plasm at 4°C for 20 
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minutes and centrifuged at 12500 g (Sorvall® RC-5B, Rotor GSA, Du Pont Instruments, 
Midland, USA).  
 Precipitation of the supernatant 
The supernatant was separated from the pellet and transferred to 2 L glass bottles. 
Saturated ammonium sulphate solution was added at a ratio of 1:1, chilled on ice and exposed 
to gentle rocking. After 1 hour the ammonium sulphate - supernatant solution was centrifuged 
at 4°C for 20 minutes and 12500 g (Sorvall® RC-5B, Rotor GSA, Du Pont Instruments, 
Midland, USA). Following centrifugation the supernatant was discarded and the pellet was re-
suspended in 15 ml PBS. The re-suspension was centrifuged once again for 10 minutes. 
Supernatants were collected in a 50 ml tube (Sarsted, Nümbrecht, Germany) and stored at -
80°C. 
Precipitation of the peri-plasm 
The peri-plasm was re-suspended in 40 ml of TES buffer (200 mM Tris-HCl, 500 mM 
EDTA, 500 mM Saccharose, all constituents from Carl Roth GmbH & Co.KG, Karlsruhe, 
Germany). Re-suspension was incubated on ice for 60 minutes and gentle shaking prior to 
centrifugation at 4°C for 40 minutes and 12500 g (Sorvall® RC-5B, Rotor GSA, Du Pont 
Instruments, Midland, USA). The supernatant was collected and the pH value adjusted to 7.5 
prior to a further centrifugation step (Eppendorf, 5424, Rotor FA-45-24-11, Eppendorf, 
Hamburg, Germany) for 15 minutes. Supernatants were collected in 50 ml tube (Sarsted, 
Nümbrecht, Germany) and stored at -80°C. 
Affinity chromatography 
The candidate scFv molecules were purified from both, the bacterial supernatant as well 
as peri-plasm by affinity chromatography via the ÄKTATM start chromatography system (GE 
Healthcare UK Ltd, Buckinghamshire, UK) using an anti-E-Tag HiTrap column (GE 
Studies performed 
123 
Healthcare UK Ltd, Buckinghamshire, UK) with a flow rate of 1 ml/min. Purified scFv 
molecules were eluted with 0.1 M glycine (pH3; Carl Roth GmbH & Co.KG, Karlsruhe, 
Germany) and neutralized with 1 M TRIS and 0.13 M NaN3 (both from Carl Roth GmbH & 
Co.KG, Karlsruhe, Germany). Purified scFv molecules were dialyzed against PBS and 
concentrated by Amicon Ultra 15 10K Centrifugal Filter Device (Merck, Darmstadt, Germany). 
The concentration of the scFv was determined performing a Bradford Assay in microtitre plates 




Five columns of a 96-well ELISA plate (C96 Maxisorp NUNC-Immuno Plate, Thermo 
Fisher Scientific Inc., Waltham, USA) were coated with 2 µg/ml EHV-1 and incubated at 37°C 
for 4 hours. Remaining columns on the plate were not coated with virus. The plate was washed 
three times with PBS+0.1 % T and blocked with 300 µl blocking solution (2% SMP, 10% FCS 
in PBS+0.1 % T) at 37°C for 2 hours. Wells were emptied and 100µl of blocking solution was 
added to every well. The positive control consisting of an EHV-1 specific equine monoclonal 
antibody (Mab 6B11 (12) was added and diluted (log2) until row H. The purified candidate 
scFv was added and diluted as well. Columns 5, 10, 11 and 12 received blocking solution to 
determine the background. The plate incubated at 37°C for 1 hour before it was washed five 
times with PBS+0.1 % T. The detection antibodies α-mouse horse radish peroxidase (HRP; 
1:2000 in 2% SMP in PBS+ 0,1 % T) for the positive control and α-E-Tag HRP (1:2000 in 2% 
SMP in PBS+ 0,1 % T) were added to respective wells and incubated for one hour at 37°C. 
Columns 5, 10, 11 and 12 only received blocking solution. Following incubation, wells were 
washed ten times with PBS+0.1 % T, followed by the addition of 100 µl TMB substrate 
(IDEXX GmbH, Ludwigsburg, Germany). After 20 minutes incubation at RT in the dark, 50 µl 
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HCl (IDEXX GmbH, Ludwigsburg, Germany) stop solution was added and OD was measured 
with the Sunrise microplate reader (Tecan, Maennedorf, Switzerland) at 450 nm. 
SDS-PAGE and western blot analysis 
Characterization of the purified scFv-3H2 was performed by SDS-PAGE (sodium 
dodecyl sulphate-polyacrylamid gel electrophoresis) and western blot analysis. The bacterial 
cell culture “pre-induction”, bacterial cell culture “post-induction”, supernatant, peri-plasm and 
purified candidate scFv were loaded onto a reducing 12% SDS-PAGE along with Precision 
Plus Protein Standard (Bio-Rad Laboratories GmbH, Munich, Germany). Mini Trans Blot Cell 
electrophoresis system (Bio-Rad Laboratories GmbH, Munich, Germany) carried out 
electrophoresis for 60 minutes at 150 V and 400 mA using a Power Pac Basic (Bio-Rad 
Laboratories GmbH, Munich, Germany). Afterwards, the gel incubated in Coomassie-Brilliant-
Blue dye (Thermo Scientific™ Pierce Coomassie Brilliant Blue R-250 und G-250, Waltham, 
USA) for 45 minutes at RT and gentle shaking. The dye was removed and gel was washed twice 
with distilled water before de-colorizing solution (40 % methanol, 10 % acetic acid, 50 % H2O; 
all constituents from Carl Roth GmbH&Co.KG, Karlsruhe, Germany) was added. The gel 
incubated in the de-colorization solution for 15 minutes, removed and the process of de-
colorization was repeated until a clear contrast was observable. Once de-colorization was 
deemed sufficient, gels were photographed (PEQLAB Biotechnologie GmbH, Erlangen, 
Germany).  
For western blotting, 12 % SDS-PAGE gels were prepared as above. Both gels were 
loaded with differing concentrations of purified EHV-1 virus in designated lanes (2µg/ml, 
5µg/ml and 10 µg/ml). Segregated proteins were loaded onto a PROTRAN BA83 nitrocellulose 
membrane (GE Healthcare, Chalfont St. Giles, UK) and electrophoresis was performed in the 
electrophoresis system mentioned above for 75 minutes at 150 V and 400 mA in transfer buffer 
(25 mM Tris, 192 mM glycine, 20% methanol (v/v); all constituents from Carl Roth 
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GmbH&Co.KG, Karlsruhe, Germany). Membranes were blocked for 2 hours at RT with 5% 
SMP containing 10% FCS in PBS+0.1 % T, followed by washing twice with PBS+ 0.1 % T 
and once with PBS. The first membrane was incubated with precipitated supernatant of 
candidate scFv-3H2 and developed at 4°C over night. The membrane was washed three times 
with PBS + 0.1 % T and twice with PBS. It was incubated with polyclonal rabbit anti-E-Tag 
antibody (1:1000; Novus Biologicals, Littleton, USA) for two hours at RT before staining 
substrate was added (Bio-Rad Laboratories GmbH, Munich, Germany). The color reaction was 
stopped with distilled water. 
A second gel was incubated with purified candidate scFv-3H2 and incubated at 4°C over 
night. Following washing steps on the next day, the membrane was incubated with polyclonal 
rabbit anti-E-Tag antibody for 2 hours at RT. Washing steps and staining steps remain 
unchanged of the protocol above.  
 
4.2.4 Results 
Virus production and purification  
Sucrose-gradient purification of EHV-1 yielded concentrations of 1900 µg/ml after the 
first purification and 700 µg/ml after the second purification. Both aliquots were confirmed to 
bind to monoclonal antibodies in ELISA assays (Figure S1 and Figure S2).  
Antibody selection 
An interplay of phage input and output titre was assessed after each panning round to 
evaluate correct processing of phage display procedures. An increasing output tire and enriched 
input titre was presumed to ensure correct application of stringency strategies (Figure 2). Phage 
output titre was based on a TG1 dilution series. In panning round one 3,645x105 cfu/ml antigen-
specific phages were eluted, in panning round two a decrease was observable (1,7x105 cfu/ml) 




Figure 2: Development of phage display input and output titres for each panning round 
(cfu/ml).  
Following each panning round, individual clones were picked and propagated on 96-
well plates by ELISA assay to determine binding capacity of individual clones to EHV-1. An 
expected increase of mean OD values of all clones per panning round was observable (Figure 
3). Mean OD in panning round one was 0.05634 (n=472), slightly less than mean OD in panning 
round two (0.08614; n=435). This almost doubled (1.8x) in panning round three, mean OD 
















Figure 3: Mean OD values including SD during phage display panning rounds.   
After panning round three, 11 clones displayed OD signals higher than 0.25 (Figure S4) 
and were further investigated by Colony PCR. It revealed one clone to harbour a scFv insert of 
expected size (~800 bp; Figure S5) plus approximately 200 bp accounting for PCR primers 
R1/R2. Remaining clones appeared to be 300 to 600 bp approximately (Figure S5).  
The clone scFv-3H2 was cultivated overnight, plasmid DNA was extracted and Sanger 
sequenced. The sequence of scFv-3H2 (GenBank accession number MW082606) in Figure 4 
shows the scFv ORF, including g3 signal sequence, equine variable region of the heavy chain, 
the linker to the light chain variable region, and the E-Tag sequence and amber stop codon. 
CDR regions contain both, hydrophobic and hydrophilic amino acid residues, yet hydrophilic 
residues predominate as desired in antibody sequences. The ORF includes antibody-specific 
Cys23 and substitutions of conserved amino acid residues Trp41, Leu89, Cys104 to Glycine, 
Methionine and Tyrosine, all the while containing Tryptophan, Leucine and Cysteine, merely 
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in different positions. A single nucleotide polymorphism (SNP) occurs in the linker sequence: 
the circled nucleotide should be Guanine instead of Adenine, which leads to an amino acid 
exchange; Glycine was substituted by Serine. Figure 5 shows a 3D prediction model of scFv-
3H2 which portrays a molecule with CDR-regions lying close to each other on the surface and 
CDR-H3 lying in the center of the molecule. CDR-H2 (Pt 0,48) and CDR-L1 (Pt 0.48) are most 




Figure 4: Nucleotide and amino acid sequence of scFv-3H2. Marked are CDRs (light blue), the (G4S)3, linker sequence (yellow) and the E-Tag and 




Figure 5: 3D prediction model of scFv-3H2. Green - heavy chain variable domain. Purple - 
light chain variable domain. Light blue – CDR. Yellow - (G4S)3 peptide linker.  
Antibody purification 
The scFv-3H2 was purified from the HB2151 E. coli culture peri-plasmic fraction as 
well as supernatant by affinity chromatography using the ÄKTATM start chromatography 
system using an anti-E-Tag HiTrap column with a flow rate of 1 ml/min. The scFv was found 
to accumulate in the E. coli periplasm and was also released into the supernatant (Figure 6). 
After purification and dialysis, all fractions were pooled and Bradford assay yielded 




Figure 6: Chromatogram profile of the purification of scFv-3H2 from peri-plasmic (A) and 
supernatant (B) fractions E.coli cell culture. Chromatographic column: ÄKTATM start 





ELISA assay was performed verifying reactivity of purified scFv-3H2 to EHV-1. As 
shown in Figure 7, scFv-3H2 (red) was not comparable to the PC mAb 6B11 (blue) in its 
reactivity to EHV-1. The positive control also reacted on wells that were not coated with EHV-
1 dilution. In comparison to remaining results of this template within the assay, this result can 
be deemed an outlier.   
 
Figure 7: ELISA assay of scFv-3H2 binding to EHV-1. Titration of positive control and scFv-
3H2 (log2) on a 96-well plate partly coated with 2 µg/ml purified EHV-1, partly not coated 
with antigen. NCA –negative control A: no template, α-E-Tag-HRP. NCB- negative control B: 
no template, no detection antibody.  
ScFv-3H2 was analysed by electrophoresis on 12% SDS-PAGE gels (Figure 8) to assess 
expression efficiency. Induction with IPTG was proven successful since cell culture pre-
induction medium contained low concentrations of proteins and post-induction cell culture 
medium expresses high concentrations of proteins. Typical molecular weight of scFv fragments 
is 27 kDa. A band at approximately 27 kDa was detected primarily in the unpurified periplasmic 
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fraction, but a faint band at 27 kDa was also noticeable in the unpurified supernatant. 
Concentrations of protein in eluted fractions are too low for detection by SDS-PAGE analysis.  
 
Figure 8: 12% SDS - PAGE analysis of scFv-3H2. Lane 1 & 10: Precision Plus Protein 
Standard. Lane 2: Bacterial culture medium pre-induction, Lane 3: Bacterial culture medium 
post-induction, Lane 4: Unpurified supernatant, Lane 5: Unpurified peri-plasm, Lane 6 – 9: 
eluted fractions.  
The target protein scFv-3H2 was further characterised with EHV-1 under reducing 
conditions in western blot analysis. For comparison, unpurified supernatant and purified 
dialysed scFv-3H2 were used on two separate blots both loaded with differing concentrations 
of EHV-1 in designated lanes (2 µg/ml, 5 µg/ml and 10 µg/ml). Neither supernatant nor purified 




Figure 9: Western blot analysis of precipitated supernatant of scFv-3H2 (A) and dialysed scFv-
3H2 (B). Differing concentrations of EHV-1 were loaded onto a 12% SDS gel and blotted on a 
nitrocellulose membrane. Antibody aliquots were incubated on the membrane before α-E-Tag 
conjugated detection antibodies were added. Lanes 1, 4, 7, 9: Precision Plus Protein Standard. 





Our proof-of-principle study successfully generated an equine antibody phage display 
library and isolated a promising scFv antibody candidate using phage display technology. The 
immunized equine antibody library in the scFv format provided the basis for this study (15). 
Immunized libraries have the advantage of containing antibody fragments that are derived from 
B-lymphocytes of already immunised individuals and have therefore undergone in vivo affinity 
maturation towards the desired antigen (16). The donor animal serving as a source of 
immunoglobulin genes for the construction of the library had previously been immunised 
against EHV-1 along with EHV-4, Tetanus and Influenza and was therefore a promising source 
of isolating an EHV-1-specific antibody. Prior to biopanning on EHV-1, a plasma sample of 
the donor animal was tested in an ELISA to confirm presence of EHV-1 antibodies (Figure S3). 
Their presence was confirmed, yet assays determining neutralising activity of these antibodies 
and excluding binding to background would have added to a thorough investigation of the 
nature of origin immunoglobulins.  
Since the likelihood of selecting a highly affine antibody fragment from this library is 
enhanced, library sizes ranging from 1x106 to 1x108 individual clones are deemed plentiful for 
the isolation of a specific antibody fragment (16, 17). The library used contained 4.8x108 
individual clones, which was declared sufficient for our purposes. Individual scFv clones were 
ligated into phagemid vector pCANTAB 5E, which contains the phage gene pIII, required for 
infection. Phagemid vectors are a popular vector system, preferred over phage vectors: in a 
phage vector system, every phage would carry three to five copies of the antibody fragments 
on its surface (multivalent display) (18). Assembly of a multivalent phage display library would 
risk creating background noise within the phage library with incomplete scFv fragments. In the 
phagemid vector system, each phage contains only one copy of the antibody fragment on its 
surface (monovalent display) (18). When phagemid vector systems are utilized, as it is the case 
in this study, a phage carrying a mutation affecting phage coat protein pIII, are used for phage 
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library assembly to improve antibody display and selection (18). This mutated phage, the 
hyperphage M13K07ΔpIII, carries a gene III deletion, which leads to a multivalent display in 
combination with a phagemid (18-21). This combination allows the generation of a larger phage 
library as a basis for selection purposes. We chose to apply this combination: the equine 
immunized library was ligated into a phagemid vector and enabled packaging as many scFv 
fragments into the phage display library by using the hyperphage in the first round and 
increasing stringency in the subsequent rounds by employing the helper phage M13K07. We 
infected the library (15) with hyper phages and yielded 7x 1011 cfu/ml (data not shown) after 
precipitation. This result corresponds with studies that also packaged recombinant antibodies 
into hyper phages yielding 1x1011 to 2.5x1011 cfu/ml, selecting human antibodies (21, 22). For 
panning purposes a defined amount of phages was exposed to antigen. This amount ranged 
from 1x1011 to 1x1013 cfu/ml which was in coherence with other studies (23, 24). Throughout 
panning rounds an increase of phage output is expected since eluted antigen specific scFv-phage 
are amplified (25, 26). In this study, a decrease rather than an increase was observed after the 
second panning round, which is a common observation and most likely due to a change from 
hyper- to helper phage (26, 27). M13K07 helper phages were used for infection in panning 
round two and three for a monovalent display and to increase stringency of the panning process 
as recommended by many other protocols (28-30). Phage output of panning round three 
increased, reflecting the expected amplification and selection process of phage display 
technology and corresponds with similar studies where phage output titres ranged from 104 to 
106 cfu/ml (23-26, 31, 32).  
While the phage output titre does not record a steep increase, the mean OD values of all 
tested clones increases with every panning, reflecting enhanced binding abilities of scFv 
fragments. Mean OD values range from 0.0156 after the first panning round to 0.158 in the 
third panning round, indicating a 10-fold increase. The values on their own appear low, but the 
enrichment factor of 10 speaks for appropriate and successful selection strategy and is reflective 
Studies performed 
137 
of selecting binders with higher affinities every round. Other studies have obtained merely a 
doubling of mean absorbance (24). Low OD values might indicate that selected antibody 
fragments are not specific to EHV-1 since the risk remains that sucrose-gradient purified virus 
aliquot is not entirely free from cell debris and binding might have occurred to contaminants of 
the aliquot.  
Our selection strategies of decreasing coating conditions and increasing washing steps 
are in coherence with previous studies, who employed the same strategies reaching similar 
results (20, 24, 33). Selection stringency conditions can be considered successful when the 
negative control within the ELISA assays is 10 to 20-fold lower than the positive control as 
suggested in a current protocol (33). In the study on hand, the absorbance of negative control 
was on average 10-fold lower than the positive control, leaving no doubt that selection 
stringency strategies were implemented correctly.  
Since suggestion in the current literature are highly controversial, one study suggested 
to declare clones worth further investigation when absorbance was 5-fold higher than the 
negative control (24), others consider clones for further evaluation when absorbance is 2.5-fold 
higher than the negative control (34). In the present study, no clone reached an absorbance of 
5-fold higher than the negative control, but clones of the third round reached absorbance 2.5-
fold higher than the negative control. Those were considered for further evaluation. This 
decision was further supported by findings of Sengupta et al. (35), who deemed clones 
noteworthy when absorbance was above 0.2. Application of a non-equine-specific antigen as 
additional negative control would have contributed to distinction of EHV-1-positive and-
negative clones. We decided to evaluate all clones from panning round three which yielded 
absorbance above 0.25 in a colony PCR to detect full-length antibody fragments.  
Similar to human (28) and macaque (30) scFv fragments, equine full-length scFv 
antibody fragments were expected to be approximately 800 bp in size. When visualised on an 
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agarose gel after colony PCR, a band at 1 kb should be expected taking PCR primer restriction 
sites into consideration. One clone, scFv-3H2, reaching an absorbance of 0.254, proofed to 
contain a full-length insert and was therefore considered for further characterisation by 
sequencing. Remaining clones reached absorbance of above 0.25 as well, however, they did not 
contain full-length scFv inserts since sizes ranged from 300 to 600 bp. The occurrence of 
defective clones is not uncommon (28, 36, 37). When constructing a recombinant antibody 
library, its quality is continuously assessed by colony PCR after each transformation reaction. 
It is recommended to assemble the complete library if at least 80 % of inserts contain full-length 
inserts (28). This library was assembled from sublibrary aliquots containing 80 % to 100 % 
full-length inserts. While this presents a high likelihood of isolating functioning, full-length 
inserts, this leaves room for packaging of possibly defective clones or empty vectors into the 
phage library (36). These may retain some antigen binding abilities as well as ampicillin 
resistance obtained from the phagemid vector and thus continue to be amplified during panning 
rounds. This could lead to background noise in terms of resource management in growth media, 
preventing or blocking antigen binding possibilities and may grow as satellite colonies on 
densely grown agar plates (36). During selection of colonies, no discrimination between 
defective and non-defective clones is possible as no marker (e.g. blue-white-screening) other 
than ampicillin resistance was used. Clones derived their ampicillin resistance from the vector, 
hence it is possible for empty vectors or defective clones to grow in spite of the presence of 
ampicillin. Defective clones showing bands of approximately 350 bp can be deemed to depict 
insert-less vectors according to Kuegler et al. (28). Clones of approximately 600 bp were 
assumed to contain incomplete scFv fragments and were not considered for further evaluation.  
Sequencing of scFv-3H2 confirmed that it contains a full-length insert consisting of a 
VH domain connected by a peptide linker (Gly4Ser)3 to a VL domain and was successfully 
ligated into phagemid vector pCANTAB 5E. Its size of 743bp corresponds with 
abovementioned findings. Sequence analysis revealed predominantly hydrophilic amino acid 
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residues, which is known to enhance flexibility (38). Serine, Glycine and Tyrosine are key 
amino acid residues in antibody sequences and ideally abundantly present. This was the case 
for scFv-3H2. The key residue Cys23 was present, yet Trp41, Leu89 and Cys104 were 
substituted by Glycine, Methionine and Tyrosine, some of which bear similar biochemical 
characteristics with the original key residues. One irregular nucleotide base exchange occurred 
in the linker sequence which resulted in glycine being exchanged by serine. Sequencing results 
were assessed thoroughly for overlapping peaks or interruptions to exclude contamination or 
erroneous interpretation, which could have influenced the translation of bases. No interruptions 
or traces of contamination were observed (Figure S5).  
Faulty linker sequences are thought to affect proper protein folding and rendering 
antibody proteins functionless (39). A 3D model of scFv-3H2 confirmed CDRs to lie in their 
expected positions, with the CDR-H3 lying at the center of the molecule as expected. Highest 
probability to interact with the antigen was obtained for CDR-H2 (Pt 0,48) and CDR-L1 (Pt 
0.48) (14). CDRs remained close to each other on the antibodies surface and folded into a 
compact molecule. This leaves to assume that the base exchange in the linker did not affect 
antibody properties of scFv-3H2 and a characterisation of this antibody is worthwhile. It must 
be kept in mind however, that Phyre2, the 3D prediction software, is limited in its capacities to 
predict accurate models. Amino acid sequences as the sole source, as it was in this study, may 
not show point mutations to have an effect on 3D representations. Further 3D models are 
sculpted on known, representative molecules rather than true structure of the antibody and 
whether or not the molecule is truly compact and stable is best assessed by noticing presence 
of cysteine residues within CDRs, particularly CDR-3 (40). Despite its seemingly compact 
structure scFv-3H2 unfortunately lacks the cysteine residues, along with mutations within the 
linker sequence. Both observations should be kept in mind during downstream applications in 
regards to molecule stability as they can have an effect on the antibody fragments binding 
ability, expression and stability (39).  
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scFv-3H2 was propagated and purified by several centrifugal processes to isolate 
periplasmic fractions from supernatant of E. coli cell cultures at the end of the 23 hr induction. 
Purification of periplasmic and supernatant fractions via ÄKTA chromatography revealed 
peaks in both, periplasmic and supernatant fractions, which is surprising, since scFv are usually 
expressed within the periplasmic fraction. This result is however in accordance with the results 
obtained by electrophoresis on 12% SDS-PAGE gels. It confirmed the majority of scFv 
expression to occur within the periplasmic fraction, even though a faint band at 27 kDa is 
detectable within the supernatant fraction as well. Studies report that an escape into the 
supernatant is not uncommon (41). Since its concentration is low and the band at 27 kDa faint, 
it could also be argued that it might be a protein expressed by E.coli rather than indicative for 
the scFv fragment. From thereinafter supernatant fraction and peri-plasmic fraction were pooled 
for further characterisation and maximisation of scFv output, which is a customary procedure 
(41).  
For further downstream application fulfilling characterisation purposes, protein 
concentrations ranging from 0.2 to 0.8 mg/ml are recommended (42-44). Higher concentrations 
would result in scFv aggregation and lower concentrations could be representative of scFv 
inclusion bodies, insoluble scFv molecules (42-44). ScFv-3H2 yielded 0.06678 mg/ml and is 
well below abovementioned thresholds. It is reported that scFv yields from E. coli production 
systems vary often (43). This is thought to be in conjunction with IPTG concentration during 
induction since merely 5 µM per L have been reported sufficient to induce soluble scFv 
molecules rather than forming inclusion bodies (43). In this study, 2mM per L were used for 
induction purposes, which might have caused the production of inclusion bodies as well. 
Inclusion bodies can be solubilized by centrifugation and refolding procedures such as urea 
treatment; unfortunately, we did not apply this treatment to recover scFv molecules. Incubation 
temperature during induction is also considered to have an effect on protein yield (43). While 
we incubated the culture at 30°C for 23 hrs, other studies incubated at 25°C and 37°C for 16 
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hours which resulted in differing yields (43). While E. coli production systems are reliable and 
robust production systems, given these observations, we recommend to perform IPTG titrations 
and temperature adjustments prior to future soluble scFv production to prevent formation of 
inclusion bodies.  
Given this low protein concentration, it is no surprise that purified scFv-3H2 failed to 
react in further assessments of binding activity by ELISA and Western Blot analysis when 
exposed to the antigen EHV-1. In ELISA assay, its binding specificities were not comparable 
to the full size mAb 6B11 positive control and did not seem to retain any of the binding 
properties of the full IgG molecule it was derived from. No binding activity is noticeable in 
Western Blot analysis either, yet no PC to confirm presence of EHV-1 proteins was applied to 
membranes either; hence it cannot be excluded that lack of binding activity of scFv-3H2 is not 
due to problems with viral coating. Furthermore, given its low concentration, preparing a 
dilution series and beginning with a 1:10 dilution was not advantageous. Additionally, even 
though panning occurred against EHV-1, due to a high genetic and antigenic similarity to EHV-
4, there is a small chance that the selected scFv might exhibit better binding affinities to EHV-
4 instead of EHV-1 (45, 46). Further assessments by e.g. ELISA would elucidate whether or 
not cross-reactivity are of concern in this study. Furthermore, the base exchange within the 
linker sequence might have had an effect on the scFv-3H2 properties after all (39).  
 
4.2.6 Conclusion 
We selected an anti-EHV-1 scFv via three rounds of phage display biopanning from an 
immunized equine scFv library using EHV-1 as target antigen (47). The selected antibody was 
expressed in E. coli, pre-dominantly within the peri-plasmic fraction, however not at sufficient 
concentrations for further characterisation by downstream applications. In future, we 
recommend to assess whether concentration and binding affinity could be enhanced by error-
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prone PCR, mutation strains, chain shuffling or DNA shuffling during the library assembly 
stage (47) or to perform IPTG titrations and temperature adjustments prior to future soluble 
scFv production to prevent formation of inclusion bodies during protein expression (43). Our 
results lay the groundwork for further investigation of recombinant equine antibodies for 
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5 GENERAL DISCUSSION 
The aim of this thesis was the construction of an equine-specific recombinant antibody 
library, which was accomplished successfully, to make up for a shortage thereof. A further aim, 
was the establishment of phage display technology as a suitable display method for isolation of 
equine scFv fragments from the newly constructed library, which was accomplished. The 
library was screened against EHV-1, since it is one of the most prevalent and detrimental 
pathogens affecting horse populations worldwide. The overall quality of the newly constructed 
library is evaluated best by considering certain key features: sequence diversity within the 
library, ease of generation of desired antibody fragment format and the format itself in regards 
to structural stability and key antibody features and suitability of the chosen display method 
(1).  
In the natural host, antibody sequence diversity is generated during B-cell proliferation in 
the presence of antigen, whereby the immunoglobulin locus undergoes SHM (1). Horses in 
particular are hypothesized to develop the greater part of antibody sequence diversity in that 
particular manner (2). In the course of generating large antibody libraries, efforts are made to 
mimic SHM, yet initially sequence diversity is solely dependent on naturally occurring diversity 
(1, 3). It is determined according to the number of individual clones within a library, which 
equates with the size of a library (1, 3-5). The immunized library constructed in this study, has 
an absolute size of 4.8x108 individual clones, whereby absolute size has to be differentiated 
from functional size: while the absolute size is an estimation of all individual clones available 
in the library, the functional size refers to all individual clones encoding full-length scFv 
antibodies (1, 3-5). Hence, the functional size is more meaningful than the absolute size since 
a high functional size indicates high occurrence of individual clones encoding full-length scFv 
antibody sequences, thereby high sequence diversity (1). Nevertheless, the probability of 
identifying individual clones encoding full-length scFv antibody sequences increases with 
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absolute library size (1). Functional size of the library on hand, was determined by colony PCR 
and 80 % of individual clones were observed to contain full-length scFv antibody fragments. 
The remaining 20 % are considered defective clones. Sequence diversity was further confirmed 
by fingerprint analysis as multiple repetitions of restriction patterns were absent. The sequence 
diversity of the equine library can therefore be considered high and is comparable to other 
studies constructing immunized libraries (6, 7), yet a broader coverage of allelic sequence 
diversity and elimination of defective clones could be pursued in future studies (1).  
One approach to improve sequence diversity is non-targeted diversification which includes 
error-prone PCR, use of mutator E. coli strains or chain shuffling (8, 9). All of these methods 
are utilized to introduce mutations, thereby randomly inserting sequence diversity into antibody 
sequences (8). Several studies have successfully increased library sizes up to 100-fold with 
these techniques (9). Yet, non-targeted diversification has also had disadvantageous effects as 
frame shift mutants occurred frequently and lead to non-functional proteins during 
diversification procedures; additionally, CDR regions, crucial antigen binding regions, were 
predominantly affected by deleterious mutations (1). The approach of targeted diversification 
within these regions could prevent deleterious mutations and contribute to sequence 
diversification (1, 8, 9). Not only would it increase functional library sizes, hence sequence 
diversity but also affinity of individual antibody clones, since it is reported that functional 
library size and individual affinities correlate (10). Methods enabling targeted diversification 
include the generation of synthetic antibody libraries introducing oligonucleotides already at 
the library generation level, trinucleotide mutagenesis, CDR-walking and CDR-cassettes (1). 
All methods could increase functional library size by inserting diversity by substitution of only 
few amino acids (4 aa to 6aa ) or entirely replacing CDR regions in silico, thereby controlling 
CDR regions and avoiding unwanted amino acids and stop codons (11-13). 
General discussion 
149 
Further considerations could be the application of vector systems containing a positive 
selection marker for protein integrity such as ß – lactamase as selection for in-frame, full size 
protein expression (1). In this case, simply clones unaffected by frameshift or stop codons 
would survive protein expression and respective antibiotic selection (1).  
In humans, recombinant antibody and library research is thus far, that it is known which 
VH framework is frequently found in human antibodies and combines well with all light chains, 
expresses well in bacteria and displays well on phages (1), which would be something to aim 
for in equine immunoglobulin research. Investigations have already observed preferential gene 
segment usage in both equine heavy as well as light chains (14-16). Out of 50 VH gene 
segments, four were found expressed frequently and two were recurring in every clone assessed 
in their studies (15). Preferential use of certain heavy chain joining and diversity gene segments 
was reported as well (15, 16). This information could be used in the in silico design of equine 
antibodies and when establishing a single VH framework frequently found in horses to combine 
with a range of light chains and subsequently expresses well in microbial production systems 
as mentioned above.  
Beside sequence diversity, ease of generation of desired antibody fragment format and the 
format itself play a crucial role during library construction as it influences antibody expression 
and lastly drug tolerance (1). ScFv fragments are a popular format due to their favourable 
expression properties in periplasm of E. coli cells and their manipulability within this system 
to enhance selection of specific, high affinity binders (1, 4, 5). In this dissertation, 
comprehensive primer sets facilitated the generation of equine scFv by amplifying variable 
antibody domains of heavy and light chains and fusion thereof by SOE-PCR. Sequences of 
exemplary antibody sequence HL1 (Manuscript I, Figure 6) and candidate scFv-3H2 
(Manuscript II, Figure 4) both revealed g3 signal sequence of phagemid vector pCANTAB 5E 
as well as variable regions of equine antibody heavy and light chains in one reading frame. 
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Presence of conserved key amino acid residues in antibodies, was confirmed, yet only Cys23 
was at the desired position. Trp, Leu and the second Cys residue were present abundantly, yet 
substituted by other residues at key positions.  
In theory, the fusion of two antibody chains into one gene, allows the expression of equal 
amounts of both chains guaranteed as one homogenous protein in amounts and concentrations 
sufficient for diagnostic and therapeutic purposes (4, 5). This is in conflict with the results on 
hand, as the selected scFv-3H2 was expressed at low concentrations. After antibody purification 
via ÄKTA chromatography, Bradford assay yielded a concentration of 0.06678 mg/ml, which 
is below recommended concentrations of 0.2 to 0.8 mg/ml for characterisation purposes (17-
19). This result could be due to aggregation and formation of inclusion bodies (17-19) or due 
to the faulty linker sequence, as a point mutation was observed and affected linker sequences 
are considered to affect proper protein folding and therefore binding capacities (20). 
Additionally, scFv-3H2 lacks stabilising Cys bridges within CDRs, rendering the molecule 
potentially instable.  
This result is not uncommon as in numerous other studies scFv antibody fragments, have 
proven to be expressed at frequently fluctuating levels within bacterial systems, be only 
moderately stable and showed a tendency to form multimers or aggregates (17-19). Given these 
findings, human recombinant antibody therapeutics, which had initially been developed in the 
scFv format, were re-combined with Fc regions of either the target species or the original 
species to enhance binding kinetics (18, 19, 21). This approach of re-combining scFv into 
mono-, bi- or multivalent scFv-Fc or Fab complexes occurs frequently since the Fc region 
renders the fragments into molecules with higher structural stability, reduced aggregation, 
higher monomeric proportions and a reduced likelihood of impairment of function (1). Thus, 
these complexes have replaced scFv in more recent libraries (1).  
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Another alternative to scFv present sdAbs: this format fulfils the requirements of high 
soluble expression in E. coli periplasm, contain long CDR3 regions and facilitate antigen 
binding due to their exposed CDR structures (1). The missing Fc part however limits sdAbs 
half-life in vivo, which could be prevented through e.g. PEGylation increasing molecule size 
thereby preventing premature kidney clearance (1). This kind of modification is costly and 
might outweigh the advantages gained by cheap bacterial expression (1). Small recombinant 
antibodies in general miss Fc’s effector functions and are only utilizable for applications that 
do not require such functions (1).  
Given our findings and multiple reports (17-19, 21-24), one could consider re-combining 
scFv-3H2 into a scFv-Fc complex prior to expression. This format has proven effective against 
other equine viral infections: a study by Ruelker et al (22) isolated a human-like scFv from a 
non-human primate scFv antibody library to find a therapeutic agent against VEEV. The anti-
VEEV-scFv was re-cloned into a bivalent scFv-Fc complex to increase stability and was 
successful in inducing protective immunity against VEEV in mice (22). Huelseweh et al (23) 
isolated four scFv fragments from two immunized macaque libraries to isolate antibody 
therapeutics against WEEV for human use. Isolated scFv fragments were also reformatted into 
scFv-Fc complexes and three out of four showed neutralizing activity against WEEV (23). 
Considering these results, the scFv fragment generated in this study, provides a valuable starting 
point for future re-combination and development of equine antibody therapeutics. A more 
straightforward recommendation is hard to come by as none of currently approved, recombinant 
antibody scFv therapeutics neither human nor veterinary, have been raised against viral agents.  
We have determined that the newly constructed equine, immunized antibody library 
provided a high diversity of antibody sequences in the versatile scFv format. This leaves to 
evaluate the suitability of phage display technology to isolate high affinity binders from this 
library: phage display technology has proven the most robust technology over the past 30 years 
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and the most frequently used display method in numerous studies (6, 25, 26). In this study, it 
proved suitable as well since it facilitated isolation of an equine antibody fragment, scFv-3H2, 
after three rounds of biopanning. Successfully implemented biopanning rounds are 
characterised by an increase of mean OD values, which is deemed reflective of selection of 
antibody candidates with higher binding affinities to the antigen of interest (27). In previous 
publications, mean absorbance of selected clones, have doubled throughout panning rounds 
(28), which is in accordance with mean absorbance of scFv clones in this dissertation as clones 
in round three had mean absorbance three-fold higher than in round one. Furthermore, an 
interplay of phage input and output titre ensures correctly implemented selection strategy of 
phage display technology (29), which was observable in the experiment on hand. The selected 
clone scFv-3H2 yielded an absorbance of 0.254, which is one of the highest absorbance yielded 
in this study, yet it could be improved and reach absorbance similar to scFv phage clones 
isolated in a study by Kirsch et al (27), which reached OD values ranging from approximately 
0.6 to 2.1. Their results must be compared to our result with caution as they use scFv phage 
clones rather than soluble scFv as produced in our study. Some antibody fragments bind only 
as antibody phage particles and might lead to false positives (27).  
Absorbance is also strongly influenced by the antigen used (30): we utilised sucrose-
gradient purified EHV-1 as the antigen of interest and applied it to all downstream applications. 
Purification of viral capsids from herpesvirus infected cells appeared successful as a clear band 
was detectable and extractable after centrifugation. Recent protocols (31) suggest herpesvirus 
purification using PBS buffer, however our experiments in advance of phage display have 
resulted in clearer and cleaner bands using TRIS buffer and subsequent ELISA confirmed 
binding between EHV-1 and an EHV-1-specific mAb. Sucrose-gradient purified EHV-1 quality 
was deemed sufficient to apply within subsequent procedures. However, purification process 
bears the risk of not being entirely free of cell debris and as the possibility of selecting 
antibodies binding to viral background rather than the antigen is possible. Further functional 
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testing (e.g. titration in cell culture or western blotting) of purified virus prior to downstream 
applications, would have elucidated the viral infectivity and virus integrity further.  
Alternative display methods could be considered with the aim of selecting binders with 
higher affinities: ribosome display would be an alternative as it omits laborious transformation 
procedures, which otherwise may lead to deleterious mutations and frameshifts, all the while 
generating libraries of sizes up to 1012 individual members (1). Ribosomal display method 
merely requires mild elution ingredients to elute high-affinity binders, which is not possible in 
technologies that rely on elution based on disruption of antibody-antigen interaction such as 
phage display (1). On the other hand, it is technically more challenging than phage display and 
solely scFv fragments can be displayed which would excluded re-cloned formats e.g. the scFv-
Fc (1). Yeast display can be excluded as alternative approach to isolate antibody fragments of 
smaller sizes since it is only applicable to full length IgG (1). A more frequently used approach 
is the abovementioned isolation of smaller antibody fragments from immunized libraries via 
phage display and re-combining the candidates into scFv-Fc as applied for the approved and 
frequently utilized therapeutic recombinant antibody Belimumab (Benlysta) (32). The two 
veterinary preparations have also been adjusted by recombination for better drug tolerance 
within the target species (33, 34). 
In regards to fighting EHV-1 infection, recombinant equine antibodies generated in our 
experiments may provide biological reagents aiding researchers in the near future to further 
elucidate viral proteins and antigenic epitopes involved in viral infectivity, replication, latency 
and host immune response as well as ultimately aid in impairment of these processes involved 
in viral pathogenesis (35).   
General discussion 
154 
5.1 Conclusion & Outlook 
Horses are and will be exposed to a variety of pathogens throughout their lives, EHV-1 
being one of the most prevalent, infectious and detrimental ones. Current prevention and 
therapeutic agents, both on the market and in research, do not prevent viremia and latent 
infection. Recombinant antibody therapeutics offer new options studying and fighting viral 
transmission.  
This dissertation presented the construction of recombinant equine antibodies in a highly 
diverse equine, immunized antibody library in the verstaile scFv format. A primer set 
specifically designed to amplify equine antibody variable regions, including linker sequences 
to enable fusion of antibody chains into the scFv format, was successful. Moreover, it enabled 
the ligation into a phagemid vector for subsequent phage library assembly. Phage display 
technology proofed suitable as a display method to isolate equine scFv from the newly 
constructed library, yet modifications to viral purification, and soluble scFv expression 
protocols should be considered. Most authors in the field of antibody generation and the results 
of this dissertation confirm the general consensus that there is more than one good solution for 
designing antibody libaries and each method should be adjusted to carefully (1). 
In future, recombinant antibody therapeutics will be of high interest as alternative to eradicate 
“hardy” pathogens, present an alternative treatment to antibiotics, where antibiotic resistance 
has played a role and treat cancerous tissue (36). Professionals will aim for standardised and 
economical production of antibody therpeutics and diagnostics with outstanding 
pharmacokinetics and sufficient half-life periods within the patient. The results of this 
dissertation will contribute and lay the groundworks for further investigation of recombinant 
equine antibodies for application in equine veterinary therapeutic or diagnostic agents and 
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6 ZUSAMMENFASSUNG & SUMMARY 
Zusammenfassung 
 Pferde sind einer Vielzahl von Krankheitserregern und Krankheiten ausgesetzt. Das 
Equine Herpesvirus Typ 1 (EHV-1) ist einer der am häufigsten vorkommenden viralen 
Krankheitserreger, die Pferde infizieren. Rund 60 % der Pferdepopulation weltweit sind mit 
diesem Virus infiziert. Die Symptome einer EHV-1-Infektion reichen von einer leichten 
Atemwegserkrankung bis zu einer möglicherweise tödlich verlaufenden neonatalen 
Pneumonie, einem Trächtigkeitsabbruch während des letzten Trimesters oder der schweren 
neurologischen Erkrankung der Equine Myeloencephalopathie (EHM). Es ist nicht nur ein hoch 
ansteckendes Virus, vor allem aber stellen Tiere, die nur latent infiziert sind, eine besondere 
Gefahr der Infektion dar. Virusinfektionen im latenten Status können jederzeit reaktiviert 
werden und schwere Krankheiten verursachen sowie zur weiteren Übertragung unter Pferden 
beitragen. Gegenwärtige Präventionsmethoden bestehen aus Impfregimen, Anpassungen der 
Pferdehaltung oder symptomatischer Behandlung. Impfregime zielen darauf ab, Virämie zu 
beseitigen und nachfolgende Krankheiten zu verhindern. Es hat sich jedoch gezeigt, dass diese 
Methoden die Dauer der Virämie nicht verändert oder vor latenten Infektionen schützt. 
Therapeutika gegen EHV-1-Infektionen wurden zu diesem Zeitpunkt nur in vitro getestet, und 
ihre Wirksamkeit hat sich als noch nicht bahnbrechend erwiesen. Man ist sich einig, dass der 
Schutz gegen EHV-1, pferdespezifische, neutralisierende Antikörper erfordert. Ein moderner 
Ansatz zur Lösung dieses Problems ist die Erzeugung rekombinanter Antikörper in 
Antikörperbibliotheken. Rekombinante Antikörper werden synthetisch hergestellt und gemäß 
einem bestimmten Wirt oder Antigen manipuliert. Infolgedessen können diese Antikörper als 
vorbeugende oder therapeutische Arzneimittel verwendet werden. Meine Dissertation zielt 
darauf ab, rekombinante equine Antikörper im single-chain-Fragment-variable Format (scFv) 
in einer Antikörperbibliothek zu konstruieren, da bisher keine derartigen rekombinanten 
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Antikörpertherapeutika für Pferde existieren. Als Qualitätsnachweis der Bibliothek, wird diese 
Bibliothek auf scFv Antikörper gegen EHV-1 untersucht. 
 Equine scFv-Antikörper wurden unter Verwendung eines Primer-Sets konstruiert, das 
zur Amplifikation der gesamten genomischen Immunglobulin-Diversität von Equiden 
entwickelt wurde. Die Primer und die PCR-Bedingungen wurden vor der scFv-Konstruktion 
getestet und optimiert. Zur Primer-Etablierung und scFv-Konstruktion wurden PBMCs eines 
Wallachs isoliert, der zuvor gegen EHV-1 immunisiert wurde. Die RNA wurde extrahiert und 
in cDNA transkribiert. Variable Antikörperregionen von schweren und leichten 
Antikörperketten wurden separat amplifiziert und während einer SOE-PCR durch eine 
Linkersequenz verbunden, wodurch scFv-Sequenzen erzeugt wurden. Zunächst wurde durch 
Klonieren und Sequenzieren bestätigt, dass alle PCR-Produkte die gewünschten Sequenzen 
enthielten und dann mit der Bibliotheksassemblierung fortgefahren. scFv-Sequenzen wurden in 
einen Phagemidvektor ligiert und in phagenkompetente E.coli-Zellen transformiert. Dieser 
Prozess der Ligation und Transformation wurde mehrfach wiederholt, bis eine 
Bibliotheksdiversität von 4,8 × 108 einzelner Klone erreicht wurde. 
 Die Bibliothek wurde mittels der Phagendisplay-Methode auf einen anti-EHV-1-
scFv-Antikörper untersucht. Während der Phagendisplay-Methode werden scFv-Sequenzen der 
Bibliothek in Bakteriophagen eingebaut. Diese Bakteriophagen exprimieren die scFv-
Sequenzen sowohl im Genotyp als auch im Phänotyp. Alle Bakteriophagen werden daraufhin 
dem Antigen (EHV-1) ausgesetzt, und diejenigen Bakteriophagen, die phänotypisch scFv-
Sequenzen exprimieren, die an EHV-1 binden, werden eluiert. Die Aussetzung der Phagen 
gegenüber dem Antigen erfolgt während der sogenannten Biopanning-Runden. Während jeder 
Biopanning-Runde werden die Bedingungen, z.B. die Konzentration des Antigens oder die 
Waschschritte stringenter eingestellt, um schwach bindende scFv-Sequenzen von stark 
bindenden scFv-Sequenzen zu trennen. Mit Hilfe von ELISA werden stark bindende scFv-
Sequenzen ermittelt, wenn das OD-Signal des scFv fünfmal höher ist als das OD-Signal der 
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Negativkontrolle. Zur Vorbereitung der Phagendisplay-Technik wurde das Antigen EHV-1 
durch Saccharosegradientenzentrifugation aufgereinigt. Die erzeugte Antikörperbibliothek 
wurde in M13KO7-Bakteriophagen verpackt und während drei Biopanning-Runden, EHV-1 
ausgesetzt. Nach der dritten Runde wurde ein spezifischer scFv-Antikörper isoliert. Der scFv-
3H2 zeigt eine starke Bindung und Sequenzierung ergab, dass es ein vielversprechender scFv-
Antikörperkandidat ist, der weiter charakterisiert wird, um das pharmakokinetische Potenzial 
für zukünftige therapeutische Anwendungen zu beweisen.  
 Meine Dissertation trägt zur Entwicklung neuartiger, alternativer Lösungen zur 
Vorbeugung und Behandlung von Krankheitserregern und Krankheiten bei Pferden bei. Die 
scFv-Antikörperbibliothek für Pferde bietet einen Ausgangspunkt für die breitere Etablierung 
von rekombinanten Antikörpern und Phagendisplay in der Entwicklung von Pferde- und 
Tierarzneimitteln zur Verbesserung der Tiergesundheit und des Tierschutzes. 
  
Zusammenfassung & Summary 
161 
Summary 
Horses are exposed to a large variety of pathogens and diseases. Equine herpesvirus 
Type 1 (EHV-1) is one of the most prevalent viral pathogens infecting horses. Approximately 
60 % of the horse population worldwide are infected with this virus. EHV-1 infection symptoms 
range from mild respiratory disease to potentially fatal neonatal pneumonia, abortion during 
late gestation or the severe neurological disease equine myeloencephalopathy (EHM). Not only 
is it a highly contagious virus but the most critical form of transmission are the silent shedders 
once the virus has undergone latency. Viral infection can be reactivated at any time and cause 
severe diseases and contribute to transmission among horses. Current prevention methods 
consist of vaccination regimes, horse husbandry adjustments or symptomatic treatment. 
Vaccination programs aim to eliminate viremia and prevent subsequent diseases. However, 
these methods have not proven to alter duration of viremia (1, 2) nor protect against latent 
infection. Therapeutics against EHV-1 infection have only been trialled in vitro at this point 
and their efficacy has not been proven to be ground breaking. It is suggested that protection and 
treatment will require equine specific neutralizing antibodies. A modern approach to resolve 
this issue, is the generation of recombinant antibodies in antibody libraries. Recombinant 
antibodies are produced synthetically and manipulated according to a specific host or antigen. 
As a result, these antibodies can be used as preventative or therapeutic drugs. My dissertation 
aims to construct recombinant equine antibodies in the single-chain-Fragment-variable format 
(scFv) in an antibody library since to date, no such recombinant antibody therapeutics exist for 
horses. As proof-of-principle, this library was screened against EHV-1. 
Equine scFv antibodies were constructed by using a primer set designed to amplify the 
whole equine genomic immunoglobulin diversity. Primers were tested and PCR conditions 
optimised before scFv construction. For primer establishment and scFv construction, PBMCs 
were isolated from a gelding that has been immunized against EHV-1. RNA was extracted and 
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reversely transcribed into cDNA. Variable antibody regions of antibody heavy and light chains 
were amplified separately and connected during SOE PCR by a linker sequence, thereby 
generating scFv sequences. In preparation of library assembly, all PCR products were 
confirmed to contain desired sequences by cloning and sequencing. ScFv sequences were 
ligated into a phagemid vector and transformed into phage-competent E. coli cells. This process 
of ligation and transformation was repeated until a library diversity of 4.8x108 individual clones 
was reached. 
The library was screened for an anti-EHV-1 scFv antibody by phage display technique. 
During the phage display technique scFv sequences of the library are incorporated into 
bacteriophages. These bacteriophages will express the scFv sequences on their genotype as well 
as on their phenotype. All bacteriophages are exposed to the antigen of interest (EHV-1) and 
those bacteriophages that are phenotypically expressing scFv sequences binding to EHV-1 are 
eluted. The exposure to antigen occurs during biopanning rounds. Throughout each panning 
rounds, conditions such as concentration of antigen or washing steps, are adjusted for more 
stringency, aiming to separate weak binding scFv sequences from strong binding scFv 
sequences. ELISA will determine strong binders, when OD signals are five times higher than 
OD signals of the negative control. Prior to the screening, the antigen of interest, EHV-1 was 
purified by sucrose gradient centrifugation. The generated antibody library was packaged into 
M13KO7 bacteriophages and exposed to EHV-1 during three rounds of biopanning. After the 
third round, a specific scFv antibody was isolated. The scFv-3H2 shows strong binding ability 
and sequencing revealed it to be a promising scFv antibody candidate, which will be 
characterised further to prove pharmacokinetic potential for future therapeutic application. 
My thesis contributes to the development of novel, alternative solutions in the prevention 
and treatment of equine pathogens and diseases. The equine scFv antibody library presents a 
starting point for the broader establishment of recombinant, equine antibodies and phage 
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7.2 Supplementary files  
7.2.1 Manuscript I: PCR primer for the construction of an equine immunoglobulin library in the single-chain fragment variable 
(scFv) format 
Table S1: Sequences used for primer design based on published equine immunoglobulin isotype IgG, subtypes IgG1-7, sequences and database entries. 
Using BLAST software, the database was screened for equine heavy and light chain sequences of the variable, joining, and first constant 
immunoglobulin gene segments.  
Primer set Gene segment region Accession number Reference 
PCR1Hpool_FOR Immunoglobulin heavy chain V-D-J  HM176092 Sun et al. (2010) 
PCR2Hpool_REV 
 
HM175940 Sun et al. (2010) 
 
HM175963 Sun et al. (2010) 
HM176085 Sun et al. (2010) 
HM175938 Sun et al. (2010) 
HM176014 Sun et al. (2010) 
HM176050 Sun et al. (2010) 
HM175992 Sun et al. (2010) 
L81155 Schrenzel et al. (1997) 
HQ403634 Tallmadge et al. (2003) 
HM175920 Sun et al. (2010) 
HM176023 Sun et al. (2010) 
VH4 Sun et al. (2010) 
VH5 Sun et al. (2010) 
HM175979 Sun et al. (2010) 
HM176009 Sun et al. (2010) 
HM175900 Sun et al. (2010) 
HM176049 Sun et al. (2010) 
HM175919 Sun et al. (2010) 
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HM175894 Sun et al. (2010) 
HM176021 Sun et al. (2010) 
HM176027 Sun et al. (2010) 
HM175968 Sun et al. (2010) 
HM175991 Sun et al. (2010) 
pVH18 Sun et al. (2010) 
VH10 Sun et al. (2010) 
pVH20 Sun et al. (2010) 
VH11 Sun et al. (2010) 
HQ403618 Tallmadge et al. (2003) 
VH3 Sun et al. (2010) 
VH9 Sun et al. (2010) 
VH13 Sun et al. (2010) 
HM175915 Sun et al. (2010) 
VH_ORF2 Sun et al. (2010) 
pVH34 Sun et al. (2010) 
pVH26 Sun et al. (2010) 
pVH10 Sun et al. (2010) 
VH_ORF1 Sun et al. (2010) 
pVH27 Sun et al. (2010) 
pVH1 Sun et al. (2010) 
VH_ORF3 Sun et al. (2010) 
VH6 Sun et al. (2010) 
pVH19 Sun et al. (2010) 
pVH6 Sun et al. (2010) 
VH_ORF6 Sun et al. (2010) 
pVH24 Sun et al. (2010) 
pVH31 Sun et al. (2010) 
Appendix 
167 
pVH30 Sun et al. (2010) 
pVH3 Sun et al. (2010) 
pVH32 Sun et al. (2010) 
VH8 Sun et al. (2010) 
VH7 Sun et al. (2010) 
JH1 Sun et al. (2010) 
JH2 Sun et al. (2010) 
HM175973 Sun et al. (2010) 
HM175987 Sun et al. (2010) 
HM175895 Sun et al. (2010) 
HM175889 Sun et al. (2010) 
HM176039 Sun et al. (2010) 
HM175984 Sun et al. (2010) 
HM176051 Sun et al. (2010) 
HM176052 Sun et al. (2010) 
HM175991 Sun et al. (2010) 
HM175969 Sun et al. (2010) 
HM175959 Sun et al. (2010) 
HM175957 Sun et al. (2010) 
HM176042 Sun et al. (2010) 
DQ125416 Almagro et al. (2006) 
L81157 Schrenzel et al. (1997) 
HM176028 Sun et al. (2010) 
HM176004 Sun et al. (2010) 
HM176011 Sun et al. (2010) 
HM175921 Sun et al. (2010) 
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Primer set Gene segment region Accession number Reference 
PCR1Hpool_REV Immunoglobulin heavy chain constant 
region 
GSP2 txid9796 
    
Primer set Gene segment region Accession number Reference 
PCR1Lpool_FOR Immunoglobulin lambda light chain V-J HM176279 Sun et al. (2010) 
PCR2Lpool_FOR 
 
HM176280 Sun et al. (2010) 
PCR2Lpool_REV HM176281 Sun et al. (2010) 
 
HM176282 Sun et al. (2010) 
HM176283 Sun et al. (2010) 
HM176284 Sun et al. (2010) 
HM176285 Sun et al. (2010) 
HM176286 Sun et al. (2010) 
HM176287 Sun et al. (2010) 
HM176288 Sun et al. (2010) 
HM176289 Sun et al. (2010) 
HM176290 Sun et al. (2010) 
HM176291 Sun et al. (2010) 
HM176292 Sun et al. (2010) 
HM176293 Sun et al. (2010) 
HM176294 Sun et al. (2010) 
HM176295 Sun et al. (2010) 
HM176296 Sun et al. (2010) 
HM176297 Sun et al. (2010) 
HM176298 Sun et al. (2010) 
HM176299 Sun et al. (2010) 
HM176300 Sun et al. (2010) 
HM176301 Sun et al. (2010) 
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HM176302 Sun et al. (2010) 
HM176303 Sun et al. (2010) 
HM176304 Sun et al. (2010) 
HM176305 Sun et al. (2010) 
HM176306 Sun et al. (2010) 
HM176307 Sun et al. (2010) 
HM176308 Sun et al. (2010) 
HM176309 Sun et al. (2010) 
HM176310 Sun et al. (2010) 
HM176311 Sun et al. (2010) 
HM176312 Sun et al. (2010) 
HM176313 Sun et al. (2010) 
HM176314 Sun et al. (2010) 
HM176315 Sun et al. (2010) 
HM176316 Sun et al. (2010) 
HM176317 Sun et al. (2010) 
HM176318 Sun et al. (2010) 
HM176319 Sun et al. (2010) 
HM176320 Sun et al. (2010) 
HM176321 Sun et al. (2010) 
HM176322 Sun et al. (2010) 
HM176323 Sun et al. (2010) 
HM176324 Sun et al. (2010) 
HM176325 Sun et al. (2010) 
HM176326 Sun et al. (2010) 
HM176327 Sun et al. (2010) 
HM176328 Sun et al. (2010) 
HM176329 Sun et al. (2010) 
Appendix 
170 
HM176330 Sun et al. (2010) 
HM176331 Sun et al. (2010) 
HM176332 Sun et al. (2010) 
HM176333 Sun et al. (2010) 
HM176334 Sun et al. (2010) 
HM176335 Sun et al. (2010) 
HM176336 Sun et al. (2010) 
HM176337 Sun et al. (2010) 
HM176338 Sun et al. (2010) 
HM176339 Sun et al. (2010) 
HM176340 Sun et al. (2010) 
HM176341 Sun et al. (2010) 
HM176342 Sun et al. (2010) 
HM176343 Sun et al. (2010) 
HM176344 Sun et al. (2010) 
HM176345 Sun et al. (2010) 
HM176346 Sun et al. (2010) 
HM176347 Sun et al. (2010) 
HM176348 Sun et al. (2010) 
HM176349 Sun et al. (2010) 
HM176350 Sun et al. (2010) 
HM176351 Sun et al. (2010) 
HM176352 Sun et al. (2010) 
HM176353 Sun et al. (2010) 
HM176354 Sun et al. (2010) 
HM176355 Sun et al. (2010) 
HM176356 Sun et al. (2010) 
HM176357 Sun et al. (2010) 
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HM176358 Sun et al. (2010) 
HM176359 Sun et al. (2010) 
HM176360 Sun et al. (2010) 
HM176361 Sun et al. (2010) 
HM176362 Sun et al. (2010) 
HM176363 Sun et al. (2010) 
HM176364 Sun et al. (2010) 
HM176365 Sun et al. (2010) 
HM176366 Sun et al. (2010) 
HM176367 Sun et al. (2010) 
HM176368 Sun et al. (2010) 
HM176369 Sun et al. (2010) 
HM176370 Sun et al. (2010) 
HM176371 Sun et al. (2010) 
HM176372 Sun et al. (2010) 
HM176373 Sun et al. (2010) 
HM176374 Sun et al. (2010) 
HM176375 Sun et al. (2010) 
HM176376 Sun et al. (2010) 
HM176377 Sun et al. (2010) 
HM176378 Sun et al. (2010) 
HM176379 Sun et al. (2010) 
HM176380 Sun et al. (2010) 
HM176381 Sun et al. (2010) 
HM176382 Sun et al. (2010) 
HM176383 Sun et al. (2010) 
HM176384 Sun et al. (2010) 
HM176385 Sun et al. (2010) 
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HM176386 Sun et al. (2010) 
HM176387 Sun et al. (2010) 
HM176388 Sun et al. (2010) 
HM176389 Sun et al. (2010) 
HM176390 Sun et al. (2010) 
HM176391 Sun et al. (2010) 
HM176392 Sun et al. (2010) 
HM176393 Sun et al. (2010) 
HM176394 Sun et al. (2010) 
HM176395 Sun et al. (2010) 
HM176396 Sun et al. (2010) 
HM176397 Sun et al. (2010) 
HM176398 Sun et al. (2010) 
HM176399 Sun et al. (2010) 
HM176400 Sun et al. (2010) 
HM176401 Sun et al. (2010) 
HM176402 Sun et al. (2010) 
HM176403 Sun et al. (2010) 
HM176404 Sun et al. (2010) 
HM176405 Sun et al. (2010) 
HM176406 Sun et al. (2010) 
HM176407 Sun et al. (2010) 
HM176408 Sun et al. (2010) 
HM176409 Sun et al. (2010) 
HM176410 Sun et al. (2010) 
HM176411 Sun et al. (2010) 
HM176412 Sun et al. (2010) 
HM176413 Sun et al. (2010) 
Appendix 
173 
HM176414 Sun et al. (2010) 
HM176415 Sun et al. (2010) 
HM176416 Sun et al. (2010) 
HM176418 Sun et al. (2010) 
HM176419 Sun et al. (2010) 
HM176420 Sun et al. (2010) 
HM176421 Sun et al. (2010) 
HM176422 Sun et al. (2010) 
HM176424 Sun et al. (2010) 
HM176425 Sun et al. (2010) 
HM176426 Sun et al. (2010) 
HM176427 Sun et al. (2010) 
HM176428 Sun et al. (2010) 
HM176429 Sun et al. (2010) 
HM176430 Sun et al. (2010) 
HM176431 Sun et al. (2010) 
HM176432 Sun et al. (2010) 
HM176433 Sun et al. (2010) 
HM176434 Sun et al. (2010) 
HM176435 Sun et al. (2010) 
HM176436 Sun et al. (2010) 
HM176437 Sun et al. (2010) 
HM176438 Sun et al. (2010) 
HM176439 Sun et al. (2010) 
HM176440 Sun et al. (2010) 
HM176441 Sun et al. (2010) 
HM176442 Sun et al. (2010) 
HM176443 Sun et al. (2010) 
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HM176444 Sun et al. (2010) 
HM176445 Sun et al. (2010) 
HM176446 Sun et al. (2010) 
HM176447 Sun et al. (2010) 
HM176448 Sun et al. (2010) 
HM176449 Sun et al. (2010) 
HM176450 Sun et al. (2010) 
HM176451 Sun et al. (2010) 
HM176452 Sun et al. (2010) 
HM176453 Sun et al. (2010) 
HM176454 Sun et al. (2010) 
HM176455 Sun et al. (2010) 
HM176456 Sun et al. (2010) 
HM176457 Sun et al. (2010) 
HM176458 Sun et al. (2010) 
HM176459 Sun et al. (2010) 
HM176460 Sun et al. (2010) 
HM176461 Sun et al. (2010) 
HM176462 Sun et al. (2010) 
HM176463 Sun et al. (2010) 
HM176464 Sun et al. (2010) 
HM176465 Sun et al. (2010) 
HM176466 Sun et al. (2010) 
HM176467 Sun et al. (2010) 
HM176468 Sun et al. (2010) 
HM176469 Sun et al. (2010) 
HM176470 Sun et al. (2010) 
HM176471 Sun et al. (2010) 
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HM176472 Sun et al. (2010) 
HM176473 Sun et al. (2010) 
HM176474 Sun et al. (2010) 
HM176475 Sun et al. (2010) 
HM176476 Sun et al. (2010) 
HM176477 Sun et al. (2010) 
HM176478 Sun et al. (2010) 
HM176479 Sun et al. (2010) 
HM176480 Sun et al. (2010) 
HM176481 Sun et al. (2010) 
HM176482 Sun et al. (2010) 
HM176483 Sun et al. (2010) 
L07562 Home et al 
    
Primer set Gene segment region Accession number Reference 
PCR1Lpool_REV Immunoglobulin lambda light chain 
constant region 
L07563 Home, Ford, Gibson (1992) 
  
L07564 Home, Ford, Gibson (1992) 
L07565 Home, Ford, Gibson (1992) 
  
L07566 Home, Ford, Gibson (1992) 
L07567 Home, Ford, Gibson (1992) 
L07568 Home, Ford, Gibson (1992) 
L07569 Home, Ford, Gibson (1992) 
L07570 Home, Ford, Gibson (1992) 















Primer set Gene segment region Accession number Reference 
PCR1Kpool-FOR Immunoglobulin kappa light chain V-J HM176254 Sun et al. (2010) 
PCR2Kpool_FOR 
 
HM176261 Sun et al. (2010) 
PCR2Kpool_REV HM176246 Sun et al. (2010) 
 
HM176245 Sun et al. (2010) 
HM176262 Sun et al. (2010) 
VkORF1s Sun et al. (2010) 
HM176228 Sun et al. (2010) 
X75611 Ford et al. (1994) 
HM175128 Sun et al. (2010) 
HM176266 Sun et al. (2010) 
HM176123 Sun et al. (2010) 
HM176226 Sun et al. (2010) 
HM176229 Sun et al. (2010) 
HM176268 Sun et al. (2010) 
HM176238 Sun et al. (2010) 
HM176165 Sun et al. (2010) 
X75612 Ford et al. (1994) 
HM176196 Sun et al. (2010) 
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HM176140 Sun et al. (2010) 
HM176161 Sun et al. (2010) 
HM176233 Sun et al. (2010) 
HM176273 Sun et al. (2010) 
HM176137 Sun et al. (2010) 
Vk2Suns Sun et al. (2010) 
Vk7Suns Sun et al. (2010) 
XM_003362935 Wade et al. (2009) 
XM_003362936 Wade et al. (2009) 
XM_003362938 Wade et al. (2009) 
XM_003362952 Wade et al. (2009) 
VkORF2s Sun et al. (2010) 
HM176207 Sun et al. (2010) 
HM176163 Sun et al. (2010) 
HM176209 Sun et al. (2010) 
HM176213 Sun et al. (2010) 
HM176214 Sun et al. (2010) 
HM176275 Sun et al. (2010) 
HM176208 Sun et al. (2010) 
HM176211 Sun et al. (2010) 
HM176156 Sun et al. (2010) 
HM176216 Sun et al. (2010) 
HM176217 Sun et al. (2010) 
HM176274 Sun et al. (2010) 
Vk13Suns Sun et al. (2010) 
Vk15Suns Sun et al. (2010) 
HM176124 Sun et al. (2010) 
HM176184 Sun et al. (2010) 
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HM176174 Sun et al. (2010) 
HM176179 Sun et al. (2010) 
HM176097 Sun et al. (2010) 
HM176248 Sun et al. (2010) 
Vk1Suns Sun et al. (2010) 
Vk19Suns Sun et al. (2010) 
HM176394 Sun et al. (2010) 
HM176410 Sun et al. (2010) 
HM176200 Sun et al. (2010) 
Vk6Suns Sun et al. (2010) 
Vk8Suns Sun et al. (2010) 
HM176152 Sun et al. (2010) 
HM176204 Sun et al. (2010) 
HM176271 Sun et al. (2010) 
HM176149 Sun et al. (2010) 
HM176139 Sun et al. (2010) 
HM176201 Sun et al. (2010) 
HM176205 Sun et al. (2010) 
HM176102 Sun et al. (2010) 
HM176160 Sun et al. (2010) 
HM176190 Sun et al. (2010) 
XM_003362934 Wade et al. (2009) 
HM176155 Sun et al. (2010) 
HM176276 Sun et al. (2010) 
XM_001916665 Wade et al. (2009) 
HM176147 Sun et al. (2010) 
HM176133 Sun et al. (2010) 
HM176232 Sun et al. (2010) 
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HM176182 Sun et al. (2010) 
HM176253 Sun et al. (2010) 
HM176259 Sun et al. (2010) 
Jk4 Sun et al. (2010) 
HM176106 Sun et al. (2010) 
HM176179 Sun et al. (2010) 
HM176194 Sun et al. (2010) 
HM176165 Sun et al. (2010) 
HM176251 Sun et al. (2010) 
HM176229 Sun et al. (2010) 
Jk1 Sun et al. (2010) 
HM176126 Sun et al. (2010) 
HM176139 Sun et al. (2010) 
HM176093 Sun et al. (2010) 
HM176101 Sun et al. (2010) 
HM176145 Sun et al. (2010) 
Jk3 Sun et al. (2010) 
HM176103 Sun et al. (2010) 
HM176102 Sun et al. (2010) 
HM176129 Sun et al. (2010) 
HM176125 Sun et al. (2010) 
Jk2 Sun et al. (2010) 
Jk5 Sun et al. (2010) 
  
  
Primer set Gene segment region Accession number Reference 
PCR1Kpool_REV Immunoglobulin kappa light chain 
constant region 




HM176159 Sun et al. (2010) 
HM176160 Sun et al. (2010) 
HM176161 Sun et al. (2010) 
HM176162 Sun et al. (2010) 
HM176163 Sun et al. (2010) 
HM176164 Sun et al. (2010) 
HM176165 Sun et al. (2010) 
HM176166 Sun et al. (2010) 
HM176167 Sun et al. (2010) 
HM176168 Sun et al. (2010) 
HM176169 Sun et al. (2010) 
HM176170 Sun et al. (2010) 
HM176171 Sun et al. (2010) 
HM176175 Sun et al. (2010) 
HM176176 Sun et al. (2010) 
HM176177 Sun et al. (2010) 
HM176178 Sun et al. (2010) 
HM176181 Sun et al. (2010) 
HM176182 Sun et al. (2010) 
HM176183 Sun et al. (2010) 
HM176184 Sun et al. (2010) 
HM176185 Sun et al. (2010) 
HM176187 Sun et al. (2010) 
HM176188 Sun et al. (2010) 
HM176189 Sun et al. (2010) 
HM176190 Sun et al. (2010) 
HM176192 Sun et al. (2010) 
HM176193 Sun et al. (2010) 
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HM176194 Sun et al. (2010) 
HM176195 Sun et al. (2010) 
HM176196 Sun et al. (2010) 
HM176197 Sun et al. (2010) 
HM176198 Sun et al. (2010) 
HM176200 Sun et al. (2010) 
HM176201 Sun et al. (2010) 
HM176202 Sun et al. (2010) 
HM176203 Sun et al. (2010) 
HM176204 Sun et al. (2010) 
HM176205 Sun et al. (2010) 
HM176206 Sun et al. (2010) 
HM176207 Sun et al. (2010) 
HM176209 Sun et al. (2010) 
HM176212 Sun et al. (2010) 
HM176214 Sun et al. (2010) 
HM176215 Sun et al. (2010) 
HM176216 Sun et al. (2010) 
HM176217 Sun et al. (2010) 
HM176218 Sun et al. (2010) 
HM176219 Sun et al. (2010) 
HM176220 Sun et al. (2010) 
HM176221 Sun et al. (2010) 
HM176222 Sun et al. (2010) 
HM176223 Sun et al. (2010) 
HM176226 Sun et al. (2010) 
HM176227 Sun et al. (2010) 
HM176228 Sun et al. (2010) 
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HM176229 Sun et al. (2010) 
HM176230 Sun et al. (2010) 
HM176231 Sun et al. (2010) 
HM176232 Sun et al. (2010) 
HM176235 Sun et al. (2010) 
HM176236 Sun et al. (2010) 
HM176238 Sun et al. (2010) 
HM176239 Sun et al. (2010) 
HM176240 Sun et al. (2010) 
HM176241 Sun et al. (2010) 
HM176242 Sun et al. (2010) 
HM176244 Sun et al. (2010) 
HM176245 Sun et al. (2010) 
HM176246 Sun et al. (2010) 
HM176247 Sun et al. (2010) 
HM176248 Sun et al. (2010) 
HM176249 Sun et al. (2010) 
HM176250 Sun et al. (2010) 
HM176251 Sun et al. (2010) 
HM176252 Sun et al. (2010) 
HM176253 Sun et al. (2010) 
HM176255 Sun et al. (2010) 
HM176258 Sun et al. (2010) 
HM176259 Sun et al. (2010) 
HM176260 Sun et al. (2010) 
HM176262 Sun et al. (2010) 
HM176263 Sun et al. (2010) 
HM176264 Sun et al. (2010) 
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HM176265 Sun et al. (2010) 
HM176266 Sun et al. (2010) 
HM176267 Sun et al. (2010) 
HM176268 Sun et al. (2010) 
HM176269 Sun et al. (2010) 
HM176270 Sun et al. (2010) 
HM176273 Sun et al. (2010) 
HM176274 Sun et al. (2010) 
HM176275 Sun et al. (2010) 
HM176277 Sun et al. (2010) 
HM176278 Sun et al. (2010) 
X75612 Ford, Home, Gibson (1994) 






Protocol S1: Modifications to restriction enzyme digestion of scFv DNA and vector DNA with 
SfiI and NotI  
The restriction digestion master mix contained 1 µl NotI (New England Biolabs GmbH, 
Frankfurt, Germany), 5 µl CutSmart Buffer, (New England Biolabs GmbH, Frankfurt, 
Germany) 1 µg of template DNA and was adjusted to the final volume of 50 µl with HPLC 
water. The mixture was incubated at 50°C over night. The following day, 5 µl CutSmart Buffer 
were added as well as 1 µl of SfiI (New England Biolabs GmbH, Frankfurt, Germany). This 
mixture was incubated over night at 37°C and inactivated the next day at 65°C for 20 minutes. 
Calf intestine phosphatase (CIP; New England Biolabs GmbH, Frankfurt, Germany) was used 
to dephosphorylate the vector DNA to prevent re-ligation by adding 1,5 µl CIP to the digested 




Figure S1: Amino acid sequence alignments of three clones per antibody chain per PCR.  
.   
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7.2.2 Manuscript II: Isolating a high-affinity, equine, single-chain antibody 
fragment (scFv) from an equine phage display library neutralizing Equine 
Herpesvirus-1  
 
Protocol S1: Confirmation of EHV-1 binding capacity after purification via ELISA. 
Forty-eight wells of a 96-well ELISA plates (C96 Maxisorp NUNC-Immuno Plate, Thermo 
Fisher Scientific Inc., Waltham, USA) were coated with 1 µg/ml (Plate 1) and 2 µg/ml (Plate 
2) of EHV-1 at 37°C for 4 hours. Remaining 48 wells were not coated. The plates were washed 
three times with PBS+0.1 % T and blocked with 300 µl blocking solution (2 % SMP, 10 % FCS 
in PBS+0.1 % T) at 37°C for 2 hours. The positive control equine monoclonal antibody mAb 
6B11 (12) was added in duplicates and diluted (log2) from row A to H on both, the coated as 
well as the un-coated half of the plate. The negative control, consisting of a monoclonal 
antibody (mAb 5B4/2F2 (13)) was applied equally. Remaining columns received blocking 
solution. After one hour of incubation at 37°C, all wells received α-mouse-horse-radish 
peroxidase (HRP; 1:2000 in 2% SMP in PBS+0.1 % T; Sigma-Aldrich, Merck KGaA, 
Darmstadt, Germany) and plates were incubated at 37°C for one hour. The plate was washed 
10 times with PBS+0.1 % T, followed by the addition of 100 µl TMB substrate (IDEXX GmbH, 
Ludwigsburg, Germany). After 20 minutes incubation at RT in the dark, 50 µl HCl (IDEXX 
GmbH, Ludwigsburg, Germany) stop solution was added and OD was measured with the 
Sunrise microplate reader (Tecan, Maennedorf, Switzerland) at 450 nm. 
Result: 
ELISA assay confirmed sucrose purified EHV-1 allows binding of the positive control and the 
course of dilution ran smoothly. It did not react on uncoated wells. The negative control did not 




Figure S1: The course of mean absorbance (OD450) values of the dilution series (log2) of the 
positive and negative control on EHV-1 coated (1 µg/ml EHV-1) as well as on uncoated wells 
to examine binding kinetics of sucrose purified EHV-1 after first viral purification. 
 
Figure S2: The course of mean absorbance (OD450) values of the dilution series (log2) of the 
PC and NC on EHV-1 coated (2 µg/ml EHV-1) as well as on uncoated wells to examine binding 
kinetics of sucrose purified EHV-1 after second viral purification. 
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Protocol S2: Confirmation of presence of anti-EHV-1 immunoglobulins within plasma of 
donor horse William, which the equine immunised library is based on. 
Forty-eight wells of a 96-well ELISA plates (C96 Maxisorp NUNC-Immuno Plate, Thermo 
Fisher Scientific Inc., Waltham, USA) were coated with 1 µg/ml EHV-1 at 37°C for 4 hours. 
The plates were washed three times with PBS+0.1 % T and blocked with 300 µl blocking 
solution (2 % SMP, 10 % FCS in PBS+0.1 % T) at 37°C for 2 hours. 20µl plasma sample was 
added to column A1-C1 and diluted (log2) until column 12. Row D was dedicated for the 
negative control and did not receive any sample. After one hour of incubation at 37°C, all wells 
received α-horse-radish peroxidase (HRP; 1:2000 in 2% SMP in PBS+0.1 % T; Sigma-Aldrich, 
Merck KGaA, Darmstadt, Germany) and incubated at 37°C for one hour. The plate was washed 
10 times with PBS+0.1 % T, followed by the addition of 100 µl TMB substrate (IDEXX GmbH, 
Ludwigsburg, Germany). After 20 minutes incubation at RT in the dark, 50 µl HCl (IDEXX 
GmbH, Ludwigsburg, Germany) stop solution was added and OD was measured with the 
Sunrise microplate reader (Tecan, Maennedorf, Switzerland) at 450 nm. 
Result: 
ELISA confirmed the presence of antibodies against EHV-1. As shown in Figure S3, plasma 
sample of the immunized gelding yielded high reactivity to EHV-1, while negative control only 








Protocol S3: ELISA protocol to detect binding affinity of randomly selected scFv colonies after 
biopanning. 
Wells of 96-well ELISA plates (C96 Maxisorp NUNC-Immuno Plate, Thermo Fisher Scientific 
Inc., Waltham, USA) were coated with 2 µg/ml EHV-1 at 37°C for 4 hours. The plates were 
washed three times with PBS+0.1 % T and blocked with 300 µl blocking solution (2 % SMP, 
10 % FCS in PBS+0.1 % T) at 37°C for 2 hours. Wells were emptied and 50µl of blocking 
solution were added to every well but well A1. It received 100 µl of blocking solution and the 
positive control consisting of an EHV-1 specific equine monoclonal antibody (Mab 6B11) was 
diluted (log2) until well D1. Wells E1 to H1 received solely blocking solution to determine the 
background. The remaining wells were incubated with 50 µl of the induced scFv supernatants. 
Samples and controls incubated for 2 hours at RT, before washing plates five times with 
PBS+0.1 % T. The detection antibodies α-mouse horse radish peroxidase (HRP; 1:2000 in 2% 
SMP in PBS+0.1 % T; Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) for the positive 
control and α-E-Tag HRP (1:2000 in 2% SMP in PBS+ 0.1 % T, abcam, Cambridge, UK) were 
added to wells and incubated at 37°C for one hour. Wells E1 to H1 received blocking solution. 
Following incubation, wells were washed ten times with PBS+0.1 % T, followed by the addition 
of 100 µl TMB substrate (IDEXX GmbH, Ludwigsburg, Germany). After 20 minutes 
incubation at RT in the dark, 50 µl HCl (IDEXX GmbH, Ludwigsburg, Germany) stop solution 
was added and OD was measured with the Sunrise microplate reader (Tecan, Maennedorf, 
Switzerland) at 450 nm. 
 
Results: 
The following graph (Figure S4) shows OD values of 87 scFv fragments out of 348 clones after 




Figure S4: OD values after ELISA assay of individual clones on a 96-well plate after panning 
round 3 as an example of selection procedures. PC – positive control equine mAb 6B11 (first 
black column). NCA- negative control A: no template, α-E-Tag-HRP (grey). NCB- negative 
control B: no template, no detection antibody (grey). Black columns - OD values >0.25. White 




Protocol S4: Colony PCR of scFvs exhibiting OD values above 0.25 after biopanning. 
A 20 µl master mix contained 2 µl of scFv supernatant, 2 µl 10x Standard Reaction Buffer with 
MgCl2 (Biotools B&M Labs S.A., Madrid, Spain), 10 µM primer R1 (5´-CCA TGA TTA CGC 
CAA GCT TTG GAG CC-3´), 10 µM primer R2 (3´-CCT TTC TGC TGT TT GAA ATC TAG 
C-5`), 10 mM dNTPs (Carl Roth GmbH&Co.KG, Karlsruhe, Germany), 1 U/µl DNA 
polymerase (Biotools B&M Labs S.A., Madrid, Spain) and adjusted to the final volume with 
HPLC water (Carl Roth GmbH&Co.KG, Karlsruhe, Germany). PCR was run in a T3000 cycler 
(Biometra, Goettingen, Germany) under the following conditions: 94°C for 10 minutes, 30 
cycles at 94°C for 1 minute, 55°C for 1 minute and 72°C for 2 minutes, followed by 72°C for 
15 minutes. Amplification products were visualized on 1% agarose gels (PEQLAB 
Biotechnologie GmbH, Erlangen, Germany). Clones of approximately 1000 bp were considered 
for Sanger sequencing with primers R1 and R2 (Microsynth SeqLab, Goettingen, Germany). 
 
Results: 
After panning round three, 11 clones displayed OD signals higher than 0.25 and were further 
investigated in a Colony PCR. It revealed one clone to harbour a scFv insert of expected size 
(~800 bp; Figure S5) plus approximately 200 bp accounting for sequencing primers R1/R2. 




Figure S5: Colony PCR of scFv clones with OD values above 0.25 after panning round 3 on a 
1 % agarose gel. Lane 1 & 16: 1 kb ladder. Lane 2 & 15: 100 bp ladder. Lane 14: negative 
control (HPLC). Lane 3 to 13: individual clones; names correspond with position in 96-well 






Figure S6: Trace data of Sanger sequencing results showing the linker sequence of scFv-3H2. Black arrows indicating the base exchange 
resulting in one amino acid substitution.
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